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ABSTRACT 
This work describes the development and investigation of a family of novel “smart” 
copolymers as non-viral gene delivery vectors. The copolymers have five blocks, and thus 
named pentablock, with a central block of a hydrophobic polymer, surrounded by two blocks 
of a hydrophilic polymer, and capped at each terminal end with cationic polymer blocks, 
arranged in an architecture to provide temperature and pH sensitivity to the copolymers. 
They are derived from commercially available triblock Pluronic copolymers. The cationic 
copolymers can efficiently condense negatively charged plasmid DNA in nanostructures with 
efficient cellular uptake. The amphiphilic nature of copolymers causes them to exist as 
micelles in aqueous solutions that help them traverse cellular membranes with minimal cell 
membrane damage. Intra-cellular trafficking of copolymer/DNA complexes revealed that 
they are up-taken by the cells predominately via endocytosis and are able to deliver the 
ferried gene into the nuclei. The copolymers efficiently protect the condensed DNA against 
degradation by nucleases while their protonation capability at low pH assists them in escape 
from endosomal vesicles into the cytoplasm. The efficiency of the copolymers to deliver 
condensed DNA into the cells in vitro was comparable to the commercially available 
polymeric transfection vectors, and they were also found to be significantly less cytotoxic. 
Adding non-ionic Pluronic copolymers to the formulation of pentablock copolymer/DNA 
complexes sterically shielded their surface charge and protected them against aggregation 
with serum proteins. These stabilized formulations were able to retain their ability to 
transfect cells even in complete growth media supplemented with serum proteins, warranting 
efficient transfection efficiency in an in vivo application. The amphiphilic nature of 
copolymers further permits copolymer/ DNA complexes to form thermo-reversible hydrogels 
at physiological temperatures. At concentrations above 15 wt%, copolymer/DNA complexes 
existed as solutions at room temperature and formed elastic hydrogels at 37°C that dissolved 
over seven days in excess buffers to release colloidally stable polyplexes. The system thus 
permits an injectable aqueous pharmaceutical preparation at room temperature that can be 
injected subcutaneously in tissues/cavities to form a localized depot in situ, which provides a 
long-term sustained release of therapeutic genes well protected inside the copolymer/DNA 
complexes. 
 1
CHAPTER 1 
GENERAL INTRODUCTION 
 
 
Gene therapy- it’s a medical art to deliver genetic information coded in nucleic acids to 
the targeted somatic cells of a patient for producing specific therapeutic proteins that can 
modulate the disease [1]. Providing a therapeutic gene may circumvent the limitations 
associated with direct administration of therapeutic proteins, like low bioavailability, 
systemic toxicity, in vivo instability, and high hepatic and renal clearance rates [2]. 
Originally designed for the treatment of hereditary genetic disorders [3], gene therapies are 
now being developed to treat cancer [4], heart diseases [5], AIDS [6], diabetes mellitus [7], 
and other treatments like tissue regeneration [8], wound healing [9] and immunization [10].  
However, despite initial promise in many animal models, the translation of gene therapy to 
the clinical arena has been slow, and has been limited by the development of an efficient 
gene delivery system, not by the paucity of gene expression systems. Among all the gene 
carriers, viruses have most widely been investigated, as they have evolved to overcome 
human immune defenses and deliver their genetic payload efficiently into the host cells [11]. 
Approximately 70% of the 1260 approved gene therapy clinical trials have been conducted 
using engineered viruses as vectors to ferry therapeutic genes, Fig. 1 and 2 [12]. However, 
viral vectors have some practical limitations. They can carry only a limited amount of genetic 
information, and there is always a remote danger of recombination events that can produce a 
replicating virus. In addition, there is also possibility of the replicating virus to integrate into 
the host genome at undesired sites and permanently altering its genetic structure. Besides, 
mammalian immune systems have developed strategies to eliminate viral invaders as well. 
Repeated administration of these viral vectors (more than once or twice) can provoke an 
immune response, strong enough to result even in the death of the host. A big jolt came to 
this viral vector gene therapy on 17 September 1999, when Jesse Gelsinger, a teenage 
volunteer, died during a clinical trial at the University of Pennsylvania in Philadelphia [13]. 
An out-of-control immune response to the virus used in the therapy was cited as the reason 
for his death. Since that incident several other set backs involving secondary oncogenesis 
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[14], or transfection of untargeted germ cell lines [15] have been encountered in clinical trials 
of viral gene therapy. These incidents have boosted a renewed interest among scientists to 
develop biologically inactive non-viral methods of gene delivery [16], and researchers have 
been forced again to make a choice: domesticate viruses, or develop intelligent synthetic 
vectors? 
The research on non-viral methods of gene delivery has been gathering steam over the last 
two decades- with the goal to design a vector that could 1) provide the transfection efficiency 
attained by viral vectors, 2) carry large amount of genetic information, 3) bypass the immune 
response, and 4) be safe. With safety and large scale manufacturing as their advantages, the 
clinical usefulness of these methods is limited by their low transfection efficiency and 
inability to confer long term transgene expression, important issues that need to be 
technologically improved. Novel cationic polymers and lipids have shown great promise as 
efficient non-viral vectors for gene and oligonucleotide delivery. Other strategies include 
particle bombardment [17, 18], electroporation [19, 20], nucleofection [21], jet injection [22], 
ultrasound [23] and direct injection of naked DNA [24, 25]. However, their applicability is 
restricted to specific circumstances, and can be only rarely applied with reasonable 
efficiency, as has been review recently [16].  
Cationic polymers or liposomes that electrostatically condense negatively charged DNA 
molecules into nanoparticles have proven to be efficient gene delivery systems, giving 
transgene expression in targeted cells of several magnitudes higher than that achieved with 
naked plasmid delivery both in vitro and in vivo [26]. Polycations are ensembles of a certain 
repeating structural unit that are easy to manufacture and scale-up. Further, they are not 
architecturally constrained, and can be specifically tailored for the proposed application by 
choosing appropriate molecular weights/degree of branching, coupling of tissue specific 
targeting moieties, and/or performing other modifications that confer upon them specific 
physiochemical and physiological properties (temperature and pH sensitivity). Various off-
the shelf polymers [27], like polyethylenimine (PEI), poly-L-lysine (PLL), methacrylates, 
dendrimers, and liposomes [28] like DOTAP (1,2-Dioleoyl-3-Trimethylammonium-Propane) and 
lipofectamine have been shown as efficient gene delivery vectors, but their use in clinical 
trials is held back by problems like cytotoxicity, in vivo colloidal stability, and low and 
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transient gene expression. New generations of block and graft copolymers, and liposomes 
designed specifically for gene delivery are now being investigated to address these issues 
[29, 30].  
An efficient cationic non-viral gene delivery vector needs to overcome numerous 
obstacles at the systemic and cellular levels as discussed in detail elsewhere [31]. Briefly, on 
systemic level, cationic vectors should avoid non-specific interactions with erythrocytes, 
vessel endothelia, and plasma proteins like albumin, fibronectin, immuoglobulins, 
complement factors, and fibrinogen. These interactions can result in aggregation and 
accumulation of polymer/DNA complexes in the “first pass organs” such as lung 
(consequently causing pulmonary embolism), liver and spleen, and finally opsonization and 
clearance by the reticuloendothelial system (RES) [32, 33]. This leads to the very short 
plasma half-lives for these vectors, decreasing their circulation time and cellular uptake, and 
negatively influencing their biodistribution and gene expression patterns, making them of 
limited value for therapeutic applications. Second, the vectors should be targeted to specific 
cell types so that they deliver the therapeutic genes only the desired cells to produce expected 
physiological effect without any side effects. On cellular level, once these vectors reach the 
targeted cells, they should effectively traverse across the cell membrane (mediated mostly by 
endocytosis); protect the ferried gene from the low pH, nucleases rich environment of 
endosomes; escape the lysosomes; enter the nucleus and, finally unpack from the gene for it 
to be up-taken by nuclei machinery for transcription (Fig. 3). Lastly, non-viral gene delivery 
methods provide only transient protein expression because of the ultimate loss of the un-
integrated plasmid DNA from the transfected nuclei. Besides, injecting gene delivery vectors 
formulated in large buffer volumes gives limited bioavailability of the bolus dose as most of 
the injected vector is lost, or is degraded rapidly in the tissue, or is removed from the tissue 
by lymphatic system. Efficient gene delivery systems that produce enough amount of 
therapeutic protein in the transfected tissue all along the duration of therapy to give an 
appreciable physiological response are needed. 
In the work presented here, we have attempted to develop novel “smart” polymers 
designed specifically for gene delivery that encompass all the above mentioned qualities of 
an ideal gene delivery vector.  These are cationic amphiphilic copolymers with five blocks of 
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three different polymers arranged in an architecture to confer temperature- and pH-sensitivity 
to them. The copolymers can condense negatively charged plasmid DNA molecules at 
physiological pH in nanoparticles of 100-200nm diameter for efficient uptake by targeted 
cells, while protecting the compacted plasmid against degradation by nucleases in extra-
cellular matrix or inside the cells. The amphiphilic nature allows these copolymers to exist in 
micellar type of structures that helps them traverse across the amphiphilic lipid bilayer of cell 
membranes with minimum cytotoxicity. The pH sensitivity permits in the protonation of 
copolymers when entrapped in low pH environment of endosomal compartments which aids 
in the disruption of such vesicles and their final escape in the cytoplasm. The copolymers 
have reactive ends in their architecture to facilitate attachment of cell-specific ligands for 
target recognition, or nuclear localization signals (NLS) for improving nuclear translocation. 
Finally, the copolymers display an interesting thermo-reversible gelation at higher 
concentrations and physiological temperatures. While they exist as solutions at room 
temperatures, the polymeric network self-assembles at body temperature to form an elastic 
hydrogel. Thus, the copolymers can be mixed with the therapeutic gene in an aqueous phase 
at low temperatures (below 10°C) where they exist as sols and are injectable. On 
subcutaneous/intramuscular injection and subsequent heating to body temperatures, the 
copolymers self-assemble into a hydrogel in situ. The hydrogel act as a reservoir for the 
entrapped plasmid DNA and can dissolve over time in the tissue fluid to provide long-term 
sustained-release of the compacted gene. This would maintain the long term local 
bioavailability of DNA vectors to the surrounding tissues by continual replacement of the 
factors that get cleared or degraded, increasing the probability of cellular uptake, improving 
the optimal use of drug, and circumventing the need for repeated administration with 
increased patience compliance. Thus, these novel copolymers can be used for systemic 
delivery of genes in solution at low concentrations, and for localized sustained gene delivery 
to specific tissues/ cavities at higher concentrations.  
Investigation and development of these novel copolymers as efficient non-viral gene 
delivery systems can facilitate improvement of the existing polymeric gene delivery 
technology, and help harness the great powers of gene therapy. 
 
 
 5
THESIS ORGANIZATION 
 
The above stated overall objectives for developing and characterizing these novel 
copolymers as non-viral gene delivery vectors were addressed by completing a set of specific 
goals (SGs), and the progress towards completion of each goal has been documented in the 
accompanying chapters of this dissertation. 
 
SG1 
To characterize the physiochemical properties of pentablock copolymers pertaining to 
plasmid DNA compaction and protection against nucleases; and, hydrodynamic size, surface 
charge, and morphology of polymer/DNA complexes in aqueous solutions. 
Chapters 3, 5 and 6 address this specific goal. Chapter 3 investigates the ability of 
pentablock copolymers to condense plasmid DNA, and protection they provide to DNA 
against degradation by nucleases. Morphology of the copolymer/DNA complexes is 
presented using Transmission Electron Microscopy (TEM). The apparent molecular mass 
and radius of gyration of copolymers and their polyplexes in aqueous solutions was 
investigated using Multi-Angle Laser Light Scattering (MALLS). Chapter 5 presents a 
detailed study on the DNA condensation by pentablock copolymers under different 
physiological conditions and polymer concentrations. Cryo-TEM was used to study the 
morphology of these micellar copolymers and their DNA condensates, as it enables direct 
real-space imaging of nanostructures in their native state in aqueous conditions by vitrifying 
the samples, avoiding staining and drying artifacts involved in conventional TEM. Chapter 6 
provides a detailed investigation of the particle size and surface charge of these 
copolymer/DNA complexes, and presents strategies to shield their surface charge and prevent 
aggregation in serum supplemented buffers that will optimize their formulation for future in 
vivo applications. 
 
SG2 
To tailor the copolymer design and, improve the colloidal stability of their DNA 
complexes with optimized formulations for maximum gene transfection in cells with 
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minimum cytotoxicity, and investigate their intracellular trafficking pathway to identify steps 
that limit their transfection efficiency. 
Chapters 3, 4, 5 and 6 collectively address SG2. In chapter 3, four different pentablock 
copolymers with different cationic content are screened for their cytotoxicity relative to cell 
membrane damage, and the transfection of efficiency of one of the copolymers is tested for 
the first time in a cancer cell line using two different reporter genes: one to account for the 
percentage of cells expressing the transfected reporter genes, and the other to provide the 
total amount of transgene expression in a population of the transfected cells. Chapter 4 
examines in detail the biocompatibility of various pentablock copolymers on two different 
cancer cell lines using several cell-based assays to elucidate the mechanism of cell death 
induced by these copolymers, and compares it with that of another commercially available 
polycationic transfection reagent. The chapter illustrates how the cytotoxicity of the 
copolymers can be tuned by tailoring their molecular weight or cationic content.  Chapter 5 
investigates the pathway utilized by pentablock copolymer/DNA complexes to transfect a 
cell- from traversing across the cell membrane to the delivery of the DNA to the nucleus. 
Fluorescent labeling techniques and confocal microscopy were used. Chapter 6 provides a 
novel strategy to screen the cationic surface charge of the pentablock copolymer/DNA 
complexes, preventing their aggregation with serum proteins and significantly improving 
their transfection efficiency and biocompatibility in complete growth media. The results 
warrant good performance of this multi-component gene delivery system in systemic 
applications in vivo. 
 
SG3 
To develop injectable self-assembled in situ forming hydrogels of pentablock 
copolymer/DNA complexes for long-term sustained gene delivery, modulate their in vitro 
dissolution profile, and improve the formulations for maximum gene stability and 
transfection efficiency. 
Chapter 7 describes the work done in the pursuit of SG3. It reports the mechanical 
properties of the hydrogels of copolymer/DNA complexes made with different formulations, 
and describe their sustained DNA release profile. The resuls present therin confirms the 
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release of condensed DNA, but not naked DNA, from the hydrogels and, examines the 
colloidal stability of released polyplexes. Finally the transfection efficiency of the polyplexes 
released from the hdyrogels is tested on cell lines in vitro, confirming that these injectable 
hydrogels display great potential as sustained gene delivery devices that have distinct 
advantages over other investigated systems. 
 
Finally, Chapter 8 summarizes the conclusions obtained from this body work, and 
Chapter 9 offers some guidelines to test these copolymers and their injectable hydrogels in in 
vivo murine models, and discusses their future applications in gene therapy. 
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Fig. 3: Intracellular trafficking of a gene delivery vector. 
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Abstract 
Gene therapy in clinical trials today is hampered by the need of a safe and efficient gene 
delivery system that can provide a sustained therapeutic effect without causing any 
cytotoxicity or invoking an unwanted immune response. Bolus gene delivery in solution 
using plasmid DNA or viral vectors results in the loss of the delivered factors via lymphatic 
system, and may cause undesired physiological responses by the escape of these bioactive 
molecules to distant sites. A controlled gene delivery system that can act as a localized depot 
of genes with sustained release profile would maintain the therapeutic level of expressed 
protein for extended period of times, circumventing repeated administrations and reducing 
the drug dosage. It would also protect the DNA in the nuclease rich extra-cellular or systemic 
environment, limiting its degradation. Several controlled release technologies developed for 
delivering therapeutic molecules have been adapted for gene delivery while more novel 
approaches are being investigated. DNA encapsulated in nanospheres and microspheres of 
degradable polymers can be administered systemically or orally to be up taken by the 
targeted tissues and provide long term release once internalized. Alternatively, DNA 
entrapped in hydrogels and polymer scaffolds can be injected or implanted at  localized 
locations as platforms for sustained gene delivery. Here either the incorporated DNA is 
released by diffusion through the polymer matrix to be up taken by surrounding cells, or 
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DNA tethered to the matrix is internalized by the infiltrating cells as they invade through the 
matrix. The present review examines these different modalities used for sustained delivery of 
viral and non-viral vectors, and various synthetic and natural polymers used to synthesize 
them. Design parameters and release mechanisms for different delivery systems are presented 
along with their prospective applications, and opportunities for continuous development. 
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1. Introduction 
Gene therapy is an experimental technique of delivering genetic material to a patient’s 
somatic cells in order to express therapeutic proteins to correct or modulate a targeted 
disease1. With the completion of the sequencing of the human genome, a lot of advances 
have been made in identifying target genes for the purposes of treating genetic and infectious 
diseases, but the bottle neck in the success of gene therapy has been in developing a safe and 
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efficient gene delivery system. Viruses are most efficient in delivering their genetic payload 
to the mammalian cells, and have been modified by the researchers to deliver the therapeutic 
genes instead2. However, the problems with immunogenicity, oncogenicity by insertional 
mutagenesis, toxicity, limitation of repeated administrations, targeting, and possibility of 
recombination events by replication, has hindered the successful use of viral vectors in gene 
therapy. Several set backs3-5 in clinical trials using viral vectors have further questioned their 
safe usage, and researchers have become more interested in developing non-viral modes for 
gene delivery6,7. 
In non-viral gene delivery, the gene of interest is inserted into a cassette of expression 
plasmid that also contains other DNA sequences for controlling the effective translocation of 
the gene, and final transcription into targeting proteins. Injection of plasmid DNA generates 
systemic protein expression. However, expression is transient due to the eventual loss of 
unintegrated plasmid DNA from transfected cell nuclei, and thus decreases rapidly over a 
week or two. Specific or non-specific mechanisms may be involved in the loss of exogenous 
gene expression. Repeated administration of gene drug is required to maintain the therapeutic 
level of the expressed protein drug for an effective therapy. Development of sustained gene 
delivery devices that can maintain the long term local availability of DNA vectors to the 
surrounding tissues can achieve a sustained systemic protein production, circumventing the 
need for repeated administration. In fact, sustained and regulated gene expression is more 
effective than repetitive single dose administrations with high transient expression for the 
treatment of certain localized disease conditions, such as angiogenesis, bone regeneration, 
restenosis (a vasculoproliferative condition), inducing neovasculature in cardiac and limb 
ischemia8-11. 
The primary drawback of several unformulated plasmid and viral based formulations, 
accompanying the large buffer volume, is the limited bioavailability of the bolus dose. Most 
of the injected plasmid runs off, or is degraded rapidly in the tissue, or is removed from the 
tissue by lymphatic system. Sustained delivery systems can maintain the elevated levels of 
delivered therapeutics within the extracellular environment by continual replacement of the 
factors that get cleared or degraded. Besides, such a system can have a high DNA loading 
efficiency, can protect the DNA from endonculeases, and has the potential to deliver a 
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controlled, predictable, and sustained supply of DNA for prolonged expression. The 
controlled presence of the genetic medicine in the cell microenvironment within desired 
range can improve the effectiveness of drug by increasing patience compliance, reducing 
toxicity and requiring fewer administrations.  
A lot of work has already been done on the development of polymeric controlled release 
systems for low-molecular weight drugs and proteins (growth factors, antibodies, hormones), 
and several of such systems have even been commercialized including Nutropin Depot, 
Gliadel wafer, Norplant, and Cypher Stent. Adapting these systems for the sustained delivery 
of DNA would be a great advantage in the practice of medicine, because delivering plasmid 
DNA to generate therapeutic proteins has many advantages over traditional protein based 
approaches. For one, gene therapy is not restricted to proteins that interact with cell-surface 
receptors. It can be used to express genes encoding intracellular proteins which could be used 
to control the fate of pluripotent cells. In this regard, gene therapy can target more cellular 
processes. The quantity and duration of protein production from gene delivery can be 
manipulated using inducible promoters, or can be restricted to a specific tissue through tissue 
specific promoters. With protein drugs, the delivery system should maintain the three 
dimensional conformation of the protein in order to maximize bioactivity. However, plasmid 
DNA, where the essential information is encoded in its linear sequence of bases, has a stable 
flexible chemistry that is compatible with established polymer-based drug delivery system. 
Because physical properties of DNA are similar regardless of its linear sequence, multiple 
plasmids can easily be incorporated into a single delivery system. A critical challenge in 
developing delivery systems for multiple proteins is developing processing conditions that 
maintain the bioactivity of all constituents. Besides, plasmid diffusion from the delivery site 
would not cause toxicity because of the high efficiency of DNA turnover in the bloodstream. 
From a commercial point of view, plasmid DNA is economical and relatively simple to 
manufacture compared to protein therapeutics and is non-toxic if manufactured properly. 
This review examines the current development of polymeric sustained gene delivery 
systems, and discusses how continuous advances can impart momentum to the success of 
gene therapy. Different strategies for controlled gene delivery and, opportunities for 
continuous development have been discussed. 
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2. Design parameters for controlled release systems 
Gene therapy can be controlled pharmaceutically at several levels. The gene delivery 
system itself can physically control the dose, location, and distribution of the administered 
gene. Designing of such delivery system should take into account a convenient and 
conventional administration route, and proper cellular targeting. On a second level, the gene 
expression systems (plasmids or viruses) can be designed to provide a controlled production 
and distribution of therapeutic proteins within the body, which may include tissue-specific 
promoters, transcript stabilizer, and which may persist in the cells according to their 
biochemical half-life. Though this second point is beyond the scope of this review, and has 
been discussed recently in detail elsewhere , it reinforces again the advantages of gene 
delivery over direct protein delivery, which is manifested in the wide therapeutic window 
gene delivery provides for long term protein production in targeted cells acting as 
bioreactors.  
12
Controlled release of the DNA vectors eliminates the risks of under and over dosing, and 
provides an extended period of time to exploit the therapeutic potential of sustained protein 
expression. The key point is that an excess of delivered factors may produce undesirable side 
effects (eg. cytotoxicity) while lower levels of gene would produce insufficient protein to 
generate the desired therapeutic or physiological effect. The release profile of the delivered 
DNA vectors should therefore be designed to keep expressed protein levels within a 
therapeutic range, and can be based on their degradation and clearance rates within the local 
environment.  
A controlled drug delivery device can be pre-designed to provide either constant or 
cyclic release of the drug over a long period of time, and can be triggered by environment or 
external events. Primary release mechanisms of gene delivery vectors from such devices can 
involve diffusion of DNA vectors through polymer matrix, degradation of polymer matrix, or 
swelling of matrix followed by diffusion of water. One or all of these mechanisms can occur 
in a single delivery system. In systems where entrapped DNA is transported by diffusion, 
concentration gradients can be established by appropriately manipulating the release kinetics. 
The diffusion of vectors can occur on a macroscopic scale, as through the pores in the 
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polymer matrix, or on a molecular level, by passing between the polymer chains (like in 
micellar packing). Strategies like controlling the rate of degradation of polymer matrix by 
adjusting density of biodegradable or hydrolysable linkers, or controlling the dissolution rate 
and pore size of polymer matrix by adjusting polymer weight concentration, can be used to 
tune the release profile. In swelling-based systems, mostly based on hydrogels, the swelling 
can be triggered by a change in environment surrounding the delivery system, such as pH, 
temperature, or ionic strength. 
The non-ionic polymeric delivery devices can be cationized to promote DNA binding 
and loading efficiency. The binding of DNA to the polymer matrix hinders its diffusion, 
thereby prolonging its release. Such systems would also release compacted DNA upon 
degradation/dissolution of the polymeric matrix, further aiding in transfecting the cells. Some 
polymers used in the sustained delivery devices that contain functional groups (like 
carboxylic acids, amines) in their backbone can be readily modified to manipulate the 
interactions between polymer and DNA. However this may sometime limit the uptake of 
DNA by cells due to strong interactions between the DNA and polymer. Alternatively, viral 
vectors, or complexes of polycation and DNA pre-formed in solution can be loaded or 
immobilized on the polymeric delivery device. Specific binding (such as antigen-antibody, or 
biotin-avidin) or non-specific interactions (like molecular interactions with lipids, proteins, or 
polymer) can be used to immobilize the vectors on the polymeric devices. The number of 
binding sites in the matrix, affinity of DNA vectors for these sites, and the degradation rate of 
polymer matrix can determine the amount of vectors that can be loaded, as well as their 
release profiles. The vectors bound to these polymer matrices may either be released by 
degradation of linkage between vector and the material, or can directly be internalized by 
infiltrating cells.  
Exploiting the therapeutic potential of genetic medicine requires the most efficacious 
mode of delivery, and arguably must be tailored specifically for different applications 
(tissues, disease conditions), with a tunable release, high bioavailability, device fabrication 
techniques that maintain bioactivity of encapsulated factors, and patient compliant 
injectability.   
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3. Delivered factors  
One of the first and most successful approaches in gene therapy involved direct injection 
of naked plasmid DNA in the interstitial space of the tissue, especially the skeletal muscles13. 
The application has been demonstrated to induce physiological effects using genes encoding 
systematically secreted proteins, such as erythroprotein (EPO)14 and interluikin-515 and, 
locally acting proteins, such as basic fibroblast growth factor16, vascular endothelial  growth 
factor17 and dystrophin18.  However, the level of transfection is often variable and 
inefficient13. The plasmid DNA injected in excess buffer gets rapidly cleared or is 
internalized by phagocytic cells (macrophages). It is very susceptible to degradation by 
nucleases in the extra-cellular matrix (ECM) or inside the cells. Further, plasmids are large 
molecules (10 -10  base pairs, >100nm hydrodynamic diameter) with high negative charge 
density that can limit their transport through tissues and can 
3 4
prevent their diffusion across 
biological barriers such as an intact endothelium, plasma membrane or nuclear membranes19. 
Clearance and degradation of plasmid DNA can also be attributed to its sequence-specific 
recognition by the immune system. Bacterially derived methylation pattern of CpG 
sequences on the plasmid backbone increase the immune response to the encoded transgene 
by promoting the production of immunostimulatory cytokines20,21. Such immune responses 
can eliminate the transgene expressing cells, and in effect reduce the duration of transgene 
expression22. Encapsulating naked DNA in sustained gene delivery systems can reduce this 
immune response by shielding CpG sequences23, increase its residence time in tissues, and 
protect it against degradation.  
Cationic polymers or liposomes that electrostatically condense negatively charged DNA 
molecules into nanoparticles have proven to be efficient gene delivery systems, giving 
transgene expression in targeted cells of several magnitudes higher than that achieved with 
naked plasmid delivery both in vitro and in vivo24. The approach is to neutralize the anionic 
surface charge of DNA, and reduce its molecular size. The polymers/liopsomes protect the 
encapsulated DNA from degradation by nucleases in ECM, blood stream, and endosomes 
inside the cells, and aid in the targeting to desired cells, transport across the cellular 
membrane, intracellular trafficking, and nucleus uptake. Various off-the shelf polymers25, 
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like polyethylenimine (PEI), poly-L-lysine (PLL), methacrylates, dendrimers, and 
liposomes26 like DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) and lipofectamine 
have been shown to be efficient gene delivery vectors, while new generations block and graft 
copolymers and liposomes designed specifically for gene delivery are being investigated to 
improve their serum stability, toxicity and transfection efficiency27,28. However, the shorter 
duration and lower level of gene expression than achieved by viral vectors are important 
issues that need to be technologically improved. One possible way to tackle the issue is long-
term release of these vectors using a sustained gene delivery system that would also improve 
their colloidal stability, decrease their cytotoxicity, and increase bioavailability. 
Viral vectors are biological systems derived from naturally evolved viruses capable of 
transmitting their genetic materials into the host cells. Many viruses including retrovirus, 
adenovirus, herpes simplex virus (HSV), adeno-associated virus (AAV) and pox virus have 
been modified to eliminate their pathogenicity (cytopathic effects) and maintain their high 
gene transfer capability2. However, the limitations associated with the use of viral vectors in 
terms of their safety, and in terms of their limited payload of cDNA, have encouraged 
researchers to increasingly focus on non-viral vectors as an alternative for gene delivery6,29. 
Further improvements are required to make these viral vectors less toxic and 
immunogenic1,29. Encapsulating viral vectors in controlled release systems can provide 
several advantages, including stability against degradation- as they have short half lives on 
the order of half hours at 37°C; reduced immonogenecity by avoiding escape to distant sites 
and making them available to only targeted cells at localized site; and reduced recognition by 
immune system by entrapping them inside the polymeric systems, limiting the binding of 
neutralized antibodies on their surface30-32. Sustained delivery may also minimize the amount 
of viral vector necessary to get the desired physiological response. 
 
 
4 Different modalities of sustained delivery devices 
A detailed examination of the advantages and limitations of different sustained gene 
delivery modalities, along with their delivery mechanism, and examples of successful 
applications is presented in this section. Both synthetic and natural polymers have been 
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employed to produce these devices. Advantages of different polymers along with various 
techniques used to encapsulate DNA vectors into the devices of these polymers are also 
provided. 
 
4.1 Nanospheres 
Nanoparticles are sub-micron sized (50 to 700nm) polymeric particles in which a drug 
molecule can be encapsulated or absorbed onto the polymeric matrix or conjugated to the 
surface33. Large surface area to volume ratio enables these nanoparticles to encapsulate large 
molecules of plasmid DNA efficiently without condensing it (electrostatic plasmid 
condensation involved in use of cationic polymers). Nanospheres loaded with plasmid DNA 
are internalized by the cells, and DNA diffuses out from the pores over time, as opposed to 
decomplexing from a cationic polymer or lipid. The sub-cellular and sub-micron size of 
nanoparticles has distinct advantages over microparticles. They can penetrate deep into the 
tissues through fine capillaries, cross the fenestration present in epithelial lining (e.g. liver), 
and have generally higher intracellular uptake compared to microparticles34,35. Though the 
transfection levels achieved with such nanoparticles in vitro are significantly lower than with 
cationic polymers and lipids, a substantial increase in expression has been observed through 
one week of culture, indicating DNA is released in a sustained manner intracellularly36-38. 
Intramuscular delivery of such nanospheres produced one to two order of magnitudes higher 
expression of plasmid DNA after seven days compared to lipofectamine, and the expression 
also sustained for longer period of times (up to 28 days) than liposomal plasmid DNA37,39,40.  
Both synthetic and natural polymers have been utilized in formulating bio-degradable 
nanoparticles. Synthetic polymers, like polylactide-polyglycolide copolymers, have the 
advantage of releasing the encapsulated DNA over a period of days to weeks, compared to 
shorter duration with natural polymers like gelatin and collagen. However, synthetic 
nanoparticles are limited by the use of organic solvents and relatively harsher formulation 
conditions. Polylactides (PLA) and poly(D,L- lactide-co-glycolide) (PLGA) nanospheres 
have been studied most extensively for sustained drug delivery because they form 
biologically compatible and metabolizable moeties (lactic acid and glycolic acid) after 
hydrolysis37,38,41. Nanosphere formulations of these polyesters are advantageous over 
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microspheres because they prevent DNA damage caused by the acidic environment of 
polymer degraded materials; the large surface area to volume ratio of nanoparticles facilitates 
fast diffusion of acidic degradation products from the particles into the tissue fluid. DNA 
loaded PLGA nanoparticles have been formulated mainly using a double emulsion solvent 
evaporation technique. Though the DNA loading efficiency is low, these nanoparticles can be 
delivered in higher doses to deliver required amounts of DNA without worrying about 
polymer associated toxicity because of their demonstrated long-term biocompatibility in 
vitro42 and in vivo43. Plasmid loaded PLGA nanoparticles have been shown to rapidly escape 
endosomes, within 10 minutes of their incubation with cells44. The mechanism of rapid 
escape is by selective reversal of their surface charge (from anionic to cationic) in the acidic 
endo-lysosomal vesicles which causes the nanoparticles to interact with the endo-lysosomal 
membrane and escape into the cytosol. In vitro studies have indicated that smaller particle 
size and uniform size-distribution are important to enhance nanoparticles-mediated gene 
expression45.  In a rat bone osteotomy model, sustained expression of reporter genes released 
from PLGA nanoparticles was observed in tissues retrieved from the gap five weeks after the 
surgery41. This suggests that such a strategy can be used to facilitate bone healing using 
therapeutic genes encoding bone morphogenic protein. Gene-coated sutures using an 
emulsion of PLGA nanoparticles, used to close an incision in rat skeletal muscles, 
demonstrated gene expression in the tissue at the site two weeks after surgery46. Such gene 
coated sutures encoding for growth factors like vascular endothelial growth factor could 
facilitate wound healing. In vitro studies have indicated that smaller particle size and uniform 
size-distribution are important to enhance nanoparticles mediated gene expression45. 
Nanoparticle-mediated wt-p53 gene delivery displayed sustained and greater anti-
proliferative activity compared to lipofectamine in a breast cancer cell line in vitro47. 
However, efficiency of these nanoparticles to generate physiological responses in vivo using 
therapeutic genes still needs to be demonstrated. 
Nanospheres of biodegradable natural polymers like gelatin and chitosan have also been 
shown to provide transfection comparable to that of lipofectamine40. DNA-gelatin 
nanospheres formed by salt-induced complex coacervation of gelatin and plasmid DNA, and 
stabilized by crosslinking gelatin matrix with crosslinking agent, produced greater and more 
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prolonged reporter gene expression after intra-muscular injections in mice40. Chitosan is a 
biodegradable natural polysaccharide derived from chitin that possesses both bioadhesion 
and mucus absorption enhancing capacities48, making it a unique adjuvant for nasal, oral or 
rectal delivery of drugs. DNA loaded chitosan nanospheres have been used for the delivery 
of mucosal gene expression vaccine. In a mouse model of respiratory syncytial virus (RSV) 
infection, a single intranasal administration of chitosan-DNA nanospheres (25 μg/mouse), 
containing a mixture of plasmid DNAs encoding RSV antigens, resulted in a significant 
reduction of viral titers and viral antigen load after acute RSV infection of these mice49.  
The surface of the nanoparticles can be modified with ligands like poly(ethylene glycol) 
for tumor targeting and prolong blood circulation during systemic administration. DNA 
encapsulated in PEG-modified gelatin nanoparticles using a water-ethanol solvent 
displacement method have been shown to provide sustained gene expression in solid tumors 
after both i.v. and i.t. injections50, and have longer tumor and plasma half-lives than 
unmodified gelatin nanoparticles with preferential localization in the tumor mass51.  
Nanospheres of polymers with cationic functional groups in their backbone can 
electrostatically bind DNA providing higher loading efficiency, more sustained release 
profile, and enhanced transfection efficiency. Nanospheres of water soluble and 
biodegradable polyphosphoesters, like poly(2-aminoethyl propylene phosphate) (PPE-EA), 
condensed plasmid DNA and provided sustained delivery as the high molecular weight 
polymer degraded through the cleavage of the backbone phosphate bonds up to 12 days in 
vitro52. The nanoparticles gave enhanced reporter gene expression after intramuscular 
injections into mice as compared to naked DNA52. Alternatively, plasmid DNA 
precondensed in nanostructures by cationic copolymers can be encapsulated into 
nanospheres. Plasmid DNA compelxed with two polylysine-based dendrons had greater 
encapsulation efficiency than naked plasmid DNA into PLGA nanospheres (less than 1μm in 
size), and displayed decreased release rate53.   
 
 
4.2 Microspheres 
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Molecules of plasmid DNA encapsulated into the microspheres of degradable polymers 
can provide sustained gene delivery in remote parts of the body after subcutaneous or intra-
peritoneal injections using conventional syringes54,55 or oral delivery56-58. These microspheres 
are not readily internalized by the cells, but are retained in the tissue providing prolonged 
DNA release. The released DNA can transfect the cells at the delivery site with the protein 
product acting locally or distributed systematically. Because the microspheres are too large to 
enter the cells by endocytosis, they can be preferentially up-taken by phagocytic cells such 
macrophages by size exclusion. Thus, microspheres provide ideal DNA carriers for 
vaccination or induction of cytotoxic T cell response. Microspheres of polymers that display 
bioadhesive properties are further suitable for mucosal immunization and can be delivered 
orally56,57,59. Mucosal immunization through gastrointestinal, nasal, or vaginal routes are 
most desirable because most pathogens enter through these routes60, and induction of 
mucosal immunity offers the most effective line of defense at the port of entry61. DNA 
loaded microspheres of bio-adhesive polymers have been shown to be absorbed by the mucus 
and traverse through the mucosal barriers while protecting the DNA against nucleases57,59. 
Further, it is difficult for microspheres to diffuse out of the injected tissue to other sites 
because of their size and thus selective gene expression at the site of injection (e.g. localized 
tumors) can be obtained preventing distribution to distant sites No accumulation of 
radioactive-labeled DNA was detected in liver, kidney, or thyroid gland after subcutaneous 
injection of gelatin microspheres containing plasmid DNA into the backs of mice54. 
Fast degrading hydrophobic polymer microspheres containing surface carboxylic acid 
groups display biological adhesive properties and can be absorbed by gastro-intestinal mucus 
and cellular linings. This is aids in delaying the passage of such DNA loaded microspheres 
through gastrointestinal tract after oral administration, increasing the DNA delivery to the 
circulation56,62. Bioerodible and biologically adhesive microspheres  (0.1-1 μm diameter) of 
polyanydride copolymers of fumaric and sebacic acid, poly (FA:SA), have been shown to 
provide improved DNA uptake into cells lining the small intestine and into hepatocytes after 
oral administration56. These DNA loaded microspheres were made using phase invertion 
nanoencapsulation (PIN). They maintained contact with intestinal epithelium for extended 
 
 23
periods of time and penetrated it, through and between the cells, increasing the absorption of 
administered plasmid DNA into the circulation. 
Biocompatible and biodegradable polymers of FDA approved poly(D,L,-lactic-co-
glycolic acid) (PLGA) are among the most commonly used material for microencapsulation 
of therapeutics. The PLGA microspheres have been studied extensively for the controlled 
delivery of proteins therapeutics and antigens to macrophages for mucosal immunization, and 
have recently been adapted to encapsulate DNA and oligonucleotides. Plasmid DNA loaded 
PLGA microspheres have been shown to elicit systemic and mucosal antibody responses 
after oral administration57 and, induce cytotoxic T cell responses59. They have also been used 
to provide sustained delivery of gene silencing nucleotides (e.g. siRNAs) with expression 
persisting for longer periods than free oligonucleotides after subcutaneous injections into 
mice63. 
Although the preparation methods for PLGA microspheres have been well 
established64,65, encapsulation of highly hydrophilic therapeutic agents with large molecular 
masses like plasmid DNA is challenging. The extremely hydrophilic character of DNA could 
lead to low entrapment levels and high initial release rates. The acidic degradation products 
from PLGA might also degrade the encapsulated DNA. Different strategies have been 
explored to improve the loading efficiency and stability of DNA into PLGA-type 
microspheres. One of the most common techniques is the double-emulsion solvent 
evaporation method66,67. However, there is partial degradation of the plasmid DNA due to the 
shear stress68 induced during homogenization process and buffer salt crystallization during 
freeze-drying which deleteriously convert plasmid from the supercoiled form to the nicked or 
linear form69,70. Also this process gives low encapsulation efficiency (~20-40%) in the 
hydrophobic core of PLGA66,71. Cryopreparation is another technique for 
microencapsulation, where aqueous phase of the primary emulsion containing the plasmid 
DNA is frozen, resulting in a solid particulate suspension70,72. Because shear stress is zero 
within a solid, minimum damage is caused to the frozen plasmid DNA during 
homogenization to form secondary emulsion68. This process also gives higher encapsulation 
efficiency (~85%) because diffusion of frozen DNA out of microspheres is prevented during 
homogenization. Inclusion of saccharides in the primary emlusion have been shown to 
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disrupt the formation of DNA-nicking crystals during homogenization and lyophilization, 
preserving its super-coiled topology70. Spray-drying method is another DNA 
microencapsulation method, where aqueous DNA solution is dispersed in organic polymer 
solution (ethyl formate, or methylene chloride) by sonication, and resulting water/oil 
dispersions are spray dried73,74. Different variables like amount of DNA, solvent for polymer, 
addition of NaHCO3 to aqueous DNA solution, sonication time, etc need to be optimized for 
highest encapsulation efficiency and retaining DNA integrity73,74. The process gives 
encapsulation efficiency between 30 to 100%, with higher ones giving higher burst release. 
Composition and molecular weight (MW) of the PLGA polymers affects the release 
profile of encapsulated DNA71,75, and affects the hydrophobicity of the microspheres, 
influencing their interaction with cells and mucosal membranes. Microspheres made with 
high MW polymers or with higher concentration of polymer can retain DNA for longer times 
due to denser polymer network or increased particle wall thickness. However, in vivo, the 
microspheres made with low MW polymers gave significantly prolonged gene expression 
that sustained up to 172 days as compared to high MW polymers where expression decreased 
in only 14 days72. High MW PLG microspheres were found to aggregate to a greater extent 
than the low MW PLG. Polymer degradation generally decreases the hydrophobicity76 and 
thus the faster degrading polymers would be less likely to aggregate. Thus, it was suggested 
that faster degrading low MW PLG microspheres had higher surface hydrophilicities that 
reduced their aggregation providing a larger surface area for gradual release of DNA in the 
cellular microenvironment72. Hydrophilic PLGA polymers give higher encapsulation 
efficiency and faster release of intact DNA compared to hydrophobic ones66,73,75. They also 
show higher rates of phagocyotosis by macrophages and dendritic cells without affecting 
their viability73.  
Biodegradable microspheres of cationized gelatin present another interesting system for 
sustained gene delivery. Gelatin is prepared form collagen, and can be readily cationized by 
introducing amine residues on to its carboxyl groups77. The micro-encapsulated DNA is 
electrostatically immobilized to the polymer matrix and is released as the microspheres are 
degraded by proteases that make the cross-linked gelatin soluble in water. This release 
mechanism is different from that based on plasmid DNA diffusion from the release carriers, 
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as observed with PLGA microspheres. Because released DNA can be bound to the degraded 
fragments of cationized gelatin, this further aids in the DNA protection against degradation 
and its cellular uptake. The kinetics of release can be controlled by the extent of crosslinking 
in gelatin. However, the duration of DNA release is limited by the enzymatic degradation of 
gelatin, observed up to ~3-4 weeks in vivo54,78. Microspheres of cationized gelatin have been 
shown to provide sustained and enhanced gene expression in vivo (up to 28 days) suppressing 
tumor metastasis and arresting the progress of disseminated pancreatic cancer cells54,55. 
Sustained release of matrix metalloproteinase gene from gelatin microspheres was shown to 
prevent the onset of renal sclerosis in streptozotocin-induced diabetic mice78. Microspheres 
containing siVEGF (a DNA vector based on a small interfering (si) RNA system that targets 
Vascular endothelial growth factor (VEGF)) were used to normalize tumor vasculature and 
have been shown to inhibit tumor growth in a NRS-1 squamous cell carcinoma xenograft 
model79. The gelatin microspheres were found around the tumor up to 10 days after injection 
while free siVEGF had vanished by that time.  
Plasmid DNA loaded chitosan microspheres have been used shown to provide long term 
gene delivery in vivo80,81. Cationic chitosan electrostatically binds DNA to form  
homogeneous and stable microparticles, providing a non-immunogenic and non-toxic system 
for mucosal delivery of plasmid DNA82. Plasmid loaded chitosan microspheres (1.45-2 μm) 
prepared by complex coacervation process using a precipitation technique83,84 gave high 
plasmid DNA encapsulation efficiency (82-92%). Sonication and organic solvents are not 
used for the preparation of chitosan microspheres, inflicting minimum damage to the DNA 
integrity. Encapsulated interleukin-2 (IL-2) expression plasmid DNA was continuously 
released from chitosan microspheres for as long as 140 days in vitro that provided similar IL-
2 expression as obtained with lipofectin, suggesting useful strategy for long term gene based 
immunotherapy85. Molecular weight and concentration of chitosan, along with amount of 
plasmid DNA affected the in vitro release profile from the microspheres80,85. Intramuscular 
injection of microspheres loaded with two plasmids encoding beta-galactosidase and 
luciferase productions gave high protein expression for both genes in mice that was sustained 
up to 12 weeks post-injection81. 
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Yun et al86 prepared hyaluronan (HA) microspheres loaded with DNA by crosslinking 
native HA using an adipic dihydrazide crosslinking chemistry at room temperatures, avoiding 
use of any organic solvents, and showed an extended release of intact DNA from these 
microspheres up to 2 months. The release rates could be controlled by adjusting the extent of 
crosslinking in the microspheres. Hyaluronan is a naturally occurring glycosaminoglycan 
distributed throughout the ECM, connective tissues, and organs of all higher animals, and is 
therefore a suitable polymer for delivery devices demanding long-term biocompatibility. 
The microspheres can be coated with antibodies or ligands to selectively adhere to cells 
expressing those receptors. HA-DNA microspheres coated with a humanized mAb to E- and 
P-selectin (by conjugating with HuEP) showed more than 40 fold increase in the adhesion of 
HUVECs activated by IL-β relative to unactivated HUVECs, and a six-fold increase in 
adhesion to CHO-P (Chinese hamster ovary cells stably expressing P-selectin) relative to 
CHO cells86. 
Microspheres have also been used for sustained delivery of viral vectors in gene therapy 
to reduce their immunogenicity and increase their half-life in tissues30. Adenoviral vectors 
were microencapsulated in biodegradable chitosan microspheres by ionotropic coacervation 
of chitosan with encapsulation efficiency higher than 84%87. In vitro, the release of viral 
vector in aqueous media was negligible but, when in contact with monolayers of the cells, an 
effective release of bioactive adenovirus was obtained. Thus, encapsulation in microparticles 
not only protect the adenovirus from the external medium, but can also delay their release 
that is fully dependent on cell contact, an advantage for mucosal vaccination purposes. The 
formulations developed were able to maintain AdV infectivity and permit a delayed release 
of the bioactives that is promoted by digestion in situ of the microparticles by the cell 
monolayers. In another study, it was demonstrated that encapsulation of recombinant 
adenovirus in biodegradable alginate microparticles effectively circumvented the vector-
specific immune response31. Reporter gene expression was significantly higher in immunized 
mice (containing virus-specific antibodies) when microencapsulated viral vectors were used 
compared to non-encapsulated ones. Recently, it was demonstrated that injection of 
degradable starch microspheres loaded with adenovirus vector (lacZ) through hepatic artery  
(tumor feeding) produced enhanced and cancer-selective gene expression in hepatocellular 
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carcinoma in rats88. Starch microspheres could be trapped within tumor to locally release 
gene vector that provided sustained and selective gene transfer than vector alone. 
Molding microspheres in 3-D constructs supplements their drug delivery capacity with 
the structural support afforded by a scaffold. Microspheres with encapsulated proteins/DNA 
can be embedded within hydrogel or matrices, resulting in prolonged release profile of 
vectors. These points are discussed in the implantable hydrogels and scaffolds section below. 
 
4.3 Hydrogels 
Hydrogels are very attractive delivery systems for hydrophilic macromolecules like 
DNA as the entrapped vectors are soluble in the hydrated gel, enabling high loading 
efficiency. They provide a protective environment for DNA, and allow easy control of 
encapsulated gene transport by adjusting cross-linking densities and modulating network 
structure. Hydrogels are formed by chemical or physical crosslinking of special class of 
polymers that imbibe a considerable amount of water while maintaining their shape. They are 
composed of hydrophilic materials that can either be synthetic or natural, or a combination of 
two. Hydrogels of naturally occurring biopolymers like chitosan, alginate, gelatin, collagen, 
and hyaluronic acid have high DNA encapsulation efficiency and are much less damaging to 
DNA than synthetic polymers and their degradation products. DNA is released from these 
hydrogels by ionic exchange or degradation of the biopolymer by cell-secreted enzymes in 
the tissue matrix. However, this gives less control over the DNA release profiles from these 
hydrogels and can reduce the ability to sustain release for longer period of times. Synthetic 
biomaterials like polyanhydrides, functionalized PEG, and amphiphilic block copolymers can 
be used to make self-assembled or cross-linked hydrogels. The mechanical properties and 
degradation rate of such hydrogels can be manipulated by varying the extent of cross-linking 
or concentration of polymer networks. They can be bioerodible, or incorporate hydrolysable 
crosslinkers or matrix metalloproteinase sites (MMP, targets of invading macrophages). The 
hydrolysable blocks degrade over time, leading to a decrease in the gel cross linking density, 
mass loss, and ultimate DNA release. Different monomer chemistries and molecular weights 
can be used to control gel dissolution rates. Synthetic hydrogels offer broader control over 
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the release characteristics than natural polymers but, the gelation conditions and the chemical 
environment must be carefully selected to limit damage of DNA integrity.  
 
4.3.1 In-situ forming Hydrogels 
Polymers whose aqueous solutions can be subcutaneously injected by needle in the 
desired tissue, organ, or body cavity followed by instant in situ hydrogel formation that 
maintains its integrity for extended period of time form a special class of controlled delivery 
systems with distinct advantages over matrices that need to be surgically implanted. The 
flowing nature of these hydrogels during injection further enables a good fit when injected 
into a body cavity or defect.  The in situ gelation can occur either by chemical 
crosslinking23,89 or by self-assembly of polymer network in response to physiological 
environmental stimuli like temperature90 or pH91. The simplicity of preparing pharmaceutical 
formulation in aqueous solution, convenient administration, and in situ gel formation without 
any organic solvents / copolymerization agents/ or external stimulation makes this a 
convenient non-invasive controlled drug delivery system. Under in vivo conditions, the 
ingress of tissue fluid into the hydrogel results in dissolution or degradation of the hydrogel 
matrix facilitating a sustained release of encapsulated DNA. Typically, these hydrogels 
dissolve or degrade into non-toxic components that can be excreted through the renal 
clearance in the body precluding invasive removal procedures. Though many studies have 
been reported on the use of in situ gelling hydrogels for delivering protein therapeutics92-94 
and hydrophobic drugs95-97, their use for gene delivery has not been extensively explored. 
Genetically produced silk and elastin like polymers (SELP) that undergo irreversible sol 
to gel transition when transferred from room to body temperature have been investigated as 
injectable sustained gene delivery systems. SELPs consist of alternating silk-like (Gly-Ala-
Gly-Ala-Gly-Ser) and elastin-like (Gly-Val-Gly-Val-Pro) blocks that can be produced by 
synthetic gene-directed biological production methods. SELPs with appropriate sequence and 
composition self-assemble at physiological temperatures to form hydrogels through 
crystallization of the silk-like blocks of the polymer chains, an irreversible, kinetic process98. 
Once localized in situ following injection, the entrapped DNA can be released from 
hydrogels by an ion-exchange mechanism while the polymer matrix degrades into relatively 
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nontoxic amino acids99. Release rates can be controlled by manipulating polymer 
concentration, cure time (time incubated at 37°C), and adding excipients that prevent or 
promote hydrogen-bond mediated chain crystallization. Sustained release of entrapped DNA 
from these hydrogels up to 30 days has been shown in vitro. The ability to precisely 
customize the structure and physicochemical properties of these protein polymers using 
recombinant techniques renders this class of polymers an interesting candidate for further 
evaluation in controlled gene delivery. 
Amphiphilic multi-block copolymers, containing hydrophobic and hydrophilic polymer 
blocks within their molecular architecture, display thermo-reversible gelation and have been 
well investigated for sustained protein and gene delivery100,101. Above the lower critical 
solution temperature (LCST) of the hydrophobic block, where it dehydrates, these 
copolymers self-assemble to form micellar like structures with a hydrophobic core stabilized 
by a hydrophilic corona. Above a critical gelation temperature (CGC), these micellar 
solutions form a lyotropic liquid crystalline phase that results in a transparent hydrogel. The 
solution to hydrogel transition is driven by an increase in volume fraction of copolymer 
micelles (as in PEG-PPO-PEG), or an increase in the size of micelles (increase in 
aggregation number, as in PEG-PLGA-PEG) due to hydrophobic interactions between 
collapsed hydrophobic blocks resulting in ordered packing of the micelles into a crystalline 
lattice100. As the water diffuses into the gel matrix, solvating a boundary layer of gel and 
decreasing the polymer concentration below CGC, the gel boundary dissolves, allowing the 
entrapped plasmid DNA to be released along with polymer molecules. They rely on 
diffusion, and disruption of weak interactions between hydrophilic and hydrophobic 
components to release DNA. Using simple, free volume-based theories, mean field theory 
and percolation theory the diffusion in heterogeneous polymer networks can be described102. 
Thermoresponsive Pluronic (PEG-PPO-PEG) gels have been used for localization and 
sustained delivery of plasmid DNA and viral vectors. Stereotaxic delivery of lentiviral vector 
in 15% Pluronic F127 to the rat brain resulted in transduction of cells, predominantly 
astrocytes, close to the injection site103. Using a localized Pluronic gel based depot of viral 
vector release in the central nervous system (CNS) would have application in brain injury or 
ischemia and spinal cord trauma with the area of tissue damage capturing the semi-solid gel. 
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Delivery of adenoviral vector in poloxamer 407 gel via an endoluminal route to the 
vasculature of balloon-injured rat carotid arteries has been shown to increase local arterial 
transfection efficiency104. Recently, Pluronic F127 gel containing adenoviral vector has been 
applied to the perivascular surface of the common carotid artery of the rat105. In vivo gene 
transfer to the adventitia resulted in sustained transgene expression capable of labeling 
migrating adventitial cells within the media and neointima of injured vessels. 
However, self-assembled Pluronic hydrogels have low mechanical strength, and a 
loosely cross-linked network structure, which results in rapid release of entrapped DNA 
molecules through diffusion during the early incubation stage106. Chemical modifications to 
Pluronics have been made which alter the gelation characteristics of the gel. The common 
systems used to modify Pluronic copolymers are polyacrylic acids, polybases, and 
biodegradable polyesters107. Addition of polyethylene glycol108 and cellulose derivatives109 to 
Pluronic F127 have been used to reduce the dissolution rate of drug from the gel. The 
addition of polyacrylic acid110 or polycarbophil has increased the muco-adhesiveness of 
Pluronics for improved nasal delivery of plasmid DNA111.  
Pluronics were also modified at both ends with functional groups to improve the 
mechanical properties of hydrogels. A family of novel pentablock self-assembling 
copolymers has been developed by adding PDEAEM to the sides of Pluronic block 
copolymers using an ATRP reaction scheme by our group112. While the copolymers show 
reversible thermo-reversible gelation properties like Pluronics113,114, the cationic PDEAEM 
groups condense the negatively charged DNA and show pH buffering capacity at low pH115. 
The polyplexes of the copolymers are biocompatible and give DNA transfection efficiency 
comparable to that of commercially available linear PEI ExGen 500®116. Copolymers 
condense DNA in solution at room-temperature that instantly form an elastic gel in situ after 
injection into the body (illustrated in Fig. 1). The gels dissolve in tissue fluid to release 
condensed DNA. While gels act as a DNA depot, the released DNA is also protected inside 
polyplex nanoparticles in both ECM and inside cells. The amphiphilic copolymers aid in the 
intracellular localization of polymer/DNA complexes by endocytosis and their release from 
endosomes after entrapment. Because plasmid DNA is electrostatically bound to copolymers, 
its release is controlled only by the dissolution profile of the hydrogels. The plasmid cannot 
 
 31
freely diffuse out of the polymeric network, preventing initial burst observed in gels/martices 
of non-ionic polymers where DNA release is governed by diffusion through pores. The 100 
μl gels of copolymer at 15 wt% concentration have been shown to release condensed DNA 
up to 7 days in vitro, compared to complete naked DNA release in less than a day using only 
Pluronic gels (unpublished data). The release profile can be easily modulated by tailoring the 
cationic content in the copolymers, and by adjusting concentration of copolymers in the 
formulation. These gels also a have higher storage modulus as compared to Pluronic gels, 
and have been shown to be easily injectable into subcutaneous tumors and skeletal muscles 
by syringes equipped with 27 gauge needles. Such biocompatible cationic self-assembling 
copolymers display great potential as sustained gene delivery devices, and have distinct 
advantages over systems that release naked DNA. 
Another example of such thermosensitive polymers is PEG-PLGA-PEG. When polymer 
solution containing a plasmid DNA encoding TGF-ß1 was administered to the excisional 
wounds at the back of diabetic mice, it formed an adhesive film in situ. Significantly 
accelerated re-epithelializaion, increased cell proliferation, and organized collagen were 
observed in the wound bed treated with thermosensitive hydrogel containing plasmid TGF-
ß1 compared to controls117. 
Polymers containing hydrolytically labile linkages that form chemically crosslinked 
hydrogels on reacting with other polymers, and are in injectable solution form for a few 
minutes after reconstitution of polymer components have also been shown as injectable 
controlled delivery systems. Functionalized branched PEG polymers, with one of them 
containing hydrolytically liable ester linkages, formed crosslinked gels via amide linkages 
that could encapsulate plasmid DNA into the polymer network without any degradation23. 
The formulation was injectable within 15 minutes after reconstitution of polymer 
components and formed crosslinked matrix in situ. The reacting PEG polymers do not 
interact with DNA but entrap it in the matrix. The gel biodegraded in tissue fluid over time 
(up to 28 days) giving a prolonged release of plasmid DNA, and significantly increased the 
duration of gene expression in immunocompetent mice up to 92 days compared to only 30 
days with naked DNA injections.   
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4.3.2 Implantable hydrogels 
4.3.2.1 Chemically crosslinked hydrogels 
Chemically crosslinked hydrogels have the flexibility to tune the degradation kinetics of 
the gels to produce tailored release profiles. Agarose, a natural polysaccharide derived from 
red algae, forms thermoreversible hydrogels, and have been used provide sustained release of 
DNA in vivo. Poly-L-lysine compacted DNA encapsulated in agarose gels provided sustained 
gene expression up to 35 days in skin tissues after intra-dermal injections in mice, compared 
to 5-7 days obtained with injections in solution, and invoked a wound-healing response 
through day 14118. The agarose hydrogel containing DNA was first gelled in 0.3ml syringe, 
and then injected intradermally using a 28.5 gauge needle. The encapsulated DNA is released 
by diffusion from the hydrogel. The DNA release profile can be controlled by changing the 
agarose concentration. Recently, controlled release of a DNA vaccine from intradermally 
implanted agarose hydrogels was shown to provide a sustained bovine herpesvirus 1-specific 
immune response similar to that obtained with two discrete administration of the vaccine 4 
weeks apart in a bovine model suggesting a novel slow-release vaccination tool in cattle 
where repeated administrations are frequently necessary119.  
Biodegradable hydrogels of gelatin and cationized gelatin offer physiochemical and 
electrostatic immobilization of plasmid DNA in the polymer matrix. Aqueous solutions of 
gelatin can be cast into various molds and made into hydrogel sheets at 4°C, which  can be 
cut into small discs (5 x5 x 51 mm3) for implanting into a localized tissue in body120. Such a  
gelatin hydrogel had a sponge with pore-size of 500 μm120. Plasmid DNA can be 
impregnated into the freeze-dried hydrogel sheets by swelling process, dropping it in solution 
on the sheets and incubating them at 4°C overnight. Encapsulated DNA is released as the 
hydrogel degrades to generate water-soluble gelatin fragments. Gelatin doesn’t degrade by 
simple hydrolysis, but is degraded by proteolysis, making it suitable for prolonged drug 
release. Gelatin hydrogels can be chemically crosslinked using reagents like glutaraldehyde 
for making denser (less water content) network, and increase the duration of biodegradation. 
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The in vivo degradation period of these hydrogels can thus be controlled from 7 to 21 ways 
depending on degree of crosslinking induced120,121. It has been observed that only gelatin 
hydrogels with higher degree of cationization (41.6 mol% or more) provided significant gene 
expression in vivo perhaps because they release DNA condensed with cationized gelatin 
fragments that improve cell adhesion and gene transfection121. Cationized gelatin-based 
hydrogels have been shown to maintain significantly higher gene expression than naked 
DNA injections for more than 21 days in the femoral muscles of mice120,121. Another 
advantage of these hydrogels is that their profile of controlled release is not influenced by the 
shape of their mold.  
Biodegradable synthetic hydrogels based on the water-soluble polymer 
oligo(poly(ethylene glycol) fumarate) (OPF) have been shown to encapsulate DNA, retain its 
activity, and provide prolonged release up to 62 days, depending of degree of crosslinking122. 
The hydrogels can be crosslinked under physiological conditions to physically entrap 
plasmid DNA, and can be molded into sheets. The sheets can be cut into discs of 
approximately 6 mm diameter and 1 mm thickness, and implanted into the body at the site of 
therapy. Composites of plasmid DNA-loaded cationized gelatin microspheres in an 
oligo(poly(ethylene glycol)fumarate) (OPF) hydrogel were found to prolong the 
bioavailability of plasmid DNA upto 42 days relative to the injected plasmid DNA solution 
control and non-embedded cationized gelatin microspheres (7 to 21 days) in an in vivo 
murine model123. While the plasmid release form gelatin microspheres was limited by 
enzymatic degradation, the duration of release can be modulated by embedding the 
microspheres in OPF gels and controlling the release by modulating the crosslinking in the 
OPF gels. The sustained release of plasmid DNA from the composite group could be 
explained by the observed slower degradation of gelatin microspheres within the OPF, and 
the prolonged retention of degraded gelatin/ DNA fragments in the hydrogel. 
 
4.3.2.2 Photo-crosslinked hydrogels 
Gels crosslinked through photo-polymerization of the monomer and DNA solutions 
enable spatial and temporal control of gel formation (and gel dissolution) under physiological 
conditions106,124. For example, by spatially modulating the degree of crosslinking, the 
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encapsulated DNA can be localized on the surface of the gels for easier uptake by infiltrating 
cell in a tissue engineering application. Degree of polymerization can be easily modulated by 
controlling the UV irradiation time106. Gels are formed by exposing a solution of monomer 
and DNA, containing a photoinitiator for polymerization, to light (eg UV at 365nm, 5-11 
mW/cm2) for 10-30min125. It is important in this process to identify methods for protecting 
DNA from detrimental effects of photoinitiator and free radicals126. Addition of transfection 
agents and/or antioxidants can greatly reduce DNA damage by radicals126. Hydrogels formed 
from photo-polymerization of multifunctional PEG monomers were shown to encapsulate 
DNA with minimal damage, and release biologically active plasmid DNA for periods of 6-
100 days depending upon the degree of photopolymerization125. Photo-polymerized di-
methacrylated oligo(lactide)-b-poly(ethylene glycol)-b-oligo(lactide) macromer was used as 
a bioerodible hydrogel platform for delivering plasmid DNA. Gold stents coated with photo-
polymerized styrenated gelatin have been shown to provide sustained release and expression 
of encapsulated DNA (adenoviral vector) up to 3 weeks in carotid arteries of rabbit127. The 
study confirmed that released DNA retained its activity after photo-encapsulation in gelatin 
hydrogels.  
Multifunctional anhydride monomers were photocrosslinked to produce hydrophobic, 
highly crosslinked polymer networks that degrade by surface erosion. Surface-eroding 
polymers can deliver molecules of a wide range of sizes at sustained, steady rates, which is 
advantageous for DNA delivery where the high molecular weight may complicate control of 
the release profiles. However, when plasmid DNA was released from photocrosslinked 
polyanhydride matrices, DNA recovery was low ( 25%)128. To reduce the damaging effects 
of polymer degradation and photoencapsulation, DNA was pre-encapsulated in alginate 
microparticles, which served as temporary coating that quickly dissolved upon microparticle 
release from the polyanhydride matrix, and increased the DNA recovery to 90%. Such 
hydrogels can provide both, a structural support and, a controlled release profile to the 
encapsulated DNA. 
Recently, photopolymerized biodegradable hydrogels of Pluronic and HA were shown as 
potential controlled gene delivery platforms106. Pluronic F127 was di-acrylated to form a 
macromer and chemically cross-linked in a micellar gel state by UV irradiation to form a 
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hydrogel in the presence or absence of vinyl group-modified hyaluronic acid (HA). 
Mechanical strength of photo-cross-linked Pluronic hydrogels was much higher than that of 
physical Pluronic hydrogels produced by simply increasing the temperature. UV irradiation 
time and the presence of the vinyl group-modified HA affected the mechanical property of 
Pluronic hydrogels to a great extent, giving less swelling ratios and slower degradation 
profile. They showed much reduced burst releases and more sustained DNA release patterns. 
Functionally active DNA was slowly released from photo-cross-linked hydrogels over 10 
days in vitro and its profile could be controlled by the degree of cross-linking.  
While photo-polymerized hydrogels could be a potential candidate for temporal and 
spatially controlled sustained gene delivery, UV irradiation process should be carefully 
designed to achieve a desirable DNA release kinetic rate with minimal DNA structural 
damage. For instance, the UV curing time could be shortened by using more potent photo-
sensitizers and/or using other vinyl monomers and macromers106. 
 
 
4.4 Implantable polymeric scaffolds 
Encapsulating DNA therapeutics in a polymeric matrix that can be implanted at the site 
of injury or disease integrates the provision of controlled gene delivery with the structural 
support afforded by a scaffold. The three dimensional scaffold can provide support for cell 
adhesion and migration, and a template for tissue formation, while also creating and 
maintaining space for it. The scaffold provides a unique opportunity to control both the 
sustained delivery of genes and the cellular environment in which the gene transfer occurs, 
while the matrix retains the DNA at the site of implantation in a protective environment. The 
matrix can be loaded with a higher amount of DNA providing prolonged therapeutic benefits 
as compared to particulate gene delivery vehicles where the amount of DNA encapsulated 
depends on the charge ratio of polymer to DNA. Besides, such matrices would distribute 
DNA throughout the 3D space of the therapy site which may be more effective than injection 
of bolus doses in aqueous solutions. The basic properties of the scaffold can also be 
augmented to create a microenvironment that exploits synergy between multiple growth and 
transcription factors. Different combinations of genes and proteins can be combined in the 
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matrix, and various adhesion molecules, peptides and ECM matrix proteins can be 
immobilized to the biomaterials to regulate cellular interactions with the matrix. Specific 
cellular cues can be incorporated in order to target the attraction of the cell types to be 
transfected. Thus, while the matrix controls the release kinetics of the entrapped genes, it can 
also provide a more complex conducive and inductive environment for migration of targeted 
cells. Another advantage of such polymeric implants is the possibility of their removal by a 
small surgical procedure if adverse events necessitate discontinuation of therapy. The basic 
requirements for a gene delivery scaffold is being biocompatible, have sufficient mechanical 
integrity, large surface area, and an ideal surface morphology. If used for a tissue 
regeneration application, the scaffold should also be biodegradable as it cannot be removed 
surgically after neotissue growth. Various synthetic and natural polymers have been 
investigated to form such implantable controlled gene delivery devices.  
 
4.4.1 Biodegradable matrices 
Scaffolds fabricated with natural polymers, such as collagen and hyaluronan (HA), 
degrade by the cell secreted enzymes and allow the cells to migrate by specific cellular 
interactions within the matrix. They have the advantage of having the intrinsic property of 
the environmental responsiveness via degradation and remodeling by cell secreted enzymes. 
They are generally non-toxic even at high concentrations as they degrade into components 
that are similar to ECMs compostion and can, therefore, be readily incorporated into bolus 
matrix delivery systems.  
Sponges made from such natural biopolymers impregnated with DNA, termed as “Gene 
activated matrix” (GAM)129, have been shown to be therapeutically effective sustained gene 
delivery systems in vivo. Plasmid DNA can be encapsulated by absorption from aqueous 
solution onto pre-formed collagen sponges to form GAM capable of gene delivery. These 
three-dimensional, moldable, porous GAMs act as an acellular scaffold that provide a 
platform for gene delivery, while acting as bioreactors for seeding cells to secrete plasmid-
encoded proteins that enhance cartilage natural healing process. The encapsulation content of 
DNA can be controlled by varying the polymer concentration and the conditions of the 
incorporation process. These biocompatible, naturally derived polymer matrices permit cell 
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infiltration for DNA uptake. Plasmid release as the matrix degrades provides a secondary 
mechanism for gene transfer to surrounding cells. Collagen based GAMs for sustained gene 
delivery have been implanted at different body sites for localized therapy and tissue 
engineering, including bone9,130, cartilage131, central nervous system132, wounds133,134, and 
cardiovascular tissues135,136. This flexibility  obviates the need for prior graft colonization in 
cell culture. Bovine-derived collagen-I based GAM have been implanted into an adult rat 
femur130 and a canine bone defect model9. Scaffolds loaded with 1mg of DNA in the rat 
model (with 5-mm gap defect) were capable of transfecting the migrating cells, and 
maintaining prolonged protein expression for up to 3 weeks that resulted in a significant 
increase in bone regeneration compared to localized plasmid or systemic hormone delivery. 
In the canine model (with 1cm bone gap) collagen matrix with 100mg of DNA were 
implanted, and the union of the gap was achieved after 8 weeks of treatment. The local 
retention and expression of plasmid DNA by granulation tissue was demonstrated for 6 
weeks after implantation. 
Collagen sponges loaded with DNA precondensed with cationic polymer or liposomes 
are superior in mediating sustained gene delivery in vitro and in vivo as compared to naked 
DNA-loaded sponges, in terms of both level and duration of gene expression137. Protective 
copolymers are particularly advantageous in promoting the transfection capacity of polyplex-
loaded sponges upon subcutaneous implantation, likely due to their stabilizing and 
opsonization-inhibiting properties. The release of DNA complexes is significantly slower 
than that of naked DNA because of the differences in physical properties, providing 
prolonged therapeutic benefits.  
Other natural proteic polymers, such as atecollagen138 and fibrin136, or polysaccharidic 
materials, such as chitosan-gelatin139, glycosaminoglycan140, and hyaluronic acid141,142, have 
also been used to substitute collagen in GAMs. Gelatin sponge matrix loaded with canarypox 
virus ALVAC recombinants encoding the murine tumor necrosis factor-α, produced 
statistically significant growth inhibition of established tumor nodules after intratumoral 
inoculation143. Hybrid collagen-gelatin, and collagen-glycosylaminoglycan scaffold have 
demonstrated enhanced activity over bare collagen GAMs. These all natural cationic matrices 
can encapsulate more plasmid DNA, and provide greater control over the fabrication of 
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scaffolds with appropriate porousness and mechanical property. For example, chitosan 
increase the rate of gel formation, and the strength of the resulting gels, and gelatin changes 
the brittleness of chitosan reversely144.  
Cylindrical minipellets (0.6mm diameter, 10mm length) of atecollagen loaded with 
plasmid DNA have been shown to provide controlled release of the gene, maintaining high 
platelet count and sustained protein expression levels in serum up to 60 days after single 
intramuscular injection138. Intact gene was detected in peripheral blood up to 40 days while it 
was barely detectable after 21 days following naked DNA injections. Atecollagen is a very 
biocompatible material, and is prepared by eliminating antigenic telopeptides from the ends 
of the collagen molecule by pepsin treatment145,146. Adding 30 wt% glucose to the 
formulation made the collagen matrix structure made coarser, allowing substantial controlled 
release of DNA. The atecollagen implant remains as a solid mass that can be handled easily, 
and can be removed surgically with the vectors to regulate the duration of gene expression138.  
 
4.4.2 Synthetic scaffolds 
Scaffolds synthesized with synthetic polymers like PLG are typically highly porous, 
which can allow efficient nutrient transport and cellular infiltration. In a tissue engineering 
application, cell infiltration from surrounding tissue is important for integration of the 
engineered tissue with the host and for the development of a vascular network through out 
the tissue to supply necessary metabolites once the tissue has developed. Synthetic polymers 
are more versatile than natural polymers for synthesizing gene delivery matrices as they 
provide greater control over matrix macrostructure, mechanical properties and degradation 
time. Hydrophilic polymers such as PEG can be crosslinked and funcationlized147.  Most 
commonly used synthetic polymers for gene delivery matrices are made of polylactic acid 
(PLA) which degrades within the human body to form lactic acid, a naturally occurring 
chemical which is easily removed from the body. Other similarily used materials include 
polyglycolic acid (PGA) and polycaprolactone (PCL)- their degradation mechanism is 
similar to that of PLA, however, they exhibit a faster and a slower rate of degradation 
compared to PLA, respectively. Copolymers of these materials, like FDA approved PLG, can 
be designed to degrade over times ranging from weeks to more than a year. Scaffolds can be 
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formed as a mesh of fibers wound together or the polymer can be processed into a highly 
porous structure147-150. 
Mixtures of DNA and PLGA have been electrospun to form a non-woven nanofibrous 
and nanocomposite scaffold. The entrapped DNA was released from such scaffolds by 
controlled degradation of the biodegradable PLGA, transfecting cells adhered to the 
matrix151. Such scaffolds capitalize on the molecular interaction of block copolymers and 
plasmid DNA in solution, giving rise to novel structures and additional functionality. Three-
dimensional scaffolds of DNA loaded PLG microspheres can be fabricated by the assembly 
and subsequent fusion of microspheres using a gas foaming/particulate leaching 
process148,152. The scaffolds had an interconnected open pore structure with high porosity, 
and exhibited sustained release of active DNA in vitro for 21 days, with minimal burst during 
the initial phase of release. Control over the release rates could be obtained through 
manipulating the properties of the polymer, microspheres diameter, and the foaming process. 
Such PLG matrices have been shown to be effective for sustained gene delivery in various 
applications of tissue engineering in vivo, facilitating enhanced matrix deposition and blood 
vessel formation in the developing tissue after implantation153.  
Biocompatible FDA approved Evac poly(ethylene-co-vinyl acetate) matrices loaded 
efficiently with up to 100mg of DNA have been shown to provide both short term and long 
term controlled release of DNA, up to 1 month, maintaining the integrity and activity of 
released plasmids67. DNA release from these Evac matrices was controlled by diffusion, and 
depended only on the size of the entrapped DNA, not on the size and geometry of the 
matrices. DNA release profiles were bi-phasic, with an initial burst followed by a slow but 
continuous release. Evac matrices have been shown as efficient and convenient vehicles for 
DNA vaccination via the murine vaginal tract that provided long-term immunity for as long 
as 56 days154. This immunization regimen avoided the need for multiple immunizations and 
invasive surgery required with other investigated methods of DNA vaccination in vaginal 
tracts155,156. The matrices were easily implanted by a simple surgical procedure157 into the 
vaginal tract of mice, and provided sustained DNA release to the vaginal mucosal surface 
overcoming the barriers caused by the estrus cycle and physical environment of the vaginal 
tract. The matrices can be removed by a simple surgery after the treatment. 
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4.4.3 Substrate immobilization  
Substrate immobilization is an alternative technique where DNA is actually immobilized 
to a surface or biomaterial that supports cell adhesion. The targeted cells migrate to the 
scaffold and engulf the DNA tethered to the polymeric matrix. This puts the DNA directly 
into the cellular microenvironment, increasing its local concentration and avoiding problems 
of mass transfer limitations or complex aggregation encountered in release systems. 
Immobilization maintains the DNA locally in the matrix, limiting any potential undesirable 
diffusion to distant sites. This also prevents any systemic loss of the drug, as it is taken up 
only the infiltrating cells. Cells cultured on the substrate can internalize the DNA either 
directly from the surface, or after release of the DNA from the surface. Immobilization 
techniques are a great tool to regulate the distribution of DNA across the scaffold and create 
gradients.    
DNA or non-viral vectors complexed with DNA can be immobilized on the polymeric 
substrate through specific or non-specific interactions for delivery from the surface. Specific 
interactions can be introduced through complementary functional groups on the vector and 
surface, such as antigen/antibody or biotin/avidin. DNA complexed with PAMAM 
dendrimers were immobilized by drying onto bioerodible PLG and collagen based 
membranes and shown to give effective transfection both in vitro and in vivo in skin cells of 
mice158. Dendrimer/DNA complexes could mediate transfection after dissociation from these 
membranes and/or when retained on the surface of the membranes. DNA co-precipitated 
with calcium phosphate was adsorbed onto two and three dimensional PLG matrices, and 
SaOS-2 cells cultured on these 3D matrices were shown to efficiently internalize the 
immobilized DNA159. Biotinylated HA-DNA complexes have been immobilized to 
neutravidin modified substrates like HA-collagen hydrogel160. Cells cultured on the hydrogel 
were transfected while those adjacent to hydrogel did not. It was further shown in the same 
study that surface patterning these hydrogels with ridges and grooves could provide oriented 
cell growth.  DNA complexed with other cationic polymers like PLL and PEI, which are 
functionalized with biotin, have also been immobilized to such neutravidin substrates161,162, 
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and were shown to give 100-fold increased transgene expression in cells cultured on these 
DNA surfaces compared to bolus gene delivery of DNA complexes162. Degree of DNA 
immobilization and transgene expression were found to be dependent on the biotin content in 
the complexes. Though higher biotin contents increased immobilization, it gave decreased 
transfection. Since transfection was observed only at locations on matrices where DNA was 
immobilized, it suggested spatially controlled gene delivery is possible by immobilizing of 
DNA complexes on the substrate in a spatially controlled manner161. This can be useful in 
creating complex tissue architechtures.  
Viral vectors have also been immobilized by both non specific or specific 
antigen/antibody interactions on collagen constructs coated with anti-viral antibodies, 
preventing escape of virus to distant locations163,164. Viral functional groups can either be 
modified with antibodies or biotin residues165, or functional groups in viruses can be 
engineered enabling binding without chemical modification which could otherwise inactivate 
the virus166,167. Collagen-coated polyurethane was thiol activated and covalently bound to 
anti-adenovirus antibodies for subsequent binding to adenovirus168. Virus nonspecifically 
bound to polystyrene beads or microspheres have shown increased transduction efficiency 
and localized and targeted gene expression adjacent to the beads in contrast to free viral 
vector delivery both in vitro and in vivo169,170. 
 
 
5 Applications  
Sustained gene delivery of viral or non-viral vectors using polymeric devices can be 
employed to promote gene transfer in the cells adjacent to the implant or, in organs deep into 
the body using systemic or oral administration. An efficient gene delivery systems design 
should consider both the specific application, and the requirements for efficacy. For example 
systems developed for nerve regeneration in spinal cord injury would be very different from 
the one used to promote angiogenesis in ischemic cardiac tissue. The polymeric gene 
delivery, depending on the gene product, can be designed to produce therapeutic proteins 
locally, like in suicide gene therapy, or wound healing treatment, or distributed systemically 
by transfected cells, as in treatment of hemophilia. Table 1 lists the in vivo studies using 
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polymeric sustained gene delivery systems that demonstrated physiological responses, and 
some of the most prominent applications of sustained gene delivery are summarized in this 
section. 
 
5.1 Cancer Therapy 
Various target therapeutic genes have been identified for gene therapy against cancer 
employing strategies like immunization, blocking molecular pathways for uncontrolled 
growth or angiogenesis, and suicide gene therapy. However, current human clinical trials 
against cancer using viral vectors are limited by adverse effects of virus itself. On the other 
hand, applications using non-viral vectors are limited by short duration and low level of gene 
expression. Because cancer cells have an invasive and aggressive growth profile, it is 
important to maintain the therapeutic level of the drug for complete eradication of the tumor 
in order to prevent any dissemination and metastasis during or after treatment. A controlled 
gene delivery method can prolong the maintenance of expressed protein drug in the system 
much longer than bolus drug delivery or controlled protein release systems, and, thus, 
provide one of the most efficient ways for eradicating neoplastic cells. Local delivery of 
cancer chemotherapeutics also reduces systemic side effects while maintaining sustained 
drug levels at the site of action. 
Injection of biodegradable gelatin microspheres incorporating plasmid DNA encoding 
for NK4 protein, an antagonist for hepatocyte growth factor (HGF), have been shown to 
suppress the progress of disseminated pancreatic cancer cells in peritoneal cavity of mice by 
inhibiting growth of nascent blood vessels (angiogenesis) and increasing apoptosis in tumor 
tissue55. The controlled gene delivery enhanced and prolonged the NK4 protein level in the 
blood circulation, resulting in significantly greater suppression in tumor number and 
increased survival time of mice as compared to bolus plasmid delivery. Similar enhancement 
of tumor suppression effects of therapeutic plasmids inhibiting angiogenesis by controlled 
release gelatin microspheres were shown on mice bearing Lewis lung carcinoma tumor54, and 
in a squamous cell carcinoma xenograft model79. A marked reduction in vascularity 
accompanied the inhibition of transfected tumor. 
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5.2 Vaccination 
The advantage of a DNA-based approach is that the vaccines can be manufactured very 
rapidly and in large quantities, while yielding an efficacious immune response at low doses. 
DNA vaccines can encode multiple immunogenic epitopes at the same time, and can evoke 
both humoral and cell mediated immune responses. DNA vaccination shows promise in a 
number of areas including infectious diseases, allergy, and cancer immunotherapy. While not 
all safety concerns have been completely addressed, human trials in HIV patients are 
encouraging171. 
Long term maintenance of immunity requires repeated administration of DNA vaccine, 
which might involve side affects due to over or under dosing, and systemic loss of drug. 
Controlled gene delivery devices can circumvent this by acting as depot for DNA vectors, 
and providing sustained release. Release profiles from most of the polymeric controlled drug 
delivery modalities include an initial burst of the drug followed by slow and steady release 
for extended periods. The initial burst of gene drug may provide enough antigen to sensitize 
immune cells and initiate immune response to a new foreign antigen. The continuous relapse 
of lesser amounts of DNA may provide long-term antigen to repeatedly boost the immune 
system and maintain the pool of antibody producing cells or memory cells. By providing 
active antigen over an extended period, reliable immunization can be achieved that can be 
sustained for longer period of time. Controlled release of a DNA vaccine from intradermally 
implanted agarose hydrogels have shown to provide a sustained anti-bovine herpesvirus 1-
specific immune response similar to that obtained with two discrete administration of the 
vaccine 4 weeks apart, in calves where repeated administrations are frequently necessary119. 
Though naked DNA vaccination strategy had been limited to intramuscular, cutaneous, 
and intradermal routes of immunization, controlled gene delivery devices can be effective in 
mucosal immunization through nasal, gastrointestinal, or vaginal routes, the port of entry for 
most pathogens61. Because naked DNA is ineffective in crossing mucosal barriers, and is 
rapidly degraded by nucleases, delivery systems that protect DNA and target it to antigen-
presenting cells are essential for the success of DNA-based mucosal vaccines. DNA loaded 
microspheres and nanospheres can be absorbed by the mucus and traverse through mucosal 
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barriers, while protecting the encapsulated plasmid and releasing DNA for prolonged periods 
to maintain long-term immunity. Microspheres, because of their size, are not readily 
endocytosed, and are, therefore, preferentially up taken by the professional APCs and 
phagocytic cells. Biodegradable microspheres of PLGA containing plasmid DNA were 
shown to retain its activity and provide sustained delivery to induce cytotoxic T cell 
responses after oral administration57,73. Polymer microspheres containing surface carboxylic 
acid groups that display biological adhesive properties can be absorbed by gastrointestinal 
mucus and epithelial cells, delaying their passage through gastrointestinal system, and 
increasing the plasmid delivery to the circulation after oral administration56,62. EVac matrices 
loaded with DNA have been shown to provide long term local mucosal immunization after 
implantation in vaginal tracts of mice154. The matrices provided sustained release of DNA to 
the vaginal mucosal surface that was functionally active and capable of transfecting vaginal 
tissues. 
 
5.3 Tissue engineering  
Inductive tissue engineering involves delivering growth factors and cytokines to the 
progenitor cells in the surrounding tissue that can direct cell differentiation and induce tissue 
formation. Delivering the pharmacological doses of these short half-life factors and 
maintaining an environment with appropriate combination of signals that induce proper cell 
function and regenerate clinically useful amounts of new tissue in vivo have been critical 
challenges. Localized delivery of genes encoding these factors using polymeric scaffolds is a 
versatile technique which puts genes directly into the path of the infiltrating cells, directing 
specific cell processes. While sustained gene delivery maintains prolonged expression of 
encoded factors, the polymeric scaffolds create and maintain space and provide a conductive 
physical support that allows tissue regeneration. The matrix must mimic the numerous 
functions of the natural extracellular matrix (ECM). Gene delivering scaffolds synthesized 
from natural or biodegradable synthetic polymers, as discussed in sections above, have 
shown marked success in various tissue engineering models, including bone 
regeneration9,129,130,150,172,173, nervous system (nerve regeneration)132,174, 
angiogenesis173,175,176, and cartilage formation131,139,140. 
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Though several fundamental scaffold design requirements have been identified177, 
guidelines for controlled delivery of genes from such scaffolds to provide maximal tissue 
formation are still poorly understood. Because the matrix provides support for cell adhesion 
and migration, and organizes cells into structures, improving the mechanical properties of the 
scaffold and mechanical stimulation of the tissue can influence tissue formation172,178. 
Scaffolds must create and maintain a space for tissue formation and should be resorbed or 
degraded at a rate that is comparable with new tissue formation. For any tissue regeneration 
application, different types of cells migrate and infiltrate the site of injury. Targeting a 
specific cell population or cell type for gene delivery can provide greater benefits and may be 
desirable for inducing differentiation toward specific fate or function. For example, in a 
nerve regeneration application, infiltrating fibroblasts cannot form functional relays or 
myelinate regenerating axons, and, therefore, gene delivery targeted to Shwann cells and 
olfactory ensheathing cells will be more effecive174. The type of gene delivered may also 
influence the maximal tissue regeneration. Though most studies have investigated delivering 
genes encoding a growth factor, a gene encoding the transcription factor that induces the 
production of growth factor in the cell machinery presents a viable alternative. The latter 
ensures the expression of all natural splice variants, and may regulate multiple separate 
genes176. Extent of transgene expression and number of cells expressing transgene by 
maintaining the microenvironmental concentration of genes can determine normal or aberrant 
tissue formation175. Gene delivery strategies with spatial (μm to mm) and temporal (days to 
months) control on transgene expression that promote an appropriate concentration of tissue 
inductive factors must be developed to recreate environmental complexities present during 
tissue formation179. Porous scaffolds fabricated from synthetic polymers, such as PLG, 
provide opportunity to simultaneously or sequentially deliver plasmid DNA, cells and 
inductive proteins to create a temporal cascade of signaling that accelerates and enhances the 
extent of tissue formation150,180. Excellent reviews exist that address these guidelines in detail 
for tissue engineering with DNA releasing scaffolds180-182. A more thorough understanding of 
biological requirements for tissue regeneration would serve to identify better strategies for 
sustained gene delivery that can best enhance the regenerative process. 
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6 Conclusions 
Delivering DNA vectors in a controlled fashion from polymeric devices provides a 
continuous supply of vectors to the targeted cells over a period of time, maintaining an 
elevated DNA concentration in the cellular microenvironment, increasing the transfection 
probability, and thus generating prolonged gene expression. These devices reduce the amount 
of genetic material needed for therapy by preventing its rapid loss from the tissue reducing 
the dose and number of repeated administration of the vectors. A localized 
injection/implantation of these controlled delivery systems in target tissues can further avoid 
escape of delivered vectors to distant sites which could otherwise lead to toxicity to 
untargeted cells and unwanted immune responses. Both synthetic and naturally occurring 
polymers have been used for synthesizing such devices. Though natural polymers allow 
encapsulation of DNA vectors under mild conditions and degrade into biocompatible 
components of extra-cellular matrix, they provide limited range of physical and chemical 
properties for modulating the release profile of the vectors.  In contrast, synthetic polymers, 
like polyesters, allow selective manipulation of many of the device properties. Specific or 
non-specific interactions can be introduced between the polymers and entrapped vectors to 
enhance loading efficiency, and to either control the release rate of vectors to be taken up by 
cells surrounding the device, or to immobilize the on polymeric surface for preferential 
uptake by the infiltrating cells. While prolonged physiological responses from these sustained 
delivery devices have been demonstrated in a number of gene therapy applications, variables 
important to the efficacy of these systems are not well understood and are under intense 
investigation. Advancement of biomaterials with specific mechanical and surface properties 
that can be easily modulated to tailor the release profile of vectors is needed for improvement 
of controlled gene delivery technology. Studies that correlate properties of these sustained 
gene devices to the distribution, duration and amount of total protein expressed by the 
delivered genes in the cells will lead to a more rational molecular-scale design of such 
delivery systems. Development of an efficient gene delivery system that can keep the level of 
expressed protein within therapeutic range for extended periods of time will be instrumental 
in the realization of clinical gene therapy. 
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Table 1: In vivo studies that demonstrated physiological response after delivery of 
therapeutically relevant genes using polymeric sustained delivery systems 
 
Delivery 
system 
Polymer Vector Species/ 
location 
Gene Result 
Nano-
spheres 
Gelatin Plasmid Mice/ Kidney TGF-βR 
siRNA 
Enhanced anti-fibrotic 
activity183  
 PLGA Plasmid Rat/ femoral 
fracture  
pSEAP Sustained gene 
expression after 5 
weeks41 
 Chitosan Plasmid Mice/intranasal RSV antigen Significant reduction of 
viral titers49 
Micro-
spheres 
PLGA Plasmid Oral Insect protein 
luciferase 
Systemic and mucosal 
antibody responses57 
 Gelatin Plasmid Mice/ 
peritoneal 
cavity 
NK4 Suppress tumor growth 
by inhibiting 
angiogenesis54,55  
 Gelatin Plasmid Mice/ renal 
subcapsule 
MMP-1 Low level of blood urea 
nitrogen (diabetic 
model)78 
 Alginate HAd5 Mice/ 
intranasally or 
i.p. 
AdCA36lacZ Circumvented vector-
specific immune 
response31 
Hydrogels Agarose Plasmid Calves/ neck 
skin 
pCIgD- 
BoHV-1 
glycoprotein 
D 
Bovine herpesvirus 1-
specific immune 
response119 
 PEG-
PLGA-
PEG 
Plasmid Diabetic mice/ 
dermal wound 
TGF-β1 Wound healing, 
accelerated re-
epithelialization117  
Scaffolds Evac Plasmid  Mice/ vagina LDH-C4 Immunization154 
 Collagen-
gelatin 
Plasmid Rabbit/ knee TGF-β1 Cartilage 
regeneration139 
 Gelatin  Canarypox 
virus 
ALVAC 
Mice/ 
intratumoral 
IL-2, IL-12, 
TNF-  
Grwoth inhibition of 
tumor nodules143 
 Collagen Plasmid Dog/ beagle 
tibia 
pMat-1 Bone regeneration9 
 Collagen AdV Rats/ dermal 
wound 
PDGF-B Granulation and 
vascularization134 
 Collagen PLL / 
plasmid 
Optic nerve FGF2, 
BDNF, NT3 
Survival of axotomized 
RGCs132 
 Collagen Plasmid Rabbit/ears 
(ischemic 
dermal ulcers)  
 PDGF Granulation tissue, 
wound closure133 
Abbreviations: HAd5- Human adenovirus type 5; PDGF- platelet-derived growth factor; RGC- retinal 
ganglion cells; FGF2- fibroblast growth factor; BDNF- brain-derived neurotrophic factor; NT3- 
neurotrophin-3; IL-2- murine cytokines interleukin 2, TNF-α- tumor necrosis factor-α 
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Fig. 1: (A) Pentablock copolymers exist as micelles in aqueous solutions, with a hydrophobic 
core and a hydrophilic corona. (B) The cationic polymers condense DNA in solution into 
nanoplexes that are easily taken up by the cells via endocytosis. Polyplex solutions 
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containing more than 15 wt% of copolymer, free flowing at 15°C or below, self-assemble to 
form reversible strong elastic hydrogels at physiological temperatures- driven by the packing 
of polymeric micelles in a crystalline lattice. (C) The aqueous pharmaceutical formulation 
can be injected non-invasively into localized tissues/cavities using syringe and 27 gauge 
needle where a hydrogel depot of the polymer/DNA complexes is formed. The hydrogel can 
dissolve in tissue fluid to release nanoplexes for prolonged period of times, circumventing 
repeated administration of bolus dose. 
 
 
 61
CHAPTER 3 
NOVEL CATIONIC PENTABLOCK COPOLYMERS AS NON-VIRAL 
VECTORS FOR GENE THERAPY 
 
Reprinted from Journal of Controlled Release 103 (1), 245-258, Copyright ©2004, Elsevier. 
Ankit Agarwala, Robert Unferb, Surya K Mallapragadaa* 
 
aDepartment of Chemical and Biological Engineering, Iowa State University, Ames, Iowa, 
USA-50011 
bIowa Cancer Research Foundation, Urbandale, IA-50322 
 
*Corresponding author 
AA is primary researcher 
RU and SKM supervised the work 
 
Abstract 
New cationic pentablock copolymers of poly(diethylaminoethylmethacrylate) 
(PDEAEM), poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO)  -(PDEAEM-b-
PEO-b-PPO-b-PEO-b-PDEAEM)-  synthesized in our laboratory were investigated for their 
potential as non-viral vectors for gene therapy. Agarose gel studies showed that the 
copolymers effectively condensed plasmid DNA to form polyplexes, and also protected 
plasmids against nuclease degradation. Light scattering and transmission electron microscopy 
were used to analyze the apparent size, molecular weight and morphology of these 
polyplexes. Lactate dehydrogenase assay was employed to find the cytotoxicity limits of the 
polymers and polyplexes on a human ovarian cancer cell line. The polymers showed much 
less cytotoxicity than commercially available ExGen 500 (linear polyethyleneimine). By 
changing the relative lengths of the blocks in the copolymers, it was found that the 
cytotoxicity of these copolymers could be tailored. The micellar structures of these 
copolymers in aqueous solutions and their pH-sensitive protonation were added advantages. 
In-vitro transfection efficiencies of the polymers using green fluorescent protein (pEGFP-N1) 
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and luciferase (pRL-CMV) reporter genes were found comparable to the commercially 
available Ex-Gen 500. Besides, aqueous solutions of these pentablock copolymers have been 
shown to exhibit thermodynamic phase transitions and thermoreversible gelation, a quality 
that could allow subcutaneous/intramuscular injections of these polymers for controlled gene 
delivery over time.  
 
Keywords: Block copolymers; Injectable; Cationic; Non-viral vectors; Gene therapy; pH 
sensitive  
 
 
1.  Introduction 
Non-viral gene therapy using cationic copolymers has recently gained increased interest 
as a potential treatment for cancer and several other genetic diseases[1-3]. It can overcome 
problems encountered with viral-based therapies, such as immunogenicity, toxicity, 
mutagenicity and potential danger of oncogenicity [2]. Non-viral gene therapy involving 
polymers provides flexibility to design a carrier having well defined structural and chemical 
properties on a large scale. The positively charged groups of the polycation enable formation 
of “polyplexes” with the negatively charged phosphates of DNA via electrostatic 
interactions. This results in DNA condensation, protection from the nuclease digestion and 
more efficient delivery of plasmid into the cell [4].  A variety of polycations have been 
proposed and investigated for polyplex formation [5], such as poly-L-lysine (PLL) [6], 
polyethylenimine (PEI) [7], polyamidoamine dendrimer [8], and (poly(2-
dimethylamino)ethyl-methacrylate) (PDMAEMA) [9]. However, these systems are very 
toxic and they tend to aggregate in vivo [10, 11]. Also, they need to be administered 
repeatedly for sustained gene expression. 
Amine methacrylate-based polymers have previously been reported as efficient 
cationic condensing agents for gene delivery [12, 13]. We have designed novel pentablock 
copolymers of PDEAEM and Pluronics®, which are triblock copolymers PEO-b-PPO-b-PEO 
[14, 15].They retain the thermoreversible gelation properties of the triblock Pluronics® [16, 
17], while providing pH-sensitive groups for DNA condensation and endosomolysis [18]. 
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The tertiary amine groups of PDEAEM are responsible for DNA condensation and providing 
pH buffering capacity to the polymer. Also, as it has been noted by Ferruti et al.[19] and 
others[20] that macromolecules with tertiary amine groups exhibit a lower toxicity than those 
with primary and secondary residues, our pentablock copolymers are expected to be more 
biocompatible than commonly used vectors such as ExGen. These pentablock copolymers 
form micelles in aqueous solutions [14] which is an added advantage as the micellar structure 
of Pluronics® has been shown to facilitate cellular entry and has been found to sensitize multi 
drug resistant tumors [21, 22]. The copolymers can be mixed with the therapeutic gene in an 
aqueous phase at low temperatures (below 4 °C) where they exist as sols and can form 
injectable polyplexes. On subcutaneous/intramuscular injection and subsequent heating to 
body temperatures, the copolymers self-assemble into gel [14, 15] that can act as reservoirs 
for sustained-release of polyplexes. These injectable delivery systems have several 
advantages over other common gene delivery systems, such as simple preparation without 
organic solvents; the lack of surgical procedures to implant matrices; easy storage at 4°C; 
ability to vary polymer fractions to tailor and minimize cytotoxicity; and lastly, controlled 
release of the polyplexes to circumvent repeated administrations needed with other polymers. 
 
2.  Materials and Methods 
2.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), fetal bovine serum, 0.25% Trypsin-
EDTA solution and Hank’s Buffered Salt Solution (HBSS) were purchased from Invitrogen 
(Carlsbad, USA). Lactate dehydrogenase (LDH) assay kit was purchased from Takara Mirus 
Bio (Madison, USA). The Renilla luciferase assay system was purchased from Promega 
Corporation (Madison, USA).  The Qiagen Maxi Prep kit was purchased from Qiagen 
(Valencia, USA).  Ex-Gen 500, linear polyethyleneimine (PEI), in vitro transfection reagent 
was purchased from Fermentas Life Sciences (Vilnius, Lithuania).  DNase I was purchased 
from Ambion (Austin, USA). Agarose was purchased from FMC/ BioWhittaker Molecular 
Applications, USA. All water used in procedures was ultrapure water with at least 18 
megaohm resistivity, prepared using a nanopore ultrafiltration unit fed with distilled, 
deionized water.         
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2.2 Plasmid DNA 
A 4.7 kb plasmid DNA encoding enhanced green fluorescent protein (pEGFP-N1) 
(ClonTech, USA) under the regulatory control of the cytomegalovirus (CMV) promoter was 
used as the reporter gene. To measure the levels of protein expression, we used a luciferase 
transfection assay, employing a 4.1 kb plasmid encoding Renilla luciferase (pRL-CMV) 
(Promega Corporation, Madison, USA). Plasmids were inserted into DH5α E.coli, incubated 
in selective Luria-Bertani (LB) medium and purified using the Maxi-Prep DNA Purification 
Kit from Qiagen (Valencia, USA).  The concentration and purity of the resulting DNA in a 
buffer (pH 7.5) of tris-HCl and ethylenediaminetetraacetic acid (EDTA) was measured by 
measuring the absorbance at 260 nm and 280 nm.  All DNA used had a 260/280 ratio of at 
least 1.80.   
 
2.3 Synthesis of pentablock copolymers  
    The pentablock copolymers (Scheme 1) were synthesized using oxyanionic or ATRP 
reaction schemes, which are discussed in detail elsewhere [14, 15]. Pentablock copolymers 
with different wt% of PDEAEM were synthesized and investigated for gene delivery. 
Molecular weights of the pentablock copolymers (Table 1), as determined by NMR and gel 
permeation chromatography, varied from 15,000 Da to 22,000 Da with polydispersity up to 
1.4. 
 
2.4 Cell Culture 
The SKOV3 human ovarian carcinoma cell line was used for cytotoxicity and 
transfection experiments. Cell cultures were maintained in a humidified environment with 
5% CO2 at 37oC and passaged regularly to remain subconfluent.  Cells were fed with DMEM 
containing 10% fetal bovine serum (FBS), unless otherwise stated. Neither antibiotics nor 
antimycotics were used, to avoid the possibility of artificial membrane permeabilization 
effects from these agents. 
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2.5 Polymer-DNA complexes (Polyplexes) 
Copolymer to DNA ratios are expressed as molar ratios of nitrogen (N) in the DEAEM of 
the pentablock copolymer to phosphate (P) in DNA, and written as N:P. The molecular 
weight of the DEAEM monomer is 171 and the average molecular weight of a nucleotide is 
approximately 308. All polyplexes were formed by the same procedure. The copolymer was 
dissolved in ultrapure water to achieve a concentration of 1mg/mL and then diluted with the 
desired media, buffer or water in a polypropylene tube.  After incubating for 5 minutes at 
20°C, this solution was added to the appropriate solution of DNA.  The tube was gently 
agitated and allowed to incubate for 30 minutes at room temperature. 
 
2.6 Molecular weight analysis and particle size determination 
Multi-angle light scattering (MALS) analysis using a DAWN MALS detector (Wyatt 
Corporation, Santa Barbara, USA) was conducted to analyze the apparent size and molecular 
weight of the synthesized copolymers and their polyplexes dissolved in ultrapure water. All 
ultrapure water used was triple filtered using 0.22-μm syringe-filters (Millipore, Billerica, 
USA) to eliminate any dust particles. Samples were again filtered through 0.22-μm syringe 
filters into clean scintillation vials to prevent particulate contamination. Vials were cleaned 
by rinsing with triple-filtered ultrapure water followed by rinsing with triple-filtered 
methanol and, then ethanol and allowed to dry in a sterile laminar flow environment. Since 
the polysulfone membranes exhibit low protein binding affinity and the 0.22-μm pore size is 
on the order of the size of hydrated DNA , no plasmid and polymer loss was expected due to 
membrane adsorption. DNA concentration in the samples was measured before and after 
filtration by measuring absorbance at 260nm to ensure no loss of polyplexes. The 
experiments were conducted in micro-batch configuration with the samples being delivered 
to the flow cell of the DAWN EOS with a syringe pump at 0.5 ml/min. MALS measurements 
were performed at 5x10
-4 
g/ml and 27
o
C 
The refractive index increments for each pentablock copolymer and the polyplexes were 
measured independently using an Optilab DSP Interferometric Refractometer (Wyatt 
Corporation, Santa Barbara, USA). Measurements were conducted at a wavelength of 690nm 
in vacuo. The temperature was set at 40°C to minimize fluctuations. Samples used were same 
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as those for MALS. Clean solvent was injected before and after each refractive index 
determination to confirm the baseline voltage and check for baseline drift. 
A JEOL 1200EX2 scanning/transmission electron microscope (Tachikawa, Japan) was 
used to visualize the morphology of polyplexes, prepared at varying N:P ratios in 0.1mM 
phosphate buffer saline.  A 10μL drop of the sample was placed onto a formvar-coated 
copper grid and allowed to adsorb.  After 5 minutes, the liquid was wicked with filter paper.  
The grid was then placed immediately into a solution of 4% w/v uranyl acetate in 50% 
ethanol and allowed to stain for 30 minutes.  The sample was rinsed by repeated immersion 
in 50% ethanol followed by two rinses in deionized water.  After rinsing, the samples were 
loaded into the vacuum stage of the microscope and visualized at 80kV under magnifications 
of 40,000X to 250,000X.  Naked DNA (pEGFP-N1) and the copolymer alone were also 
examined. 
  
2.7 Gel retardation assay 
To study the pentablock copolymer condensation with DNA, agarose gel electrophoresis 
of the self- assembled polyplexes at different N:P ratios were conducted, comparing their 
mobility.  A total of 1µg of pEGFP-N1 DNA per lane was used. After adding 10x sucrose 
loading buffer to the samples, 15 μL of each sample was loaded to an appropriate well in a 
0.7% agarose gel containing 0.1 μg/mL ethidium bromide.  The gel was run in TBE buffer at 
60V for approximately an hour.  Visualization and image capture was accomplished using a 
UV-transilluminator under a Kodak EDAS 290 digital imaging suite (Fisher Scientific; 
Pittsburg, USA).  A 1kb+ DNA ladder and only DNA served as controls. 
 
2.8 Nuclease resistance assay  
To investigate the ability of the pentablock copolymers to protect DNA from enzymatic 
degradation, polyplexes at different N:P ratios were incubated with DNase I for an hour, and 
run on an agarose gel.  Appropriate buffers and the enzyme DNase I (RNase-free) were 
added to yield either 4 or 50 IU per micrograms of DNA.  Naked pEGFP-N1 DNA served as 
a negative control, and naked DNA with DNase I served as a positive control for DNase 1 
activity. 
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In addition, a change in the absorbance of polyplex solutions at 260nm was observed to 
detect DNA fragmentation by DNase I. Polymer solution in nanopure water was added to 
plasmid DNA in TE buffer (pH 7.5) to get desired N:P ratios with 20μg of DNA/ml final 
concentration, (i.e. 0.4 OD of DNA at 260nm). After incubating the polyplexes for an hour, 
100IU of DNase I were added (yielding 5 IU/μg DNA) with 10x DNase I buffer to make the 
final volume of polyplex solution to 1ml, and the change in absorbance at 260nm was 
monitored. 
The gelation of polyplexes at 370C is important for the ability of these polymers to act as 
controlled gene delivery devices. To confirm that polyplexes do show gel-sol transitions like 
the polymers themselves, polymer-DNA complex solutions in TE buffer at 4°C containing 
22.5% by wt pentablock copolymer B and plasmid at N:P ratio of 25:1 were warmed to room 
temperature to form gels. Further, these gels were dissolved at room temperature into TE 
buffer, and small aliquots of the samples were run on a 0.7% agarose gel, both in the 
presence and absence of 10IU of DNase I to investigate the ability of the gel-forming 
polyplexes to protect the DNA even after dissolution of the gels.  
 
2.9 Cytotoxicity assay 
Lactate dehydrogenase (LDH) is an integral cytosolic enzyme that is secreted out in the 
medium following the rupture of cell membrane [20], since it is a potential site of interaction 
of cationic macromolecules [23]. Cells were cultured into 96-well tissue culture plates at a 
density of approximately 27,500 cells per well. After incubation overnight, the DMEM was 
removed, and replaced with appropriate polymer solutions in 200μL fresh DMEM. Cells 
were allowed to incubate in the presence of the test substances for 24 to 48 hours. 100μL of 
media was then collected in an optically clear 96-well microtiter plate, and LDH 
concentration was assayed using a commercial kit (Takara Bio LDH cytotoxicity detection 
kit, Otsu, Japan). The absorbance at 500nm was measured for each well using a BioTek EL-
340 plate reader (Winooski, USA).  Media alone and media with only cells were used to 
obtain a background LDH level for normalization.  Cells exposed to 0.1% Triton X-100 in 
DMEM were used as a positive control, and set as 100% LDH release. The relative LDH 
release is defined by the ratio of LDH release over total LDH in the intact cells. Less than 
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10% LDH release was regarded as an acceptable level in our experiments. All samples were 
run in four replicates, and experiments were repeated twice. After incubation with polymers, 
changes in morphology and detachment of cells from the dish were also observed using an 
Olympus IMT-2 (Melville, USA) inverted, phase-contrast light microscope equipped with an 
objective of 100x magnification. 
 
2.10 In-vitro transfection  
2.10.1 Detection of Green Fluorescent Protein 
Green fluorescent protein (GFP) was used for the assessment of in-vitro transfection 
efficiency of the copolymers in SKOV-3 cell line. Various formulations of polyplexes were 
made in serum free media OptiMEM at different N:P ratios with a fixed amount of pEGFP-
N1 (6µg of DNA per well in a 6-well multiwell plate). Cells seeded in 6-well plates were 
incubated overnight up to 70% confluency prior to transfection. Growth medium was then 
removed and replaced with the test solutions of polyplexes along with 1 ml OptiMEM. The 
cells were incubated for 5 to 12 hours at 37°C, after which the transfection medium was 
replaced with fresh DMEM containing 10% FBS, and cells were incubated for another 44hrs 
to express the reporter gene. The advantage of using pEGFP as a reporter gene is that it can 
be observed both qualitatively and quantitatively. Cells expressing GFP were visualized 
directly on an Olympus IMT-2 (Melville, USA) inverted, phase-contrast light microscope.  
Images were recorded using an attached Nikon Coolpix 990 digital imaging system, without 
disrupting the cells.  Flow-cytometry was used to obtain the percentage of cells transfected 
with the pEGFP-N1. Cells were harvested from the plates using HBSS and trypsin-EDTA 
treatment, and were suspended in 3ml HBSS in centrifuge tubes.  These were centrifuged at 
1200 rpm for 10 minutes. The supernatant was removed and the cell pellet was washed in 
3ml HBSS to remove background fluorescence from the media. After repeating the 
centrifugation, cells were finally suspended in 0.5ml HBSS and were transferred to flow 
cytometry cuvettes for analysis. Flow cytometry was performed using a Beckman-Coulter 
Epics ALTRA Fluorescence-activated cell sorter (Fullerton, USA).  ExGen 500 was used as 
a positive control, and was expected to yield high efficiency of transfection.  Cells exposed 
only to DNA (without polymer) were used as negative controls. 
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2.10.2 Detection of Luciferase activity 
In order to determine the total protein expressed by a reporter gene per total cellular 
protein, a luciferase assay was employed, using pRL-CMV as the reporter gene. Cells were 
seeded in a 96-well plate up to 70% confluency prior to transfection, and were then 
transfected with various polyplexes solution in 200µl OptiMEM using 1.5µg of DNA per 
well.   After 5 hours incubation in OptiMEM, the solution was replaced with fresh DMEM 
containing 10% FBS, and incubated for 44hrs.  Cells were then lysed using a lysis buffer 
(Renilla Luciferase Assay Lysis Buffer, Promega) and the luminescence of the expressed 
reporter protein was measured on an automated Berthold Mithras LB940 (Bad Wildbad, 
Germany) multilabel luminometer using the Promega Renilla Luciferase Assay System 
(Madison, USA). Positive and negative controls similar to those for pEGFP were used. Total 
recovered cellular protein content of the cells was determined by a modified Bradford assay, 
using a CB-Protein AssayTM Kit. Bovine serum albumin standards were prepared. Twenty 
microliters of the samples from luciferase detection protocol were placed in individual wells 
of a 96-well plate and diluted with nanopure water to 100µl. CB-Protein AssayTM reagent 
(100µl) was added into each well and mixed well. The plate was allowed to incubate for 15 
minutes and absorbance was measured at 595nm. The amount of protein was read from the 
standard curve. 
The statistical significance of the results of transfection was evaluated by Student’s t-test 
for the transfection study. To compare the mean and standard deviations of more than 2 
cases, Tukey’s procedure was used. Software JMP 5.1 was used for statistical analysis. Four 
replicates of each case were done in each experiment, and all experiments were repeated 
twice.  
 
 
3. Results and Discussion 
3.1 Molecular weight analysis and particle size 
Zimm plots were used to analyze the MALS data. For the pentablock B, containing 26% 
PDEAEM (Table 1), the weight average molecular weight was found to be (3.118 ± 
0.097)x106 g/mol, and the radius of gyration as 18.3 ± 2.0 nm. The refractive index 
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increment, dn/dc value, for the copolymers was found to be 0.0155(ml/g). Light scattering 
data from polymer solutions in triple filtered ultrapure water with concentrations of 0.4, 0.8, 
1.0 and 1.2mg/ml was used for analysis. The second virial coefficient, which quantifies the 
polymer-solvent interaction, was found to be (-9.457 ± 0.387)x10-5 mol mL/g2. The negative 
value suggests a poor interaction between polymer and the solvent, indicating that the 
polymer has hydrophobic components. This further supports evidence [14] that the 
pentablock copolymers self-assemble to form micelles due to hydrophobic interactions with 
water. Dividing the molecular weight of these polymer aggregates obtained from MALS by 
the molecular weight of a polymer unimer suggests that each micelle is made of 
approximately 132 unimers of the pentablock copolymer. 
For the polyplexes of pentablock B with pRL-CMV plasmid at N:P ratio 5:1, wt average 
mol weight was found to be (2.151 ± 0.091)x107 g/mol, with a radius of gyration of  32.3 ± 
1.6 nm. The dn/dc value for these polyplexes was earlier found to be 0.0074ml/g. Light 
scattering data from polyplex solutions of 0.6, 0.8, and 1.0 mg/ml concentrations was used 
for analysis. The second virial coefficient was found to be (-2.004 ± 0.147)x10-6 mol mL/g2. 
This indicates that polyplexes too, which are formed by the condensation of DNA by 
polymer micelles in solution, do not have favorable interactions with water. The negative 
value suggests that attractive interactions between the polyplexes are strong enough to pull 
the molecules into an aggregates from the dilute solution[24]. 
TEM images were obtained to observe the morphology of polyplexes. Fig 1 shows an 
image of polyplexes with pentablock C and pEGFP at N:P ratio of 5:1. In the image, 
condensates appear to be in two forms; first, toroidal ring structures, and second, structures 
with a linear morphology, which usually have loops at either end. Similar structures were 
obtained irrespective of the ratio of the polymer to DNA. Real time images of such toroidal 
and rod-like condensates formed with cationic polymers like PEG-poly(amidoamine) triblock 
copolymer and plasmid DNA have been reported earlier in other studies as well [25, 26]. The 
average diameter of rings was approximately 50nm and the average length of rods was 
approximately 100nm. This is very much in compliance with the MALS data shown above. 
However, dehydration of the samples for TEM imaging disrupts the micelles of polyplexes 
which otherwise would have formed in an aqueous environment, affecting the apparent size 
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and morphology of the condensates. To appreciate the complex architecture of the polymer-
DNA condensates, images of uncondensed pEGFP plasmids, and only polymer were also 
taken (images not shown here). TEM images show distinct differences among the polyplexes, 
DNA and polymer, with these toroidal and linear structures seen only in the polyplexes. 
        
3.2 DNA complexation 
Experiments were performed to investigate whether the pentablock copolymers form 
complexes with plasmid DNA pEGFP-N1. Fig. 2 shows the results from a gel retardation 
assay. DNA was visualized by fluorescence of ethidium bromide.  Lane 7 containing naked 
plasmid pEGFP-N1 showed at least three distinct bands, corresponding to the different states 
of supercoiling in the double-stranded plasmid DNA. The movement of plasmid DNA was 
retarded as the amount of pentablock copolymer in a complex increased, suggesting that 
pentablock copolymer formed a strong complex with plasmid DNA (lanes 1-6). Lanes 1-3 
had pentablock A and lanes 4-6 had pentablock C. Almost complete retardation was achieved 
at N:P ratio of 1:1, which reflects that negatively charged DNA was completely neutralized 
and complexed by the cationic polymer, forming self-assembled polyplexes via ionic 
interactions. At N:P ratios of 5:1 and 10:1, the band appeared to move slightly upward, 
suggesting that these polyplexes had an overall positive charge. 
 
3.3 Protection against nuclease degradation 
The agarose gel in Fig 3 shows that the pentablock copolymer protected plasmid DNA 
against DNase I digestion. Naked plasmid pEGFP-N1 in lane 1 served as a negative control, 
and naked plasmid with DNase I in lane 2 served as a positive control. Lane 8 contained 
1kb+ ladder for the control. Lanes 3 to 7 contained polyplexes of pentablock C with Dnase I.. 
Dark bands of DNA at the top of lanes 5 and 6 showed that plasmid DNA was still present 
and was not digested by DNase I. Thus, N:P ratios of 5:1 and above were sufficient to 
complex the DNA and protect it against nuclease degradation. Lane 7 showed that at 
unusually high concentrations of DNase I (50 IU / µg of DNA, as compared to 4 IU in other 
lanes) all DNA was digested. Lanes 5 and 6 showed slightly weaker bands in fluorescence 
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intensity as compared to naked plasmid in lane 1, probably because ethidium bromide could 
not efficiently intercalate the already complexed DNA in polyplexes. 
We also monitored the change in absorbance of polymer-DNA complexes solution at 
260nm to detect any increase in nuclease resistance. Upon, addition of 100 IU of DNase I to 
native DNA solutions (5 IU/ µg of DNA), an immediate increase in the absorbance of 
solution was observed due to the fragmentation of plasmid DNA molecules (Fig 4). 
However, the rate of degradation decreased significantly on addition of polymer to the DNA 
solution. At N:P ratio of 8:1 and above, scarce change in absorbance was detected upon 
addition of DNase I. From a comparison of the slope of the curves, reflecting a rate of 
degradation, suppression in DNase I activity was estimated as 73.7% at N:P ratio 2:1, 78.9% 
at N:P ratio 4:1, 99.9% at N:P ratio 8:1, and 100% at N:P ratio 12:1. This indicated that the 
pentablock copolymer is effective in protecting the plasmid DNA against degradation by 
DNase I at N:P ratios of 2:1 and above. 
The gelation studies showed that the polyplexes did indeed form gels at room 
temperature at high concentrations. The gel dissolution studies showed, as seen in Fig 5, that 
polyplexes were indeed released from this gel. Lane 1 had naked DNA, lane 2 had released 
polyplexes, and lane 3 had released polyplexes with 10IU of Dnase I. We found that all the 
DNA in lanes 2 and 3 were intact at the top of the lanes, and the excessive unbound cationic 
polymer was seen to move in upward direction towards the negative electrode. This result 
showed that polyplex gels dissolved to release complexed DNA (polyplexes), and not just 
polymer or naked DNA.  
 
3.4 Cytotoxicity 
The pentablock copolymers with different weight percentages of PDEAEM were tested 
for their toxicity on the SKOV3 cell line. ExGen 500 was also tested. A cut-off concentration 
was found for each polymer at which less than 10% cell death was observed. Later, all 
transfection experiments were performed within these cut-off concentrations of the 
polyplexes. As shown in Fig 6, cell viability increased as weight-percentage of PDEAEM in 
the pentablock decreased, due to a dilution effect of the cationic groups in copolymers. The 
results were also expressed in terms of the cut-off molar concentrations of the cationic groups 
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(nitrogen residues) of the polymers. These results show that at lower wt% of PDEAEM in the 
pentablock copolymers, higher molar concentrations of the cationic groups can be tolerated 
by cells, and these cationic groups are actually responsible for all DNA condensation and 
protection. This also reflects the fact that the Pluronics® have a beneficial role in improving 
the biocompatibility of the pentablock beyond just diluting the number of cationic groups, 
because an increase in wt% of Pluronics® in the pentablock results in an increased cut-off 
molar concentration of cationic groups, which otherwise should have been same for all 
pentablock copolymers.  This is presumably due to the shielding effect of the PEO in the 
Pluronics®. Besides, our pentablock copolymers were found to be much less toxic than the 
commercially available in vitro transfecting reagent ExGen 500. ExGen 500 was found to 
have a lower cut-off molar concentration of the cationic groups due to absence of these 
shielding groups. 
Microscopic images of the SKOV3 cells in Fig 7 show how the cell morphology changed 
as polymer concentration increased in toxicity. In the presence of no polymer (Fig 7A), cell 
bodies were large, confluent and covered the entire surface of the plate. However, at higher 
concentrations (0.05mg/ml) of the polymer (Fig 7C), cell bodies were small, sparse and 
dispersed, indicating cell death. At an optimum concentration of 0.03mg/ml (Fig 7B), cells 
appeared to be healthy and sub-confluent. As seen from Fig 6, this concentration of 
pentablock C is close to the cut-off concentration measured by the LDH assay. 
 
3.5 In-vitro transfection 
3.5.1 Green Fluorescence Protein assay 
          Flowcytometry was used to measure the percentage of cells transfected by pEGFP-
N1. Transfected cells showed transient expression of the reporter gene over time. Fig 8 
shows the percentage of cells transfected at different N:P ratios using the pentablock B 
(copolymer with 26% PDEAEM) measured 44 hours after removing the polymer. Up to 17% 
transfection was achieved by the pentablock copolymer, which is very much comparable to 
the 20% transfection obtained from the commercially available and much more toxic ExGen 
500. Also, higher transfection was obtained at higher N:P ratios of the polymer. However, at 
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very high N:P ratios, the toxicity increased due to increased polymer content, and the cells 
died before getting transfected or expressing the protein from the transfected gene.  
 
3.5.2 Luciferase assay 
In order to determine the total amount of reporter protein expressed by the cells, a renilla 
luciferase assay was employed. Polymers at different N:P ratios with pRL-CMV plasmid 
were tested for the amount of transfection obtained. Fig 9 shows the amount of luciferase 
expressed in terms of relative luminescence units (RLU). The experiments were conducted in 
a 96-well plate with 1.5µg of DNA/well. At this DNA dose, the amount of protein expressed 
increased on increasing the N:P ratio from 1:1 to 2:1 and 3:1 for pentablock copolymer B. 
However, at N:P ratios of 4:1 and above, the amount of polymer used surpassed the cut-off 
concentration at which cells could be viable, and hence a decrease in protein expressed was 
observed. Positive control ExGen 500 also showed an increase in transfection with increase 
in N:P ratio from 1:1 to 2:1. However, at higher N:P ratios, an increase in cell death 
decreased the protein expression considerably. Hence the values shown in Fig. 9 are for 
ExGen N:P ratios of 2:1, and compared to higher ratios for the pentablock copolymers, for 
the same amount of DNA. It is appreciable that RLUs obtained from the much more 
biocompatible pentablock copolymers are of the same order as RLUs from ExGen 500. Total 
cellular protein content of the cells was assayed using a Bradford assay kit, and was not 
found to be significantly different in different cases. On an average, total amount of cellular 
protein was found to be 3.56µg in each well. 
Since the pentablock copolymers have the ability to undergo thermoreversible gelation, 
with slow release of polyplexes over time, the effect of exposure time on transfection was 
investigated. Fig 10 shows a time dependent study of the transfection efficiencies of the 
polymers. At a N:P ratios of 2:1, pentablock copolymer B showed a significant increase in 
transfection if cells were incubated with polyplexes for 12 hours instead of just 5 hours. 
Further, the amount of transfection thus obtained was comparable to the transfection by 
ExGen 500 (N:P 1:1) for 12 hours exposure. Statistically, the transfection efficiencies of 
ExGen 500 and the pentablock copolymers were not significantly different. This shows that 
the pentablock copolymers are equally efficient at transfecting cells in vitro as Ex-Gen 500. 
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The N:P ratios of 3:1 for the pentablock copolymers and 2:1 for Ex-Gen resulted in increased 
cell death with reduced transfection for this extended 12 hours incubation. 
 
4. Conclusions 
The key challenge for plasmid based gene therapy is to surmount the limiting steps in 
intracellular movement including endosomal release, cytoplasmic transport, and nuclear 
uptake, while enhancing the retention of plasmids in the nucleus. 
The new pentablock copolymers synthesized in our laboratory show great promise as 
non-viral vectors for gene therapy. The copolymers are water soluble, pH-sensitive and have 
thermo-reversible gelation properties. Their ability to effectively condense DNA into 
polyplexes, and protect plasmids from nuclease degradation is an important first step towards 
use as vectors for gene delivery. The condensed polyplexes are small enough to allow 
cellular uptake. MALS showed that polymer exists in the form of micelles, which complex 
with the plasmid DNA to form condensed polyplexes. TEM images of the polyplexes show 
that plasmid was condensed into ring (diameter ~ 50nm) or rod like structures (length ~ 
100nm). Since samples were dehydrated for obtaining the TEM images, disrupting the 
micelles formed by polyplexes in aqueous environment, cryo-TEM studies in the future will 
preserve the micellar structure and provide a more accurate image. 
The pentablock copolymers have minimal toxicity which can be altered by changing the 
percentage of the cationic component. Increasing the wt% of Pluronics® in the copolymer 
was found to have a beneficial effect on the biocompatibility of the copolymers beyond just a 
dilution effect. We hypothesize that this may be due to the shielding of cationic charges of 
the pentablock copolymers by the PEO in the Pluronics®, making the polymers less toxic to 
cells. Also, our pentablock copolymers were found to be much less toxic (up to 50 times in 
wt concentration) than the commercially available in vitro transfecting reagent Ex-Gen 500. 
Effective transfection of reporter genes was observed within the toxicity limit of the 
copolymers. The amount of transfection increased with extended time of incubation if 
polymer concentration was within the cell viability limit. Our observed transfection 
efficiency using the pentablock copolymers was not significantly different from that of Ex-
Gen 500 when cells were incubated for 12 hours with the polyplexes. Besides, the presence 
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of PEO blocks in the pentablock copolymers has the potential to reduce non-specific 
interactions in vivo when targeting moeties such as epidermal growth factor (EGF) [27, 28] 
are attached to the ends of the chains, significantly increasing the cellular uptake by 
neoplastic cells expressing increased amounts of EGF receptors on their cell membranes. 
Nuclear localization sequences (NLS) [29] may also be conjugated to the pentablock 
copolymers, which would increase the nuclear uptake of the polyplexes, overcoming a major 
hindrance in transfection. The biggest potential advantage of our new pentablock copolymers 
is their ability to form gels at body temperatures and enable localized delivery to tumors with 
a slow release of polyplexes for sustained gene expression without multiple administrations. 
The gelation properties and drug-release studies from the polymer using a dye have been 
reported in other papers from our group[14, 15]. We have also verified that polymer-DNA 
complexes do form gels at appropriate concentrations and temperature; and agarose gel 
electrophoresis retardation study show that these gels dissolve to release polyplexes 
(complexed DNA), and not just polymer or naked DNA. Development of a safe, efficient 
synthetic gene delivery vector system that can be used to transport suicide genes to neoplastic 
cells will provide an effective alternative for cancer therapy [30, 31].   
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Table I: Molecular weight and polydispersity indices (PDI) of the pentablock copolymers 
used in this study.  
 
Pentablock 
copolymer 
Mn 
(NMR) 
Mn 
(GPC) 
PDI %PDEAEM 
A 15,000 40,112 2.36 17 
B 17,300 23,516 1.235 26 
C 22,000 30,664 1.206 40 
D 19,973 20,365 1.338 62 
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Scheme 1: Structure of pentablock copolymers. The number of repeating units of the 
PDEAEM blocks, n, was varied to control the properties of the copolymer.  
 
Fig 1: TEM image of the polyplexes obtained from the condensation of pEGFP by 
pentablock C at 5:1 N:P ratio. 
 
Fig 2: Agarose gel electrophoresis showing DNA complexation. Lanes 1-3 contain 
polyplexes formed at increasing N:P ratios with the pentablock A (1) 1:1  (2) 5:1  (3) 10:1. 
Lanes 4-6 contain polyplexes formed at increasing N:P ratios with pentablock C (4) 1:1  (5) 
5:1 (6) 10:1. Lane 7 contains naked pEGFP-N1 DNA, and lane 8 contains a 1kb+ DNA 
ladder.  
 
Fig 3: Agarose gel electrophoresis showing protection of plasmid pEGFP-N1 against 
DNase I digestion. Each lane has 1μg of DNA. Lane 1 contains only naked DNA. Samples in 
lanes 2 to 6 were incubated with 4 IU of DNase I / μg of DNA for an hour before running the 
gel. Lane 2 contains DNA with DNase I. Lanes 3 to 7 contain polyplexes formed at 
increasing N:P ratios with pentablock C:(Lane 3) 1:2  (Lane 4) 1:1  (Lane 5) 5:1  (Lane 6) 
10:1 (Lane 7) 5:1. Polyplexes in lane 7 were incubated with 50 IU of DNase I. Lane 8 
contains a 1kb+ DNA ladder.  
 
Fig 4: Nuclease resistance of polyplexes against DNase I activity at different N:P ratios. 
20μg of DNA/ml final concentration was used, and each sample was incubated with 5 IU 
DNase I / μg DNA. 
 
Fig 5: Agarose gel electrophoresis of polyplexes released from a polymer-DNA complex 
gel. Lane1 contains naked plasmid, lane 2 has released polyplexes, and lane 3 has released 
polyplexes treated with 10IU of DNase I.  
 
Fig 6: Cut-off concentrations of different polymers under which they are not toxic to 
SKOV3 cell lines for up to 48 hr. The left axis has molar concentrations (moles/μl) of 
nitrogen residues of the polymer, while the right axis has weight concentrations (mg/ml) of 
the polymers. 
 
Fig 7: Morphology of the SKOV3 cells after incubation for 48 h with pentablock C. (A) 
No polymer (B) 0.03 mg/mL (C) 0.05 mg/mL. 
 
Fig 8: In vitro transfection of pEGFP into SKOV3 cells using pentablock B and ExGen 
500 at various N:P ratios          
      
Fig 9: In vitro transfection of pRL-CMV in SKOV3 cell line using pentablock B and 
ExGen 500. Effect of N:P ratio on transfection of SKOV3 cells.      
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Fig 10: Effect of the time of incubation with polyplexes on luciferase expression in vitro 
in SKOV3 cell lines using pRL-CMV and pentablock copolymer B. 
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Scheme 1: Structure of pentablock copolymers. The number of repeating units of the 
PDEAEM blocks, n, was varied to control the properties of the copolymer.  
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Fig 1: TEM image of the polyplexes obtained from the condensation of pEGFP by 
pentablock C at 5:1 N:P ratio. 
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Fig 2: Agarose gel electrophoresis showing DNA complexation. Lanes 1-3 contain 
polyplexes formed at increasing N:P ratios with the pentablock A (1) 1:1  (2) 5:1  (3) 10:1. 
Lanes 4-6 contain polyplexes formed at increasing N:P ratios with pentablock C (4) 1:1  (5) 
5:1 (6) 10:1. Lane 7 contains naked pEGFP-N1 DNA, and lane 8 contains a 1kb+ DNA 
ladder.  
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Fig 4: Nuclease resistance of polyplexes against DNase I activity at different N:P ratios. 
20μg of DNA/ml final concentration was used, and each sample was incubated with 5 IU 
DNase I / μg DNA 
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Fig 5: Agarose gel electrophoresis of polyplexes released from a polymer-DNA complex 
gel. Lane1 contains naked plasmid, lane 2 has released polyplexes, and lane 3 has released 
polyplexes treated with 10IU of DNase I.  
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Fig 6: Cut-off concentrations of different polymers under which they are not toxic to 
SKOV3 cell lines for up to 48 hr. The left axis has molar concentrations (moles/μl) of 
nitrogen residues of the polymer, while the right axis has weight concentrations (mg/ml) of 
the polymers. 
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Fig 7: Morphology of the SKOV3 cells after incubation for 48 h with pentablock C. (A) 
No polymer (B) 0.03 mg/mL (C) 0.05 mg/mL. 
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Fig 8: In vitro transfection of pEGFP into SKOV3 cells using pentablock B and ExGen 
500 at various N:P ratios     
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Fig 9: In vitro transfection of pRL-CMV in SKOV3 cell line using pentablock B and 
ExGen 500. Effect of N:P ratio on transfection of SKOV3 cells.      
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Fig 10: Effect of the time of incubation with polyplexes on luciferase expression in vitro 
in SKOV3 cell lines using pRL-CMV and pentablock copolymer B. 
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Abstract 
Novel pentablock copolymers of poly(diethylaminoethylmethacrylate) (PDEAEM), 
poly(ethylene oxide) (PEO) and poly(propylene oxide) (PPO), (PDEAEM-b-PEO-b-PPO-b-
PEO-b-PDEAEM) were synthesized as vectors for gene delivery, and were tested for their 
biocompatibility on SKOV3 (human ovarian carcinoma) and A431 (human epidermoid 
cancer) cell lines under different in vitro conditions using various assays to elucidate the 
mechanism of cell death. These copolymers form micelles in aqueous solutions and can be 
tuned for their cytotoxicity by tailoring the weight percentage of their cationic component- 
PDEAEM. Copolymers with higher PDEAEM content were found to be more cytotoxic, 
though their polyplexes were less toxic than the polycations alone. Pentablock copolymers 
displayed higher cell viability than commercially available ExGen 500® at similar N:P ratios. 
While cell death with ExGen® was found to be accompanied by an early loss of cell 
membrane integrity, pentablock copolymers caused very little membrane leakage. Caspase-
3/7 assay confirmed that none of these polymers induced apoptosis in the cells. These 
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pentablock copolymers form thermo-reversible gels at physiological temperatures, thereby 
enabling controlled gene delivery. Toxicity of the polymer gels was tested using an agarose-
matrix, simulating an in vivo tumor model where injected polyplex gels would dissolve to 
release polyplexes diffusing through the tumor mass to reach the target cells. 25wt% 
copolymer gels were found to be non-toxic or mildly cytotoxic after 24hr incubation. 
Transfection efficiency of the copolymers was found to be correlated to cytotoxicity and 
depended on DNA dose, polymer concentration and N:P ratios. Transgene expression 
obtained was comparable to that of ExGen®, but ExGen® exhibited greater cell death.  
 
Keywords: Block-copolymers; Cytotoxicity; Cationic; Gene-delivery; Temperature- sensitive  
 
 
1. Introduction 
In the recent past, biocompatible polymers have been widely explored for biomedical 
applications such as DNA and RNA delivery to targeted cells1-3, drug carrier systems for 
proteins and peptides4,5, and scaffolds for tissue regeneration6. The term biocompatibility 
implies that these polymers are non-cytotoxic, non-immunogenic, and demonstrate an 
appropriate host response in specific applications7,8.  
Gene therapy treats a genetic deficiency by delivering genetic information in the form of 
nucleic acids to the targeted cells. Although great advances have been made in identifying 
target structures for gene therapy, and in the biotechnological production of nucleic acids, the 
progress has been mainly hampered by the lack of safe gene delivery systems that are 
efficient and non-toxic1,9. A variety of cationic polymers have been proposed and 
investigated recently for gene delivery10,11. Prominent examples include poly-l-lysine 
(PLL)12-14, polyethyleneimine (PEI)15-17, polyamidoamine (PAMAM) dendrimers18, 
chitosan19,20, and methacrylate/methacrylamide polymers21,22. Cationic polymers condense 
negatively charged DNA through electrostatic interactions forming stable complexes called 
polyplexes. For an efficient DNA-delivery vector, these polyplexes should deliver their 
genetic payload with minimum damage to the cells such as cell membrane rupture, 
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inflammation, or apoptosis.  However, the existing polymeric gene-delivery systems are 
either toxic, aggregate in vivo, or they do not show good transfection efficiencies23,24.  
Mechanisms and reasons for toxicity caused by polycationic macromolecules are not yet 
fully understood. It has been noted that the toxicity is dependent on the polymer molecular 
weight, surface charge density, structure, flexibility, and three-dimensional arrangement of 
cationic charges 7,25. Whether this toxicity is mediated by interaction of polycations with the 
cell membrane, or by activation of some intracellular signal transduction pathway after 
cellular uptake, is an issue of debate7,26-28. Contradictory studies have been reported and there 
is no general agreement on the causes of polymer toxicity. While Gebhart and co-workers29 
showed that molecular weight (MW) of chitosans did not affect cell viability, a very recently 
published report30 shows that chitosan derivatives show dependence on size and MW for 
both toxicity and transfection efficiency.  Florea et al.26 showed that branched PEI produced 
similar toxicities across a range of molecular weights in COS-1 and Calu-3 cells, 
contradicting other studies on PEI done with different cell lines that showed that PEI toxicity 
increased with an increase in MW7,31. Researchers have also shown that transfection 
efficiency of polymer vectors is correlated to their toxicity29,32. Hill et al. studied 
poly(amidoamine)s (PAAs) and showed that only polymers that exhibited some toxicity were 
able to transfect A549 cells. Florea et al.26 found that transfection efficiency of PEI was 
correlated with toxicity in Calu-3 cells, but not in COS-1 cell line. These studies suggest that 
toxicity of a particular polymer should be evaluated individually, and on more than one cell 
line. 
Homopolymers of DMAEM (dimethylaminoethylmethacrylate) have previously been 
shown to complex DNA and transfect COS-7 and OVCAR cells22. However, they were toxic 
and exhibited only up to 3-6% transfection. In addition, good transfection was obtained only 
at high molecular weights (Mw> 300kDa), which is not suitable for renal clearance in in vivo 
applications. Recently, we had reported novel pentablock copolymers PDEAEM-b-PEO-b-
PPO-b-PEO-b-PDEAEM synthesized in our laboratory as promising non-viral vectors for 
gene delivery33. While their cationic component PDEAEM is responsible for condensation of 
DNA and endosomal escape of polyplexes, hydrophilic PEO chains in the copolymer shield 
the cationic surface charges of PDEAEM thereby decreasing their toxicity. Furthermore, 
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these copolymers form micelles34 which facilitate transport across the lipid bilayer of cell 
membranes. At higher concentrations and physiological temperatures, these micelles self-
assemble to form thermo-reversible gels35; a characteristic property that can potentially be 
used to form subcutaneously injectable systems for long-term gene delivery. Self assembly of 
these copolymers and the properties of their macroscopic gels have been discussed in detail 
earlier36,37. In the present study, we have investigated the effect of various factors such as 
wt% of PDEAEM in the copolymers, their concentration in media, time of incubation, and 
N:P ratios (molar ratios of nitrogens (N) in pentablock copolymer to phosphates (P) in 
DNA), on the toxicity of the polymers and, have attempted to understand the mechanism by 
which these cationic copolymers cause cell death. Commercially available in vitro 
transfection reagent ExGen 500® has been used as a control for the study. The results 
obtained are intended to be used to tailor the formulations for in vivo studies, where suicide 
genes can be delivered to the localized tumors in a sustained fashion using injectable thermo-
reversible gels as depot of polyplexes, circumventing repeated administration to maintain the 
therapeutic levels of the protein.  
 
 
2. Materials and Methods 
2.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), OptiMEM I®, fetal bovine serum (FBS), 
0.25% trypsin-EDTA solution and Hank’s Buffered Salt Solution (HBSS) were purchased 
from Invitrogen (Carlsbad, CA). HEPES salt was obtained form Sigma-Aldrich Co. 
(#H4034) to make Hepes buffer saline. Lactate dehydrogenase (LDH), and MTT assay kits 
were also purchased from Sigma-Aldrich Co. (Tox-7 and Tox-1, respectively). Renilla 
luciferase assay system and Caspase-Glo® 3/7 assay kit were purchased from Promega 
Corporation (Madison, WI). ExGen 500® (written as ExGen henceforth), the in vitro 
transfection reagent, was purchased from Fermentas Life Sciences (Hanover, MD). DNase I 
was purchased from Ambion (Austin, TX). Low melting agarose of PCR grade from Fisher 
Scientific (cat#BP2410) was used for making agarose matrices over the cells. Ultrapure 
water with at least 18 megaohm resistivity was used in all studies. 
 97
2.2 Polymers 
The pentablock copolymers (Table I) were synthesized using oxyanionic or ATRP 
reaction schemes, which are discussed in detail elsewhere34,35. The chemical structure of 
pentablock copolymers is shown in scheme 1. Pluronic® F127 [(PEO)100-b-(PPO)65-b-
(PEO)100] was used as the macroinitiator in pentablocks A, B, and C and E, while pentablock 
D used Pluronic® F68 [(PEO)78-b-(PPO)30-b-(PEO)78]. Pentablock copolymers with different 
wt% of PDEAEM were investigated for gene delivery. Molecular weights of the pentablock 
copolymers (Table I), as determined by NMR and gel permeation chromatography (described 
elsewhere35), varied from 15kDa to 22kDa with polydispersities of up to 1.4. The pentablock 
A (containing 17% PDEAEM by wt) used in this study however had a higher polydispersity 
of 2.36.  
 
2.3 Cells 
The SKOV3 human ovarian carcinoma cell line, and A431 (ATCC CRL-1555), a human 
epidermoid carcinoma cell line obtained from ATCCTM (Virginia, USA), were used for 
cytotoxicity and transfection experiments. DU145, a human prostrate cancer cell line, 
obtained from Iowa Cancer Research Foundation, was also used for some transfection 
experiments. Cell cultures were maintained in a humidified environment with 5% CO2 at 
37°C and passaged regularly to allow them to remain sub-confluent. Cells were fed with 
DMEM supplemented with 10% fetal bovine serum (FBS) and 1μM L-glutamine, unless 
otherwise stated. Neither antibiotics nor antimycotics were used to avoid the possibility of 
artificial membrane permeabilization effects from these agents. 
 
2.4 Plasmid DNA  
A 4.1 kb plasmid encoding Renilla luciferase (pRL-CMV) (Promega Corporation, 
Madison, WI) was used as the reporter gene. DH5α E.coli cells were transformed with the 
plasmid DNA and incubated in selective Luria-Bertani (LB) medium. Amplified plasmid 
DNA was purified using the Maxi-Prep DNA Purification Kit from Qiagen (Valencia, CA). 
The concentration and purity of the resulting DNA in a buffer (pH 7.5) of Tris-HCl and 
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ethylenediaminetetraacetic acid (EDTA) was determined by measuring the absorbance at 260 
nm and 280 nm. All DNA used had a 260/280 ratio of at least 1.80. 
 
2.5 Polyplexes  
Copolymer to DNA ratios are expressed as molar ratios of nitrogens (N) in pentablock 
copolymer to phosphates (P) in DNA, and written as N:P. The molecular weight of the 
DEAEM monomer is 185 and the average molecular weight of a nucleotide is approximately 
308. Using the fact that 1μg of DNA contains 3nmol of phosphates, the amount of polymer 
required for corresponding N:P ratios was calculated (Table I). All polyplexes were formed 
by the same procedure. Copolymers were first dissolved in Hepes buffer saline (HBS - 
20mM of HEPES with 145mM NaCl) pH 7.4, unless otherwise stated, to obtain a 
concentration of 1mg/ml. This polymer solution was then diluted with the desired media or 
buffer in a polypropylene tube. After incubating for 5 minutes at room temperature, this 
diluted polymer solution was added to DNA (in TE buffer) contained in another tube. The 
tube was gently agitated and allowed to incubate for 30 minutes at room temperature. 
 
2.6 Lactate dehydrogenase assay 
 Lactate dehydrogenase (LDH) is an integral cytosolic enzyme that is secreted out in the 
medium following the rupture of cell membrane25. Since the potential site of interaction of 
cationic macromolecules is the cell membrane, measuring the amount of LDH released in the 
medium has long been a preferred way to estimate membrane damage7. Cells were cultured 
in 96-well tissue culture plates at a density of approximately 1.2x104 cells per well. After 
incubation overnight, growth media was removed, and replaced with 200μl polymer solutions 
in appropriate media. Cells were incubated with polymer solutions for 6 to 48 hours, after 
which 100µL of media was then collected in an optically clear 96-well microtiter plate, and 
LDH concentration was assayed using a commercial kit (Tox-7 from Sigma-Aldrich Co) 
according to the supplier’s protocol. The absorbance of each well was measured at 490nm 
using a BioTek EL-340 plate reader (Winooski, USA). Background absorbance at 630nm 
was subtracted from the main readings. Media alone and media with only cells were used to 
obtain a background LDH level for normalization. Cells exposed to 0.1% Triton X-100 in 
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DMEM were used as a positive control, and set as 100% LDH release. The relative LDH 
release is defined by the ratio of LDH released over total LDH in the intact cells. Less than 
10% LDH release was regarded as an acceptable level in our experiments. All samples were 
run in four replicates, and experiments were repeated twice.  
 
2.7 MTT assay 
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay was used for 
the quantitative determination of cell viability. The assay is based on the cleavage of the cell 
membrane permeable yellow tetrazolium salt MTT into purple formazan by the "succinate-
tetrazolium reductase" system (EC 1.3.99.1) which belongs to the respiratory chain of the 
mitochondria, and is active only in metabolically intact cells.  
MTT assay was performed according to the method of Edmondson38. After incubating 
the monolayer of cells with polymer solutions for 6 to 48hrs in a 96-well plate, as described 
above for the LDH assay, polymer solutions were aspirated and replaced with 200μl of fresh 
DMEM without serum. 20μl of MTT stock solution prepared in phosphate buffer saline 
(PBS) pH 7.4 was then added to each well giving a final MTT concentration of 0.5mg/ml. 
After 4hr of incubation in a CO2 incubator, the unreacted dye was removed by aspiration and 
the insoluble formazan crystals were dissolved by incubating with 200μl dimethylsulfoxide 
(DMSO) for 2h in a humidified atmosphere (37°C, 5% CO2). Finally, the MTT absorbance 
was measured at 570nm. Background absorbance measured at 630nm was subtracted from 
the main readings. Viability was reported relative to control cells not exposed to the 
polymers. 
 
2.8 Microscopic observations 
After incubation with polymers, changes in morphology and detachment of cells from 
the dish were also observed using an Olympus IMT-2 (Melville, USA) inverted, phase-
contrast light microscope equipped with objectives of 10x and 4x magnification.  
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2.9 Agarose diffusion assay 
Our novel pentablock copolymers show sol-gel transitions. At w/w concentrations of 
20% or more, aqueous solutions of the copolymers form a gel at physiological temperatures. 
The gels dissolve in presence of excess water, as the polymer concentration decreases. 
Polymer concentration in the gels is around 1000 times higher than the concentrations in 
aqueous solutions at which about 80% of the cells are metabolically viable. However, the 
polymer gels dissolve slowly, and in an in vivo situation where the polymer gel complexed 
with the therapeutic gene would be subcutaneously injected at the site of tumor, polyplexes 
would have to diffuse through a mass of tissues to reach the targeted cells. Therefore, to 
mimic this situation, the polymer gels (containing 25 wt% of polymer) were placed on the 
top of an agarose gel layer covering SKOV3 cells underneath. The agarose matrices were 
made in DMEM, containing 10% FBS and 1% agarose. The polymer was allowed to diffuse 
to the cells for 24 hrs. The experimental model is shown in Fig 1. 
This method, derived from the work of Guess et al.39, was adapted from ISO procedures 
for cytotoxicity testing (ISO 109993-5. Biological evaluation of medical devices- Part 5: 
Tests for cytotoxicity: in vitro methods). Monolayers of SKOV3 cells were grown to 
confluence in 6 well plates, after which the culture medium was replaced with 3ml serum 
supplemented (10%) DMEM, containing 1% agarose, to generate a protective agarose layer. 
To avoid heat denaturation of serum proteins, agar was melted and cooled to 45°C before 
adding it to DMEM containing 10% FBS. The plates were left at room temperature for 15 
minutes to let the agarose solidify (melting point 32°C).  After the agarose layer was formed, 
3ml of vital stain neutral red solution (0.01% in PBS) was added to each well, and the plate 
was left to incubate for 30min at 37°C and 5% CO2. Excess dye was then removed and 
polymer gels were placed at the center on top of these solidified agarose matrixes. The cells 
were then incubated for another 24hrs. This assay is based on the migration or diffusion of 
toxic substances from the test article through the agarose to the cellular monolayer. The slow 
diffusion of leachable substances through the agarose results in a concentration gradient 
around the test article and a zone of dead cells if the leachable substances are toxic. Sample 
biocompatibility was estimated by observing cell lysis and zone of dead cells (marked by 
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decolorized zones) under and around the specimen by light microscopy at 150X 
magnification.  
The decolorized zones were scored as follows: 0 = no decolorization detectable; 1 = 
decolorization only under the specimen; 2 = zone not greater than 5 mm from the specimen; 
3 = zone not greater than 10 mm from the specimen; 4 = zone greater than 10 mm from the 
specimen; 5 = the total culture is decolorized. Cell lysis was defined as loss of cell membrane 
integrity, visible in light microscopy. Cell lysis was scored as follows: 0 = no cell lysis 
detectable; 1 = less than 20% cell lysis; 2 = 20% to 40% cell lysis; 3 = > 40% to < 60% cell 
lysis; 4 = 60% to 80% cell lysis; 5 = more than 80% cell lysis. 
For each specimen, one score was given, and the median score value for all parallels 
from each specimen was calculated for both the decolorization zone and the lysis zone. The 
cytotoxicity was classified as follows: 0-0.5 = non-cytotoxic; 0.6-1.9 = mildly cytotoxic; 2.0-
3.9 = moderately cytotoxic; 4.0-5.0 = markedly cytotoxic. The median (instead of the mean) 
was calculated to describe the central tendency of the scores because the results are expressed 
as an index in a ranking scale. 
 
2.10 Characterization of polymer induced cell death 
To elucidate whether the cell death induced by these polymers and polyplexes is 
apoptotic or necrotic in nature, staurosporine (Sigma #S-6942) was employed as a positive 
control for apoptosis. Staurosporine is an alkaloid that is a potent inhibitor of 
phospholipid/calcium-dependent protein kinase (protein kinase C), selectively inducing 
apoptosis40. SKOV3 cells were incubated in 96-well plates with polymers, polyplexes (as 
described earlier), and 200nM staurosporine for 5h. The effect of staurosporine on LDH 
release and metabolic activity of the cells was compared to that of the polymers and 
polyplexes. The Caspase-GloTM 3/7 Assay was employed to measure caspase-3 and -7 
activities in the treated cell cultures. These caspases play key effector roles in apoptosis in 
mammalian cells, and their presence confirms the induction of apoptosis. The assay provides 
a proluminescent caspase-3/7 substrate that contains the tetrapeptide sequence DEVD (Asp-
Glu-Val-Asp), a caspase-3/7 recognition site. The presence of activated caspases in the cells 
will result in the cleavage of the substrate, generating a “glow-type” luminescent signal 
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produced by luciferase. Luminescence is proportional to the amount of caspase activity 
present. The assay was performed in a 96-well plate with SKOV3 cells, according to the 
supplier’s protocol. Briefly, after incubating the cells with the test compounds for specified 
times in a white-walled 96-well plate, 100μl of Caspase-GloTM 3/7 Reagent was added to 
each well containing 100μl of treated cells in culture medium. Prior to this, culture plates and 
reagent were allowed to equilibrate to room temperature. Luminescence was measured on a 
Veritas™ Microplate Luminometer after incubating the treated cells with the reagent for 1 to 
3hrs. 
 
2.11 Luciferase Transfection 
In order to determine the total protein expressed by a reporter gene per total cellular 
protein, a luciferase assay was employed, using pRL-CMV as the reporter gene. Cells were 
seeded in a 96-well plate up to 70% confluency prior to transfection, and were then 
transfected with various polyplex solutions in 200µl OptiMEM I® using 1µg of DNA per 
well, unless otherwise stated.   After 4 to 10 hrs incubation in OptiMEM I®, the solution was 
replaced with fresh DMEM containing 10% FBS, and incubated for 44hrs.  Cells were then 
lysed using a lysis buffer (Renilla Luciferase Assay Lysis Buffer, Promega) and the 
luminescence of the expressed reporter protein was measured on an automated Veritas™ 
Microplate Luminometer using the Promega Renilla Luciferase Assay System (Madison, 
USA). ExGen was used as a positive control, and was expected to yield high efficiency of 
transfection.  Cells exposed only to DNA (without polymer) were used as negative controls.  
 Total recovered cellular protein content of the cells was determined by a modified 
Bradford assay, using a CB-Protein AssayTM Kit. Bovine serum albumin standards were 
prepared. Twenty microliters of the samples from luciferase detection protocol were placed 
in individual wells of a 96-well plate and diluted with nanopure water to 100µl. CB-Protein 
AssayTM reagent (100µl) was added into each well and mixed well. The plate was allowed to 
incubate for 15 minutes and absorbance was measured at 595nm. The amount of protein was 
read from the standard curve. 
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2.12 Statistics    
Where appropriate, the data is presented as mean and standard deviation (SD). Four 
samples were used for each case in all the experiments and, mean and SD were calculated 
over them.  Significant differences between two groups were evaluated by Students’ t-test 
and between more than two groups by one-way ANOVA analysis of variance, followed by 
Tukey’s test. The level of significance was set at p<0.05, unless otherwise stated. 
 
 
3 Results 
3.1 Effect of different wt% of PDEAEM on pentablock copolymer cytotoxicity 
Pentablock copolymers containing different wt% of PDEAEM were incubated with 
SKOV3 and A431 cell lines in DMEM (10% FBS) for an extended period of 48hr to 
determine the effect of the cationic block on the polymers’ cytotoxicity. After 48hrs, the 
damage to cell membranes, and their residual metabolic activity were evaluated using LDH 
and MTT assays, respectively. Figs 2a and 2b show trends in the membrane leakage and cell 
viability of SKOV3 cells respectively, and Figs 3a, 3b give the same trends for A431 cell line 
respectively. Two things are evident from these graphs. First, as the wt% of PDEAEM 
increases in the copolymers, there is a gradual increase in the damage to the cell membrane 
and a decrease in cell viability. Second, for each copolymer (except pentablock D containing 
60% PDEAEM for A431 cells) a concentration can be noted from the graphs below which 
the polymer causes less than 10% membrane damage and/or allows more than 80% of the 
cells to still be metabolically viable.  The copolymer containing 60% PDEAEM was found to 
be cytotoxic to A431 cells at almost all concentrations. The copolymers provide a unique 
way to tune the cytotoxicity for efficient use in gene therapy, as opposed to cationic polymers 
such as ExGen whose cytotoxicity can be controlled only by reducing the amount of polymer 
used. These results suggest that below a certain concentration, pentablock copolymers can 
have extended tissue-contact times of up to 48hrs without causing significant damage to the 
cells, which is of significance for in vivo studies. Also, it can be observed that A431 cells are 
slightly more sensitive to the copolymers than SKOV3, exhibiting more toxicity at similar 
polymer concentrations.  
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3.2 Toxicity increases with exposure time         
During in vitro transfection, cells were incubated with polyplexes in a low serum media 
OptiMEM I® to avoid polymer loss due to binding with serum proteins. Since cells need to 
be grown in 10% serum supplemented media for good protein expression of the transfected 
gene, they were first incubated with polyplexes for a limited time, and then the polymer 
solutions were replaced with fresh media containing FBS to let the transfected gene be 
expressed. 
Fig 4 shows the effect of incubation time of polyplexes with the cells on their toxicity. 
Polyplexes of pentablock copolymer B (26% PDEAEM), containing 1μg plasmid pRL-CMV 
and different amounts of copolymer, were incubated with the SKOV3 cells for 6 to 14hr in 
OptiMEM I®. For all polymer concentrations, it was observed that cell viability decreased on 
extending the incubation time of polyplexes with the cells. Typically at 50μg/ml, it decreased 
from 100% to 60% when incubation time was extended from 6 to 14hr. After 14hr of 
exposure, cell viability was reduced to 60% even at lower copolymer concentrations of 
30μg/ml. 
Cells were also incubated with just polymer solutions to examine how DNA 
complexation affects their cytotoxicity. Figs. 5a,b show that polyplexes were less toxic to the 
cells than the cationic polymers alone. The cellular membrane damage was significantly 
reduced by the DNA complexation to the polymer, possibly due to the shielding of positive 
charges on the polycations. At N:P ratio of 8, with polymer concentration of ~80μg/ml, the 
LDH release reduced from 86% to 7% after DNA complexation. Significant increase in the 
metabolic activity was also found at higher polymer concentrations corresponding to N:P 
ratios of 6 and above. This is in agreement with results seen by researchers for other 
polymers7,30,41.  
Toxicity of pentablock copolymers was compared to ExGen at concentrations 
corresponding to same N:P ratios, thus actually comparing the concentration of their cationic 
components that are responsible for DNA condensation and endosomolysis. SKOV3 cells 
were incubated for 6hrs with the polyplexes of two polymers in OptiMEM I®. Fig 6a shows 
that polyplexes of ExGen caused extensive cell membrane damage, as compared to that 
caused by pentablock copolymers. At a high N:P ratio of 8, while pentablock copolymers 
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showed only 10% LDH release, ExGen showed up to 85% LDH release. Further, as seen in 
Fig 6(b), MTT assay showed that at all N:P ratios, cell viability was significantly higher in 
the presence of the pentablock copolymers than with ExGen. These results clearly suggest 
that pentablock copolymers are less cytotoxic than ExGen, and perhaps the two polymers 
interact with the cells in a different fashion, inducing cell death by different mechanisms. 
 
3.3 Apoptosis vs necrosis 
Apoptosis is the carefully regulated process of cell death42. In contrast to the swelling 
and membrane rupture in necrosis, a cell undergoing apoptosis rapidly condenses into small 
enclosed fragments, which can then be phagocytosed by neighboring cells. Apoptosis can be 
characterized by the loss of mitochondrial membrane potential, activation of caspases, loss of 
plasma membrane asymmetry, and the condensing and eventual fragmentation of the cellular 
DNA43.  
Damage to the cell membrane, which can be determined by the LDH assay, is known to 
occur either in necrotic cells or in the late stage of apoptosis. On the other hand, loss of 
mitochondrial inner transmembrane potential is often associated with the early stages of 
apoptosis and may be one of the central features of the process44. Collapse of this potential 
results in the decoupling of the respiratory chain, which reduces the ability of dying cells to 
reduce compounds such as tetrazolium salt MTT into colored formazan product, as can be 
determined by the MTT assay. Since staurosporine selectively induces apoptosis into the 
cells, its effect on the LDH and MTT assays can be compared to those of ExGen and 
pentablock copolymers to try to understand the mechanism of cell death. 
As expected in apoptosis, Fig 7 shows that cells incubated with 200nm staurosporine for 
5hrs gave little LDH release, even though their metabolic activity was almost reduced to 
zero. Similar to this, as the concentration of pentablock copolymers increased, there was a 
significant decrease in metabolic activity of cells, but no significant change in the cell 
membrane damage. This hints that cell death in the presence of the pentablock copolymers 
might not be by necrosis, but might be through an apoptotic route. In contrast, as the 
concentration of ExGen increased, the decrease in metabolic activity of the cell population 
was accompanied with large LDH release. This indicates that cell death caused by the rapid 
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loss of membrane integrity (necrosis) primarily accounted for the decrease in number of 
viable cells in the presence of ExGen. 
The Caspase-GloTM 3/7 Assay was performed to check the induction of apoptosis in the 
cells. SKOV3 cells were incubated with polymer-DNA complexes at different N:P ratios, and 
the activity of caspases was measured at three different times of incubation- 3hrs, 4hrs, 6hrs. 
Different polymer concentrations and times of incubation were used to empirically find the 
conditions that would activate caspases in the cells. Staurosporine was used as the positive 
control. Fig 8 shows the results of these caspase assays. Staurosporine induced apoptosis by 
activating caspases after 4hrs and 6hrs of incubation, but no caspase activity was detected 
after 165 minutes incubation. However, no significant caspase activity was detected at any 
incubation time for any tested N:P ratio of pentablock copolymers’ or ExGen polyplexes. At 
higher incubation times or higher polymer concentrations, increased cell death was clearly 
visible using light microscopy, as it has been shown in LDH and MTT assays above.  
These results indicate that neither ExGen nor pentablock copolymers induced apoptosis 
in the treated cells. However, they did affect the cells differently. Unlike ExGen, that 
extensively ruptured the cellular membrane leading to cell death, pentablock copolymers 
appear to cause cell death by some alternative mechanism45-47. This has implications in 
minimizing the inflammatory processes accompanying cell death in the presence of the 
pentablock copolymers as opposed to the presence of ExGen. 
 
3.4 Luciferase Transfection  
The transfection efficiency of polymers depends on the amount of polymer used (N:P 
ratio) to condense the DNA, the amount of the DNA dose, and time for which cells are 
incubated with the polyplexes. The upper limit of all these factors in turn depends on the 
cytotoxicity of the polymer. As N:P ratio increases, amount of free polymer in the media 
increases, increasing the cell death, thereby effectively decreasing reporter protein 
expression. A higher DNA dose would generate more reporter protein, but will require higher 
amount of polymer for condensation, thus again being limited by the polymer toxicity 
profile. Also, increased exposure of cells to the polyplexes would allow polyplexes an 
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extended period of time to enter into the cells, but that would again increase the toxicity, as 
shown above in Fig 4.  
Keeping these above stated factors in mind, several different carcinoma cell lines were 
transfected with luciferase plasmid using pentablock copolymers, while ExGen was used a 
positive control. Ideal N:P ratios and ideal incubation times of polyplexes with the cell lines 
were obtained empirically for both the polymers, following manufacturer’s protocol for 
ExGen. Fig 9 shows the transfection obtained with pentablock B using 1μg pRL in SKOV3, 
A431 and DU145 cells. Polyplexes were incubated for 10hrs with the cells. As can be 
observed, pentablock copolymers were able to transfect all three cell lines. However, amount 
of gene expression obtained at similar N:P ratios was different in different cell lines. While 
luciferase expression increased significantly in all three cell lines by increasing N:P ratio 
from 4 to 6, the increase was much higher in DU145 cells than in SKOV3 or A431 cell lines. 
Also, while in SKOV3 cells luciferase expression peaked off at N:P ratio 8 and then 
decreased, it was almost the same (not significantly different) for different N:P ratios in 
A431 cells. 
As observed in Figure 9, the amount of luciferase protein expressed in the SKOV3 cells 
increased with the amount of copolymer used to condense the DNA (N:P ratio). However, 
after a certain polymer concentration, the luciferase expression decreased on further 
increasing the N:P ratio. Similar trends were observed in Figure 10 for ExGen. Toxicity of 
the polymers at these N:P ratios can be correlated from Figures 5 and 6. 
In Figure 11, comparing the transfection efficiency of pentablock copolymers and 
ExGen, it can be observed that maximum amount of luciferase expressed using pentablock 
copolymer E was approximately only 19 times less than that by given by ExGen. Polyplexes 
of both the polymers were incubated in OptiMEM I® with the cells for 3.5hrs using 0.6μg of 
pRL/well in a 96-well plate. It should be noted here that ExGen has been optimized over the 
years to give this good transfection, while optimum formulation of pentablock copolymers is 
still being investigated. Again, this figure also shows that there is an optimum concentration 
for both the polymers at which they give maximum transfection. Above that concentration, 
increased toxicity camouflages expression of the transfected gene.  
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Luciferase activity(RLU) in each well is not normalized by the total amount of 
protein(mg) as that gives artificially high values(RLU/mg) in the samples where total protein 
level has been reduced by the cell death. Instead, since all experiments were performed with 
same initial number of cells per well (~1.2 x 104) in a 96-well plate, luciferase expression is 
reported as RLU/well for each case.  
 
3.5 Polymer gel cytotoxicity studies 
Since the agarose matrix was transparent, images of the cells around the polymer gel and 
directly below the gel were taken using a light microscope after 24hrs of incubation. Fig 12 
shows these images of cells at 60x and 150x magnification. Since the cells were treated with 
the vital stain Neutral Red before placing the polymer gel on them, a decolorized zone on the 
plate can be observed if there were any cell deaths. The images show that there was a small 
decolorized spot (diameter < 1mm) directly below the polymer gel. However, the cells 
around it were stained red and seemed to be as healthy as those far away from the polymer 
gel. There was also no visible significant cell lysis around the polymer gel. The polymer gels 
of pentablock copolymers A, B and C were tested, and all of them appeared to be either non-
cytotoxic, or mildly cytotoxic. The results with their cytotoxicity scores have been 
summarized in Table II. The modulus and dissolution rate of these polymer gels depend on 
their molecular weight (MW)35. Copolymers with higher MW chains form stronger gels that 
dissolve over a longer period. Therefore pentablock B, which had lowest Mw (weight average 
MW), did not have a high modulus at 25 wt%, and dissolved and spread faster on the agarose 
matrix thus, causing cell death over larger radii.  
 
4 Discussion 
In this study we have evaluated cytotoxicity of new pentablock copolymers under 
different in vitro conditions. Different assays and cell types were used to determine various 
aspects of toxicity. Molecular weight of the synthesized copolymers was maintained below 
20kda, as that is the cut-off mass for renal excretion by the kidney, thus assuring final 
removal of copolymer from the body in an in vivo study. Copolymers with different wt% of 
PDEAEM blocks were studied to assess the effect of this cationic group on copolymers’ 
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toxicity. PDEAEM blocks of the copolymers, containing tertiary nitrogens, condense DNA 
and, are responsible for their pH buffering capacity that helps in the release of polyplexes 
from endosomes. Therefore, increasing PDEAEM content in the copolymers would increase 
both the amount of DNA they can condense, and their transfection efficiency. However, it 
was observed that as the wt% of PDEAEM increased from 17% to 60%, cell viability 
decreased significantly in SKOV3 and A431 cancer cell lines. Copolymers were incubated 
with cells in FBS supplemented DMEM for 48hrs at different concentrations. Copolymers 
with higher percentages of PDEAM (pentablock C and D) caused more leakage of the cell 
membrane, followed by decrease in metabolic activity, while those with up to 26% 
PDEAEM did not cause much cell membrane damage even at high concentrations. This 
increase in toxicity of copolymers can be explained by the fact that copolymers with higher 
wt% of PDEAEM block have higher cationic surface charge, and thus higher charge density.  
This higher cationic charge resulted in increased damage to the anionic cell membranes, as 
has been suggested by researchers for other polycations7. However, for all the copolymers 
(except for pentablock D on A431 cells) a concentration can be determined from the graphs 
below which they exhibited less than 10% LDH release and/or more than 80% cell viability 
even after 48hrs of incubation. This is of great significance for gene therapy applications 
involving longer tissue-contact time in vivo. 
A431 cells were found to be more sensitive to the copolymers, exhibiting comparatively 
less cell viability than SKOV3 cells at same polymer concentrations, especially in terms of 
cell membrane damage. This might be due to the different compositions of the membranes 
and glycocalyx of different cell lines7.  
Since pentablock copolymers C and D, containing 40 and 60wt% PDEAEM 
respectively, showed good transfection only at concentrations where high cell death was also 
observed (transfection data not shown), further detailed screening of other in vitro conditions 
was reported only with the pentablock copolymer B(26% PDEAEM). 
Polyplexes were found to be less toxic than the polycations alone. Complexing DNA 
with the polymer reduced the LDH release by up to 80% at N:P ratio of 8. A significant 
increase in cell metabolic activity was also observed. This indicates that free cationic 
copolymers perhaps damage cells due to their positive surface charge interacting with 
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cellular lipid membranes and other internal cell organelles. On binding with DNA, some of 
this surface charge is shielded, thus reducing their toxicity. Changes in the conformation of 
polycationic macromolecules on binding with DNA might also be a reason for this reduced 
toxicity. This is very much in agreement with other researchers7,41, but in contrast with 
Gebhart et al29, who reported using an MTT assay with Cos-7 cells that polyplexes of 
PEI(50K) and ExGen reduced the percent survival of cells by 40% compared to the 
polycations alone. At higher N:P ratios, though some of the polycation is used to condense 
DNA, the rest of it is available in the free charged form to interact with the cells, thus 
explaining decrease in cell viability.  
Toxicity of the polyplexes of pentablock copolymers was found to increase as their time 
of incubation with the cells in OptiMEM I® increased from 6 to 14hrs. Though at lower 
concentrations, polyplexes were not toxic even up to 10hr of incubation time, at higher 
concentrations, cell metabolic activity decreased significantly. This suggests that to transfect 
cells in vitro, there is an upper time-limit for which polymer-DNA solutions can be incubated 
with the cells in OptiMEM I®. After that, the polymer-DNA solution should be replaced 
with fresh media containing FBS for good growth of the cells. 
The toxicity of pentablock copolymers was compared to ExGen (22kda linear PEI). Both 
polymers seemed to affect the cells in different ways. While ExGen caused extensive damage 
to the cell membrane integrity, followed by a decrease in metabolic activity of the cells, 
pentablock copolymers showed no significant cell membrane damage even when the 
metabolic activity decreased below 80%. At the same N:P ratios, however, pentablock 
copolymers exhibited significantly higher cell viability than ExGen.  
These results led to investigation of the different mechanisms by which the two 
polymers interact with the cells. The cytotoxicity of polycationic macromolecules with 
different structures is influenced by various properties such as molecular weight, charge 
density, three dimensional arrangements of the cationic residues, structure, and 
conformational flexibility25,48. The types of amines in the polymer have also been reported to 
play a role in the toxicity. Ferruti et al13 had reported, based on his study with modified PLL, 
that polymers with tertiary amines exhibit lower toxicity that those with primary and 
secondary residues. Dekie et al49 had also noted that presence of primary amines on the poly 
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L-glutamic acid derivatives had a significant toxic effect on red blood cells. The observations 
presented here agree with other studies and show that that the pentablock copolymers, that 
have tertiary nitrogens, are significantly less toxic than ExGen, which has series of primary 
nitrogens, even though their molecular masses are almost the same (close to 20kda). 
Charge density of the polycations, resulting from the number and three dimensional 
arrangement of the cationic residues, together with the flexibility of the polycations, is 
another important factor influencing cytotoxicity. These factors determine the accessibility of 
the cationic charges to the cell surface50,51. Rigid molecules have more difficulty in attaching 
to the cell membrane than flexible ones. Interaction of cationic macromolecules with 
membrane proteins and phospholipids disturbs membrane function and structure28,52. ExGen 
is a linear and flexible polycation with a very high charge density (248nmol of nitrogen 
residues per μg), thus causing more damage to the anionic cell membranes. On the other 
hand, pentablock copolymers which exist as spherical micelles in an aqueous environment, 
have more of a globular structure with comparably less charge density (1-3nmol of nitrogen 
residues per μg), thus causing less damage to the cell membrane. Other such examples of 
polymers that show good biocompatibility because of their globular structures are PAMAM 
and cHSA (cationized human serum albumin), as reported by Fischer et al7. Another 
advantage of pentablock copolymers is that they have hydrophilic chains of PEO that shield 
the surface charge of the cationic PDEAEM, further decreasing their toxicity. In addition to 
this, the hydrophobic chains of PPO, which are known to interact with the cellular lipid 
membranes inducing structural changes53,54, enable easy access of pentablock copolymers 
into the cells and help in their translocation within the cells55,56. Furthermore, Pluronic® 
micelles had been shown to enhance sealing of permeablized membranes damaged by 
ionizing radiations or electroporation, thus preventing cell necrosis57,58; and increasing the 
rate of wound and burn healing59,60. Since pentablock copolymers form similar micelles, they 
might also be exhibiting these biological-response modifying activities of Pluronic®, thus 
explaining less cell membrane damage caused by the copolymers. These characteristics of 
pentablock copolymers are advantageous for in vivo studies, since less leakage of cell 
membranes of the treated cells would cause less inflammation to the surrounding cells. 
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The mechanism of cytotoxicity caused by polycations is not fully understood. In this 
study, two different possible mechanisms were observed. While the toxic effects of ExGen 
seemed to principally result from its interaction with the cell membrane, causing rapid 
rupture of cell membrane, followed by decrease in metabolic activity; the cytotoxicity of 
pentablock copolymers appeared to involve some mechanism other than just a membrane 
lytic effect.  
To obtain further insight into the mechanism of cell death, and differentiate between 
apoptotic and necrotic routes, a Caspase-GloTM 3/7 assay was employed. Demonstration of 
biochemical changes in the cells such as activation of caspases is commonly used to 
characterize apoptosis. Cells treated with positive control Staurosporine showed high activity 
of caspases, thus confirming induction of apoptosis. Staurosporine induced cell death showed 
typical features of apoptosis in MTT and LDH assays, such as complete loss of metabolic 
activity while cell membrane was still intact. For ExGen and pentablock copolymers, 
different polymer concentrations were tested for different incubation times with the cells. 
However, no significant caspase activity was detected for any of them, indicating that 
apoptosis was not occurring with either of the polymer. MTT assays however indicated 
reduced cell viability at these concentrations. This suggests that cells were dying, but not by 
apoptosis. An early and rapid loss of plasma membrane integrity by ExGen suggests a 
necrotic type of cell death, as noted by other researchers7. However, since pentablock 
copolymers neither cause damage to the cell membrane, nor induce apoptosis, but still reduce 
metabolic activity at high concentrations, additional mechanism of cytotoxity involving an 
intra-cellular route seems to be involved. There is a possibility that these polycations have 
specific interactions with a membrane component after cellular uptake45,46, that activate some 
signal transduction pathways inside the cell47, leading to cell death.  
Pentablock copolymers were tested for their transfection efficiency on different cell lines 
under various in vitro conditions using a luciferase plasmid. Pentablock copolymer B, 
containing 26% w/w PDEAEM, gave appreciable transfection in all the three cell lines 
tested. Since different cell lines have different composition of their membranes and 
glycocalyx, and different cell division rates, the rates of entry of polyplexes across the cell 
membrane and nuclear membrane differ in each of them. This affects both, the toxicity and 
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the transfection efficiency of the polymers, and explains why the level of luciferase 
expression was different in different cell lines at similar N:P ratios. While transfection in 
SKOV3 cells peaked at N:P ratio 8 and then decreased at N:P 10, it was not significantly 
different in A431 cells at N:P ratios of 6, 8, and 10. These results suggest that different cell 
lines have different optimum conditions under which they give best transfection, and should 
therefore be evaluated individually. 
Fig 9 and 10 show that the transfection efficiency of polymers in SKOV3 cell line peaks 
at certain N:P ratios and decreases after that. This means that above these N:P ratios, the 
toxicity of polymers increases to the extent that the cells die before they can express the 
transfected gene. Thus, at those high N:P ratios, even though transfection is good, not too 
many cells are left viable to express the transfected gene, thereby displaying less luciferase 
expression per well. The only way to work at higher N:P ratios and obtain high transfection 
while not increasing the polymer toxicity is to reduce the amount of DNA dose, as 
demonstrated in experiments with pentablock copolymer E (containing 28% w/w PDEAEM) 
(fig 11). The maximum amount of total luciferase expression obtained in SKOV3 cells with 
pentablock E was only 19 times less than the maximum given by ExGen. Two reasons can 
well explain this high gene expression by pentablock E in figure 11 compared to pentablock 
B in figure 10(a). First, it had slightly higher content of PDEAEM than pentablock B, thus 
being able to condense more DNA per polymer micelle. Second, in experiments with 
pentablock E, only 0.6μg of pRL/well was used (instead of 1μg used otherwise). Since lesser 
amount of polymer was required to condense 0.6μg DNA than 1μg DNA, it was possible to 
work at high N:P ratios (up to 10:1) with 0.6μg DNA and get higher transfection without 
compromising toxicity. It should be noted that with pentablock B complexed with 1μg 
plasmid (fig 10a), luciferase expression peaked at N:P 8:1, and it decreased beyond that 
value. These results clearly indicate that transfection efficiency of the polymers is critically 
correlated with their cytotoxicity, and that it can be optimized by adjusting the DNA dose 
and corresponding N:P ratios. Another thing to be noted is that though ExGen gives higher 
transfection than pentablock copolymers, it is also accompanied with high toxicity, as shown 
in figure 6 for corresponding N:P ratios. So some of the transfection observed might be from 
the cells that had subsequently died. 
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The agarose-matrix experiments simulating a tumor-model suggested that polymer gels, 
containing up to 1000 times higher polymer concentration than that used for experiments in 
liquid growth medium, did not kill the cells after diffusing through the agarose-matrix. 
Pentablock copolymers A, B and C, containing different wt% of PDEAEM block were tested 
on these agarose-gel matrices. Polymer gels of all these polymers were found to be non-toxic 
or mildly toxic. This indicates that in an in vivo experiment, a polymer gel can be implanted 
at the site of tumor, releasing polymer micelles over a period of time, without causing 
significant cell death in the vicinity. Thus, such a gel could even deliver genes complexed 
with the polymer in a sustained fashion to the targeted cells, providing extended gene 
expression, and maintaining desired level of the expressed therapeutic proteins without 
repeated injections. Complexes of DNA and pentablock copolymers have also been found to 
form gels, as reported earlier by our group33, and these gels were found to dissolve in excess 
buffer to release complexed plasmids, and not free plasmid.  
It should be clearly noted here that in our polymer-DNA gel system, gels dissolve to 
release polyplexes, which are subsequently up taken by the targeted cells. Recently, several 
polymer systems, like hydrogels of gelatin61, implantable polymer matrices (EVAc: poly 
(ethylene-co-vinyl acetate)) and injectable microspheres (PLGA and PLA)62, have been 
reported in the literature that encapsulate naked DNA and release it in a controlled fashion to 
the cells. In these cases, however, the encapsulation materials are inert and do not aid in the 
transfection.  No system has been reported till date to our knowledge that delivers complexed 
DNA (polyplexes) to the cells in a sustained fashion. Since polymer-DNA complexes give 
much higher transfection than naked DNA, it’s evident that our novel polymer-DNA gels can 
be instrumental in improving the gene therapy. 
 
 
5 Conclusions 
Pentablock copolymers were tested for their cytotoxicity under various in vitro 
conditions. Toxicity of these copolymers was found to increase relative to the wt% of their 
cationic block PDEAEM, and can thus be tuned by tailoring the cationic content in the 
copolymers while still preserving their DNA complexation properties. Below certain 
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concentrations, different pentablock copolymers could be incubated with cells in complete 
media for up to 48hr without exhibiting significant cell death. Polyplexes were found to be 
less toxic than polycations alone, as DNA condensation shields their surface charges. 
However, polyplexes caused more cell death at longer incubation time with the cells. 
Polyplexes of pentablock copolymers were found to be much less toxic than ExGen. While 
ExGen caused rapid loss of cell membrane integrity, followed by decrease in cell viability; 
pentablock copolymers caused less than 10% membrane leakage even at high concentrations 
where metabolic activity was reduced to less than 80%. None of the polymers however were 
found to induce apoptosis in the cells. Pentablock copolymers were hypothesized to cause 
cell death by activating some signal transduction pathway once they get into the cells. 
Optimum conditions that showed maximum transgene expression with minimal cell death 
were obtained by varying the DNA dose, the polymer concentration and N:P ratios. The 
transfection was found to be correlated to the toxicity of the polyplexes. Transfection 
obtained with pentablock copolymers was comparable to that shown by ExGen. Pentablock 
copolymers form thermo-reversible gels at higher concentrations and physiological 
temperatures. The agarose-matrix experiments with the 25wt% polymer gels proved that they 
were non-toxic or mildly toxic. This suggests that if formed subcutaneously at the site of 
tumors, pentablock copolymer gels can release polyplexes over a period of time, which can 
then diffuse through tumor tissues to the targeted cancer cells without damaging neighboring 
healthy tissues.  The thermo-reversible gelation features along with the good transfection 
efficiencies and tunable cytotoxicities make these new copolymers promising vectors for 
gene delivery.   
 
 
Acknowledgements  
The authors would like to thank Michael Determan for the synthesis and characterization 
(gel permeation chromatography, NMR) of pentablock copolymers. The synthesis and 
characterization of the pentablock copolymers was funded by US-DOE under contract 
number W-7405-ENG-82. The gene delivery work was supported by a Bailey Career 
Development grant. 
 116
References 
 
1. Schmidt-Wolf GD, Schmidt-Wolf IGH. Non-Viral and hybrid vectors in human gene therapy: 
an update. TRENDS in Molecular Medicine 2003;9(2):67-72. 
2. Merdan T, Kopecek J, Kissel T. Prospects of cationic polymers in gene and oligonucleotide 
therapy against Cancer. Adv. Drug Delivery Reviews 2002;54:715-758. 
3. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Advanced 
Drug Delivery Reviews 2002;54(5):631-651. 
4. Jeong B, Kim SW, Bae YH. Thermosensitive sol-gel reversible hydrogels. Advanced Drug 
Delivery Reviews 2002;54(1):37-51. 
5. Kost J, Langer R. Responsive polymeric delivery systems. Advanced Drug Delivery Reviews 
2001;46(1-3):125-148. 
6. Lauffenburger DA, Schaffer DV. The matrix delivers. Nature Medicine 1999;5(7):733-734. 
7. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of 
polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 
2003;24:1121-1131. 
8. De Groot CJ, Van Luyn MJA, Van Dijk-Wolthuis WNE, Cadee JA, Plantinga JA, Otter WD, 
Hennink WE. In vitro biocompatibility of biodegradable dextran-based hydrogels tested with 
human fibroblasts. Biomaterials 2001;22(11):1197-1203. 
9. Verma IM. A Tumultuous Year for Gene Therapy. Molecular Therapy 2000;2(5):415-416. 
10. Liu F, Huang L. Development of non-viral vectors for systemic gene delivery. Journal of 
Controlled Release 2002;78(1-3):259-266. 
11. Schatzlein AG. Non-viral vectors in cancer gene therapy: Principles and progress. Anti-
Cancer Drugs 2001;12(4):275-304. 
12. Gondsho A, Irie K, Susaki H, Iwasawa H, Okuno S, Sugawara T. Tissue-targetting ability of 
saccharide-poly(L-lysine) conjugates. Biol. Pharma. 1994;17:275-282. 
13. Ferruti P, Knobloch S, Ranucci E, Gialnasi E, Duncan R. A novel chemical modification of 
poly-L-lysine reducing toxicity while preserving cationic properties. Proc Int Symp Control 
Rel Bioact Matter 1997;24:45-46. 
14. Zauner W, Brunner S, Buschle M, Ogris M, Wagner E. Differential behaviour of lipid based 
and polycation based gene transfer systems in transfecting primary human fibroblasts: a 
potential role of polylysine in nuclear transport. Biochimica et Biophysica Acta (BBA) - 
General Subjects 1999;1428(1):57-67. 
15. Boussif O, et al. A versatile vector for gene and oligonucleotide transfer into cells in culture 
and in vivo: Polyethyleneimine. Proc. Natl. Acad. Sci. USA 1995;92:7297-7301. 
16. Iwai M, Harada Y, et al. Polyethylenimine-mediated suicide gene transfer induces a 
therapeutic effect for hepatocellular carcinoma in vivo by using an Epstein-Barr virus-based 
plasmid vector. Biochim, Biophys. Res. Commun. 2002;291:48-54. 
17. Godbey WT, Barry MA, Saggau P, Wu KK, Mikos AG. Poly(ethylenimine)-mediated 
transfection: a new paradigm for gene delivery. J Biomed Mater Res 2000;51(3):321-8. 
18. Tang MX, Fedemann CT, Szoka Jr FC. In vitro gene delivery by degraded polyamidoamine 
dendrimers. Biocnjug. Chem. 1996;7:703-714. 
19. Richardson SCW, Kolbe HVJ, Duncan R. Potential of low molecular mass chitosan as a 
DNA delivery system: biocompatibility, body distribution and ability to complex and protect 
DNA. International Journal of Pharmaceutics 1999;178(2):231-243. 
20. Erbacher P, Zou S, Bettinger T, Steffan AM, Remy JS. Chitosan-based vector/DNA 
complexes for gene delivery: biophysical characteristics and transfection ability. 
Pharmaceutical Research 1998;15(9):1332-1339. 
 117
21. P. Van De Wetering, N.M.E. Schuurmans-nieuwenbroek, M.J. van Streenbergen, D.J.A. 
crommelin, W.E. Hennink. Co-polymer of 2-(dimethylamino)ethyl methacrylate with 
ethoxytriethylen glycol methacrylate or N-vinyl-pyrroliodone as  gene transfer agents. J. 
Control. Release 2000;64:193-203. 
22. van de Wetering P, Cherng JY, Talsma H, Crommelin DJA, Hennik WE. (2-
dimethylamino)ethyl-methacrylate based copolymers as gene transfer agents. J control Rel 
1998;53:145-153. 
23. Brazeau GA, Attia S, Poxon S, Hughes JA. In vivo myotoxicity of selected cationic 
macromolecules used in non-viral gene delivery. Pharm. Res. 1998;15:680-684. 
24. Dash PR, Read ML, Barret LB, Wolfert MA, Seymour LW. Factors affecting blood clearance 
and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene therapy 
1999;6:643-650. 
25. Choksakulnimitr S, Masusa S, Tokda H, Takakura Y, Hashida M. In vitro cytotoxicity of 
macromolecules in different cell culture systems. J control Rel 1995;34:223-41. 
26. Florea BI, Meaney C, Junginger HE, Borchard G. Transfection efficiency and toxicity of 
polyethylenimine in differentiated Calu-3 and nondifferentiated COS-1 cell cultures. AAPS 
PharmSci 2002;4(3):E12. 
27. Hill IRC, Garnett MC, Bignotti F, Davis SS. In vitro cytotoxicity of poly(amidoamine)s: 
relevance to DNA delivery. Biochimica et Biophysica Acta (BBA) - General Subjects 
1999;1427(2):161-174. 
28. Morgan DML, Larvin VL, Pearson JD. Biochemical characterisation of polycation-induced 
cytotoxicity to human vascular endothelial cells. J. CELL SCIENCE 1989;94(3):553-559. 
29. Gebhart CL, Kabanov AV. Evaluation of polyplexes as gene transfer agents. Journal of 
Controlled Release 2001;73(2-3):401-416. 
30. Kean T, Roth S, Thanou M. Trimethylated chitosans as non-viral gene delivery vectors: 
Cytotoxicity and transfection efficiency. Journal of Controlled Release 2005;103(3):643-653. 
31. Fischer D, Bieber T, Li Y, ElsÃ¤sser H-P, Kissel T. A Novel Non-Viral Vector for DNA 
Delivery Based on Low Molecular Weight, Branched Polyethylenimine: Effect of Molecular 
Weight on Transfection Efficiency and Cytotoxicity. Pharmaceutical Research 
1999;16(8):1273-1279. 
32. van de Wetering P, Cherng J-Y, Talsma H, Hennink WE. Relation between transfection 
efficiency and cytotoxicity of poly(2-(dimethylamino)ethyl methacrylate)/plasmid 
complexes. Journal of Controlled Release 1997;49(1):59-69. 
33. Agarwal A, Unfer R, Mallapragada SK. Novel cationic pentablock copolymers as non-viral 
vectors for gene therapy. Journal of Controlled Release 2005;103(1):245-258. 
34. Anderson BC, Cox SM, Bloom PD, Sheares VV, Mallapragada SK. Synthesis and 
Characterization of Diblock and Gel Forming Pentablock Copolymers of Tertiary Amine 
Methacrylates, Poly(Ethylene Glycol) and Poly(Propylene Glycol). Macromolecules 
2003;36:1670-76. 
35. Determan MD, Cox JP, Seifert S, Thiyagarajan P, Mallapragada SK. Synthesis and 
characterization of temperature and pH responsive pentablock copolymers. Polymer 
2005;46(18):6933-6946. 
36. Determan MD, Guo L, Thiyagarajan P, Mallapragada SK. Supramolecular Self-Assembly of 
Multiblock Copolymers in Aqueous Solution. Langmuir 2006;22(4):1469-1473. 
37. Determan MD, Chieh-Tsung L, Thiyagarajan P, Mallapragada SK. Self-assembly of 
Temperature and pH-Responsive Pentablock Copolymers. Polymeric Materials:Science and 
Engineering 2005;23:808. 
38. Edmondson J. A Rapid and Simple MTT-based Spectrophotometric Assay for Determining 
Drug Sensitivity in Monolayer Cultures. J. Tissue Cult. Methods 1988;11:15-17. 
 118
39. Guess WL, Rosenbluth SA, Schimdt B. Agar diffusion method for toxicity screening of 
plastics on cultured cell monolayers. J Pharm Sci 1965;54:1545-1547. 
40. Koh J-Y, Wie MB, Gwag BJ, Sensi SL, Canzoniero LMT, Demaro J, Csernansky C, Choi 
DW. Staurosporine-Induced Neuronal Apoptosis. Experimental Neurology 1995;135(2):153-
159. 
41. Godbey WT, Wu KK, Mikos AG. Poly(ethylenimine) and its role in gene delivery. J Control 
Release 1999;60(2-3):149-60. 
42. Miller LJ, Marx J. Apoptosis. Science 1998;281(5381):1301. 
43. Lincz LF. Deciphering the apoptotic pathway: All roads lead to death. Immunol Cell Biol 
1998;76(1):1-19. 
44. Green DR, Reed JC. Mitochondria and Apoptosis. Science 1998;281(5381):1309-1312. 
45. Leroy D, Schmid N, Behr J-P, Filhol O, Pares S, Garin J, Bourgarit - JJ, Chambaz EM, 
Cochet C. Direct identification of a polyamine binding domain on the regulatory subunit of 
the protein kinase casein kinase 2 by photoaffinity labeling. Journal of Biological Chemistry 
1995;270(29):17400-17406. 
46. Arnold L.J. J, Dagan A, Gutheil J, Kaplan NO. Antineoplastic activity of poly(L-lysine) with 
some ascites tumor cells. PROC. NATL. ACAD. SCI. U. S. A. 1979;76(7):3246-3250. 
47. Vepa S, Scribner WM, Natarajan V. Activation of endothelial cell phospholipase D by 
polycations. American Journal of Physiology - Lung Cellular and Molecular Physiology 
1997;272(4 Pt 1):L608-L613. 
48. Rihova B. Biocompatibility of biomaterials: hemocompatibility, immunocompatiblity and 
biocompatibility of solid polymeric materials and soluble targetable polymeric carriers. 
Advanced Drug Delivery Reviews 1996;21(2):157-176. 
49. Dekie L, Toncheva V, Dubruel P, Schacht EH, Barrett L, Seymour LW. Poly--glutamic acid 
derivatives as vectors for gene therapy. Journal of Controlled Release 2000;65(1-2):187-202. 
50. Ryser HJ. A membrane effect of basic polymers dependent on molecular size. Nature 
1967;215(104):934-936. 
51. Singh AK, Kasinath BS, Lewis EJ. Interaction of polycations with cell-surface negative 
charges of epithelial cells. Biochimica et Biophysica Acta (BBA) - Protein Structure and 
Molecular Enzymology 1992;1120(3):337-342. 
52. Morgan DML, Clover J, Pearson JD. Effects of synthetic polycations on leucine 
incorporation, lactate dehydrogenase release, and morphology of human umbilical vein 
endothelial cells. J. CELL SCIENCE 1988;91(2):231-238. 
53. Batrakova EV, Miller DW, Li S, Alakhov VY, Kabanov AV, Elmquist WF. Pluronic P85 
enhances the delivery of digoxin to the brain: In vitro and in vivo studies. Journal of 
Pharmacology and Experimental Therapeutics 2001;296(2):551-557. 
54. Kostarelos K, Tadros TF, Luckham PF. Physical Conjugation of (Tri-) Block Copolymers to 
Liposomes toward the Construction of Sterically Stabilized Vesicle Systems. Langmuir 
1999;15(2):369-376. 
55. Melik-Nubarov NS, Pomaz OO, Dorodnych TY, Badun GA, Ksenofontov AL, 
Schemchukova OB, Arzhakov SA. Interaction of tumor and normal blood cells with ethylene 
oxide and propylene oxide block copolymers. FEBS Letters 1999;446(1):194-198. 
56. Batrakova EV, Li S, Vinogradov SV, Alakhov VY, Miller DW, Kabanov AV. Mechanism of 
pluronic effect on P-glycoprotein efflux system in blood-brain barrier: Contributions of 
energy depletion and membrane fluidization. Journal of Pharmacology and Experimental 
Therapeutics 2001;299(2):483-493. 
57. Hannig J, Zhang D, Canaday DJ, Beckett MA, Astumian RD, Weichselbaum RR, Lee RC. 
Surfactant sealing of membranes permeabilized by ionizing radiation. Radiation Research 
2000;154(2):171-177. 
 119
58. Lee RC, Hannig J, Matthews KL, Myerov A, Chen C-T. Pharmaceutical therapies for sealing 
of permeabilized cell membranes in electrical injuries. Annals of the New York Academy of 
Sciences 1999;888:266-273. 
59. Agren MS. An amorphous hydrogel enhances epithelialisation of wounds. Acta Dermato-
Venereologica 1998;78(2):119-122. 
60. Cao YL, Lach E, Kim TH, Rodriguez A, Arevalo CA, Vacanti CA. Tissue-engineered nipple 
reconstruction. Plastic And Reconstructive Surgery 1998;102(7):2293-2298. 
61. Kushibiki T, Tomoshige R, Fukunaka Y, Kakemi M, Tabata Y. In vivo release and gene 
expression of plasmid DNA by hydrogels of gelatin with different cationization extents. 
Journal of Controlled Release 2003;90(2):207-216. 
62. Luo D, Woodrow-Mumford K, Belcheva N, Saltzman WM. Controlled DNA Delivery 
Systems. Pharmaceutical Research 1999;16(8):1300-1308. 
 
 
 120
Table I: Molecular weights (MW) and polydispersity indices (PDI) of different pentablock 
copolymers. 
 
Pentablock 
copolymers 
wt% 
PDEAEM 
Mw 
(GPC) 
Mn 
(NMR) PDI 
nmol of 
Nitrogen/μg 
amount containing 
3nmol of nitrogen* 
A 17 40,112 15,000 2.36 1.01 2.96μg 
B 26 23,516 17,300 1.23 1.45 2.08 μg 
C 40 30,664 22,000 1.21 2.03 1.48 μg 
D 60 20,365 19,973 1.34 2.73 1.10 μg 
E 28 28,400 17,525 1.25 1.52 1.98 μg 
ExGen - - 22,000 - 248.64 12.1 ng 
 
*It is the amount of polymer required to condense 1μg of plasmid DNA such that molar ratio 
of nitrogens of the polymer to the phosphates of DNA is 1, using the fact that 1μg of DNA 
has 3nmol of phosphate. Synthesis of pentablock D used Pluronic® F68 as the macroinitiator 
while all others used Pluronic® F127. Mw: Weight average MW, Mn: Number average MW. 
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Table II: Summary of test results from agarose overlay analysis. Approximately 4mg of 
polymer gels containing 25 wt% of the polymer were placed on the top of agarose layer. 
 
Specimen Zone Index Lysis Index Cytotoxicity score Comment 
     
Pentablock A 0.5 0 0.5 Non-cytotoxic 
Pentablock B 2 1 1 Mildly cytotoxic 
Pentablock C 1 1 1 Mildly cytotoxic 
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Scheme 1: Structure of pentablock copolymers. 
 
Fig 1: Diffusion of polymer through a 1% agarose matrix of DMEM with 10% FBS, 
simulating a tumor-model. 
 
Fig 2: Cytotoxicity of pentablock copolymers with different wt% PDEAEM, on SKOV3 cell 
line after 48hr incubation in FBS supplemented DMEM, (a) percentage toxicity evaluated in 
terms of cell membrane damage using LDH assay, (b) residual metabolic activity evaluated 
by MTT assay, (n=4±SD). 
 
Fig 3: Cytotoxicity of pentablock copolymers with different wt% PDEAEM, on A431 cell 
line after 48hr incubation in FBS supplemented DMEM, (a) percentage toxicity evaluated in 
terms of cell membrane damage using LDH assay, (b) residual metabolic activity evaluated 
by MTT assay, (n=4±SD). 
 
Fig 4: Dose and time dependent effect of the polyplexes of pentablock copolymer B on 
SKOV3 cells incubated in OptiMEM I®. Residual metabolic activity was evaluated by MTT 
assay. Polyplexes contained 1μg of pRL, (n=4±SD). 
 
Fig 5: Comparing the cytotoxicity of polyplexes of pentablock copolymer B with that of the 
polycations alone on SKOV3 cells after 6hr incubation in OptiMEM I®, (a) LDH assay, (b) 
MTT assay. Polyplexes contained 1μg of pRL-CMV, (n=4±SD). * indicates p<0.1; ** 
indicates p<0.05; *** indicates p<0.01 
 
Fig 6: Cytotoxic effect of polyplexes of pentablock copolymer B and ExGen on SKOV3 cells 
after 6hr incubation in OptiMEM I®, (a) LDH assay, or (b) MTT assay. Polyplexes contained 
1μg of pRL-CMV, (n=4±SD). * indicates p<0.1; ** indicates p<0.05, ***indicates p<0.01 
 
Fig 7: Dose dependent effect of different polycations incubated with SKOV3 cells for 5hr. P: 
pentablock copolymer B, Ex: ExGen 500, strp: Staurosporine (200nM), (a) membrane 
damage by LDH assay, (b) percentage viability evaluated by MTT assay, (n=4±SD). * 
indicates p<0.1 
 
Fig 8: Activity of Caspases 3/7 in SKOV3 cells after incubation with different compounds 
for specified times, as found using Caspase-GloTM 3/7 assay. Ex:  ExGen 500, P: Pentablock 
copolymer B, Strsp: 200nm Staurosporine. All solutions were made in OptiMEM I® media. 
(n=4±SD). 
 
Fig 9: Luciferase expression obtained in DU145, SKOV3 and A431 cell lines by transfecting 
them with polyplexes of pentablock copolymer B and 1μg DNA at different N:P ratios, 
(n=4±SD). 
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Fig 10: Luciferase expression in SKOV3 cells after transfecting 1µg of DNA per well in a 
96-well plate with ExGen, at different N:P ratios. Polyplexes were incubated with cells for 
11hrs in OptiMEM I®, (n=4±SD). 
 
Fig 11: Luciferase expression in SKOV3 cells after transfecting 0.6µg of DNA with 
pentablock copolymer E and ExGen at different N:P ratios. Polyplexes were incubated with 
cells for 3.5hrs in OptiMEM I®, (n=4±SD). 
 
Fig 12: SKOV3 cells under agarose-gel matrix after 24hr incubation with a 25wt% gel of 
pentablock copolymer A placed on top of agarose matrix, at (a) 60x magnification, (b,c) 
150x magnification- regions right below and around the polymer gel. Scale bar=1mm. 
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Scheme 1: Structure of pentablock copolymers. 
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Fig 1: Diffusion of polymer through a 1% agarose matrix of DMEM with 10% FBS, 
simulating a tumor-model. 
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(a) 
 
(b) 
 
Fig 2: Cytotoxicity of pentablock copolymers with different wt% PDEAEM, on SKOV3 cell 
line after 48hr incubation in FBS supplemented DMEM, (a) percentage toxicity evaluated in 
terms of cell membrane damage using LDH assay, (b) residual metabolic activity evaluated 
by MTT assay, (n=4±SD). 
 127
(a) 
-20
0
20
40
60
80
10 25 40 55
Polymer conc (μg/ml)
%
 to
xi
ci
ty
A, 17% PDEAEM
B, 26% PDEAEM
C, 40% PDEAEM
D, 60% PDEAEM
 
(b) 
0
20
40
60
80
100
120
140
10 25 40 55
Polymer conc (μg/ml)
%
 v
ia
bi
lit
y
A, 17% PDEAEM
B, 26% PDEAEM
C, 40% PDEAEM
D, 60% PDEAEM
 
Fig 3: Cytotoxicity of pentablock copolymers with different wt% PDEAEM, on A431 cell 
line after 48hr incubation in FBS supplemented DMEM, (a) percentage toxicity evaluated in 
terms of cell membrane damage using LDH assay, (b) residual metabolic activity evaluated 
by MTT assay, (n=4±SD). 
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Fig 4: Dose and time dependent effect of the polyplexes of pentablock copolymer B on 
SKOV3 cells incubated in OptiMEM I®. Residual metabolic activity was evaluated by MTT 
assay. Polyplexes contained 1μg of pRL, (n=4±SD). 
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Fig 5: Comparing the cytotoxicity of polyplexes of pentablock copolymer B with that of the 
polycations alone on SKOV3 cells after 6hr incubation in OptiMEM I®, (a) LDH assay, (b) 
MTT assay. Polyplexes contained 1μg of pRL-CMV, (n=4±SD). * indicates p<0.1; ** 
indicates p<0.05; *** indicates p<0.01 
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Fig 6: Cytotoxic effect of polyplexes of pentablock copolymer B and ExGen on SKOV3 cells 
after 6hr incubation in OptiMEM I®, (a) LDH assay, or (b) MTT assay. Polyplexes contained 
1μg of pRL-CMV, (n=4±SD). * indicates p<0.1; ** indicates p<0.05, ***indicates p<0.01 
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Fig 7: Dose dependent effect of different polycations incubated with SKOV3 cells for 5hr. P: 
pentablock copolymer B, Ex: ExGen 500, strp: Staurosporine (200nM), (a) membrane 
damage by LDH assay, (b) percentage viability evaluated by MTT assay, (n=4±SD). * 
indicates p<0.1 
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Fig 8: Activity of Caspases 3/7 in SKOV3 cells after incubation with different compounds 
for specified times, as found using Caspase-GloTM 3/7 assay. Ex:  ExGen 500, P: Pentablock 
copolymer B, Strsp: 200nm Staurosporine. All solutions were made in OptiMEM I® media. 
(n=4±SD). 
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Fig 9: Luciferase expression obtained in DU145, SKOV3 and A431 cell lines by transfecting 
them with polyplexes of pentablock copolymer B and 1μg DNA at different N:P ratios, 
(n=4±SD). 
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Fig 10: Luciferase expression in SKOV3 cells after transfecting 1µg of DNA per well in a 
96-well plate with ExGen, at different N:P ratios. Polyplexes were incubated with cells for 
11hrs in OptiMEM I®, (n=4±SD). 
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Fig 11: Luciferase expression in SKOV3 cells after transfecting 0.6µg of DNA with 
pentablock copolymer E and ExGen at different N:P ratios. Polyplexes were incubated with 
cells for 3.5hrs in OptiMEM I®, (n=4±SD). 
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Fig 12: SKOV3 cells under agarose-gel matrix after 24hr incubation with a 25wt% gel of 
pentablock copolymer A placed on top of agarose matrix, at (a) 60x magnification, (b,c) 
150x magnification- regions right below and around the polymer gel. Scale bar=1mm. 
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Abstract 
This paper investigates the morphology of novel amphiphilic pentablock copolymers of 
poly(ethylene oxide) (PEO), poly(propylene oxide) (PPO), and poly(diethylamino ethyl 
methacrylate) (PDEAEM) and their condensates with plasmid DNA using cryo-TEM, and 
the intra-cellar path they take to reach the cell nuclei. The copolymers existed as spherical 
micelles of 20-30 nm diameters in the micrographs and condensed the plasmid DNA into 
compact, defined thread like structures with extended linear or ring like forms. At higher 
polymer/DNA ratios condensates were more compact, and were larger in number, decorated 
with the micelles of excess copolymer.  Similar compact structures were observed at even 
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lower polymer/DNA ratios at endosomal pH 4.7 where copolymer had increased protonation. 
Intra-cellular tracking of copolymer/DNA polyplexes using fluorescent labeling and confocal 
microscopy revealed that they were taken up by the cells all along the perimeter of the cell 
membrane, with some prominent localized discrete spots. Polyplexes were found to be 
trapped in endo/lysosomal vesicles for up to 7 hrs after transfection. Labeled DNA could be 
detected in the nucleus of the transfected cells 10 hrs post transfection, with most of it in 
perinuclear region, and very little in the rest of the cytoplasm. The fluorescence of labeled 
DNA was more diffuse in the perinuclear region compared to discrete spots observed with 
cells transfected with using ExGen 500®. Complexes of ExGen/DNA could be detected in 
perinuclear region and inside cell nuclei by only 4.5 hr and 6 hr, indicating their diffusion 
through cytoplasm was faster and involved mechanisms other than those associated with 
pentablock copolymers. The nuclear import of polyplexes, and not their trafficking to the 
perinuclear region, was found to limit the transfection efficiency of the copolymers. 
Expression of green fluorescence protein (GFP) in the cells transfeced with GFP plasmid 
using pentablock copolymers confirmed the transfection. This study identifies critical steps 
upon which to focus for improving the DNA condensation process and enhance their intra-
celluar trafficking which can lead to improvement in gene delivery technology using cationic 
polymers. 
 
Keywords: Confocal microscopy, Cryo-TEM, Block copolymers, Transfection, 
Fluorescence, Polyplexes 
 
 
1. Introduction 
Cationic polymers that can condense negatively charged DNA into nanoparticles have 
been reported to be efficient and versatile non-viral gene delivery vectors in a number of 
applications in vivo, and are currently being evaluated in several clinical gene therapy 
trials1,2. The critical problems that limit the gene delivery efficiency of existing polymeric 
systems are low and transient transfection efficiency, cytotoxicity, and colloidal stability of 
their complexes with DNA3,4. While several novel and second generation copolymers have 
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been reported to address these issues5,6, understanding the the morphology of polymer/DNA 
complexes and identifying the limiting steps in their intra-cellular trafficking after cellular 
uptake is critical in improving the transfection efficiency of these copolymers.  
Polycations condense negatively charged plasmid DNA into compact, ordered 
mononuclear or polynuclear complexes (20-200nm in diameter) via electrostatic 
interactions7. DNA condensation is a reversible, linear polymer to globule transition process. 
Approximately 90% of the electrostatic repulsion between DNA segments must be 
neutralized to allow condensation to occur8. Studies have demonstrated that at a certain 
critical ratio of the polycation to DNA, the latter undergoes localized bending and distortion, 
which facilitates formation of rods, toroids7 and spheroids9 like nanoparticles.  
Cryo-TEM has been utilized in a number of applications in the study of DNA 
molecules10,11, and micellar structures of amphiphilic block copolymers12,13. Rapid cryogenic 
vitrification of sample solutions in cryo-TEM enables direct real-space imaging of 
nanostructures in their native state in aqueous conditions, avoiding staining and drying 
artifacts involved in conventional TEM. This is of great significance in investigating multi-
component self-assembled structures that are formed by a combination of interactions. 
Supercoiling of the plasmid DNA14 have been visualized successfully using cryo-TEM. 
Gustafsson and colleagues revealed the structural features of complexes formed between 
plasmid DNA and cationic liposomes15. Simberg et al10,16 displayed heterogeneity in size and 
structure of cationic lipid-DNA complexes, and their aggregation with serum proteins. 
Our research into the cationic polymer agents for gene delivery has been focused on 
novel amphiphilic block copolymers of poly(ethylene oxide) (PEO), poly(propylene oxide) 
(PPO), and poly(diethylamino ethyl methacrylate) (PDEAEM), with a family of these 
synthesized17 and subjected to various physiochemical17,18 and biological 
characterizations19,20. These copolymers exist as micelles in aqueous solutions, formation 
driven by low lower critical solution temperature (LCST) of central PPO group that forms a 
hydrophobic core stabilized by a hydrophilic corona of PEO and PDEAEM chains. The 
hydrodynamic diameter of these polymeric micelles is around 25 nm17 which is relatively 
small compared to other colloidal drug carriers such as liposomes and emulsions21.  These 
cationic copolymers, with partially protonated tertiary nitrogen of PDEAEM blocks at pH 
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7.4, condense the DNA into nanoparticles of size around 100 to 150nm dia, as shown by 
DLS, MALLS and TEM, and protect it against degradation by nucleases19,22. We have shown 
that these copolymers successfully transfect several different cancer cell lines with 
transfection efficiencies comparable to linear PEI (ExGen 500®) while exhitbing significantly 
less cytotoxicity compared to ExGen 500®20. In this report we have attempted to understand 
the effect of polymer concentration and environmental pH on the formation of these 
polyplexes by studying their morphology using cryo-TEM. An increased knowledge of such 
structures will benefit the understanding of DNA condensation process and facilitate 
improvement of the gene delivery efficiency of these copolymers. 
A lot of speculations have been made on the mechanism of transfection by 
polycations23,24 but the processes governing their intracellular transport remain elusive. 
Several studies have been reported on the intra-cellular paths taken by DNA condensates of 
PEI and PLL25-27 which, however, conflict on whether polyplexes of PEI get trapped into the 
endosomes to escape later, or they don’t ever get into the endosomes at all.  The studies also 
showed that polyplexes of PLL and PEI followed different paths from the cell membrane to 
the nucleus, and used that to explain the different transfection efficiency of the two 
polycations. These reports definitely suggest that a different polycation can have different 
mechanism of cell transfection and should therefore be investigated individually. Therefore, 
here we have attempted to examine using fluorescent labeling and confocal microscopy the 
intracellular paths taken by the pentablock copolymer/DNA complexes during gene 
transfection. This work would help identify the critical rate limiting steps in the intra-cellular 
trafficking of the copolymers, thereby allowing for the development of strategies to 
overcome these barriers. 
 
 
2 Materials and Methods 
2.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), OptiMEM I®, heat inactivated qualified 
fetal bovine serum (FBS), 0.25% trypsin-EDTA solution and Hank’s Buffered Salt Solution 
(HBSS), ExGen 500® (written as ExGen henceforth), EDTA, TAE buffer, Lysotracker Red® 
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DND-26, DAPI (4'-6-Diamidino-2-phenylindole), and ethidium monoazide (EMA) were 
purchased from Invitrogen (Carlsbad, CA). HEPES salt was purchased from Sigma (St 
Louis, MO). Ultrapure water with at least 18 megaohm resistivity was used in all studies.
 
2.2 Polymers 
Pluronic F127 [(PEO)100-b-(PPO)65-b-(PEO)100] micro pastille surfactant was donated by 
BASF (Florham Park, NJ) and used without further modification. Pentablock copolymers of 
PDEAEM-b-PEO-b-PPO-b-PEO-b-PDEAEM were synthesized using an ATRP reaction 
scheme as explained in detail elsewhere . Molecular weight and poly-dispersity of the 
copolymers were measured using H  NMR 
17
1  (in deuterated chloroform) and GPC (THF 
mobile phase, poly(methylmethacrylate) calibration standards). Copolymers reported in this 
study had 20wt% of PDEAEM, with architechture- PDEAEM8-PEO100-PPO65-PEO100-
PDEAEM8 and Mn = 18520 and Mw/Mn = 1.14. Copolymers were synthesized with a 
molecular weight less than 20KDa so that in an in vivo application they can be removed from 
the body via renal clearance system after gene delivery. It can be calculated that 1μg of this 
copolymer has 1.03 nM of nitrogen residues. The molecular weight of the DEAEM monomer 
is 185. 
 
2.3 Cells 
The SKOV3 human ovarian carcinoma cell line, obtained from ATCCTM (Manassas, 
VA), was used for all experiments. Cell cultures were maintained in a humidified 
environment with 5% CO2 at 37°C and passaged regularly to allow them to remain sub-
confluent. Cells were fed with DMEM growth media supplemented with 10% FBS and 1μM 
L-glutamine, unless otherwise stated. Neither antibiotics nor antimycotics were used to avoid 
the possibility of artificial membrane permeabilization effects from these agents. 
For confocal microscopy, cells were grown onto glass coverslips coated with a cell 
adhesive poly(L-lysine) (PLL) film. The cover slips were placed in 6-well cell culture plates. 
Approximately 10,000 cells were plated on each coverslip by placing 500µl of growth media 
containing the cells. Once the cells adhered to the coverslips, growth media was in each well 
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was to made up to 2 ml. The cells were then incubated overnight to allow them to become 
70% confluent before transfection.  
2.4 Plasmid DNA 
Plasmid DNA pEGFP-N1 with 6732bp (Clontech, Mountain View, CA), encoding for 
green fluorescence protein (GFP), was used as the reporter gene. DH5α E.coli cells were 
transformed with the plasmid DNA and incubated in selective Luria-Bertani (LB) medium. 
Amplified plasmid DNA was purified using the Maxi-Prep DNA purification kit from 
Qiagen (Valencia, USA). The concentration and purity of the resulting DNA in TE buffer, 
pH 7.4 was determined by measuring the absorbance (A) at 260 nm and 280 nm. All DNA 
used had a A260/A280 ratio of at least 1.80. 
DNA was labeled with the fluorescent probe ethidium monoazide (EMA, 8-azido-3-
amino-6-phenyl-5-ethylphenanthradinium chloride). EMA can be photolysed in the presence 
of nucleotides to yield fluorescently labeled nucleic acids23,28. The labeled plasmid emits red 
fluorescence at around 600 nm when excited with a 488 nm laser. Covalently bound EMA-
DNA was prepared as follows, adapted from procedures described previously29,30. To 200 µg 
of pEGFP-N1 in 2 mL water, 5 µg of EMA was added, giving a 50:1 molar ratio of 
nucleotide to probe. After a 30 min incubation period on ice in dark, the solution was 
exposed to UV light of principal wavelength 312 nm for 20min. Excess EMA and the 
intercalated but not covalently bound EMA was removed by performing ethanol precipitation 
three times. In each cycle, the DNA was precipitated using sodium acetate buffer, pH 4.7 by 
incubating at -20°C for an hour, then pelleted by centrifugation at 15000 rpm at 4°C for 10 
min, and suspended in fresh TE buffer, pH 8.0. The finally obtained labeled DNA pellet was 
suspended in 100 µL TE buffer, pH 7.4 to be used for transfection experiments.  
 
2.5 Polyplexes 
Polymer/DNA complexes were prepared at different molar ratios of nitrogen (N) in the 
pentablock copolymer to phosphates (P) in DNA, written as N:P. The average molecular 
weight of a nucleotide is approximately 308. Using the fact that 1μg of DNA contains 3 nM 
of phosphates, the amount of polymer required for corresponding N:P ratios was calculated. 
Polyplexes were formed by following the precise order of mixing DNA and pentablock 
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copolymers, described in detail elsewhere20. Pentablock copolymers dissolved in 0.5x HBS, 
pH 7.0 (Hepes buffer saline- 20 mM of HEPES with 145 mM NaCl) were added to the 
plasmid DNA contained in a 1.5ml Eppendorf tube with final volume made to 200 uL using 
excess buffer. The tube was vortexed gently and allowed to incubate for 20 min at room 
temperature. For cryo-TEM, samples were prepared with different N:P ratios in 0.5x HBS 
buffer at desired  pH such that final DNA concentration in the samples was 10 μg/mL.  
For transfecting cells on cover slips to be used for confocal microscopy, all polyplexes 
were prepared with 3 μg plasmid at N:P ratio of 13 with final volume made up to 1ml using 
OptiMEM I® growth media. To test the transfection efficiency of copolymers, SKOV3 cells 
growin in 12-well cell-culture plates were transfected with polyplexes containing 3ug 
DNA/well in 1ml OptiMEM I®.   In all cases, the polymer solutions were aspirated 3 hr after 
incubation with cells. Cells were washed with HBSS buffer and further incubated for desired 
period of time in complete growth media to detect expression of GFP. Cells incubated with 
naked DNA (without polymer) were used as controls. Number of cells expressing the GFP 
protein 48hrs after transfection with pEGFP was counted by Flow-Cytometry, as described 
before19. 
 
2.6 Cryo-TEM 
Vitrified specimens of the polymer/DNA complexes were prepared for transmission 
electron microscopy (TEM) in a controlled environment vitrification system (CEVS) at 25°C 
and 100% relative humidity, as previously described 31. Briefly, a drop of the solution was 
applied onto a perforated holey-carbon film, supported on an electron microscopy 200 mesh 
copper grid, and held by tweezers in the vitrification system chamber. The sample was 
blotted with a filter paper, and immediately plunged into liquid ethane at its freezing point (–
183°C). Samples were examined in a Philips CM120 or an FEI T12 G2 cryo-dedicated 
transmission electron microscopes (Eindhoven, The Netherlands), operated at 120 kV, using 
either an Oxford CT-3500 (for the CM120; Oxford Istruments, Abingdon, England) or a 
Gatan 626 (for the T12; Gatan, Pleasanton, CA) cooling holders and transfer stations. 
Specimens were equilibrated in the microscope below –178°C, examined in the low-dose 
imaging mode to minimize electron beam radiation damage, and recorded at a nominal 
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underfocus of about 2µm to enhance phase-contrast. Images were acquired digitally by a 
Gatan MultiScan 791 (CM120) or a US1000 (T12) cooled charge-coupled device camera 
(Gatan, Pleasanton, CA) using the Digital Micrograph 3.1 software package. 
 
2.7 Labeling 
Half an hour prior to observing cells under the confocal microscope, growth media was 
replaced with a 70 nM freshly prepared LysoTrackerTM Red DND-26 solution in complete 
growth media. Cell incubation continued at 37°C until confocal imaging was performed. The 
lysosomal marker emits red light in far red region, peaking at 620 nm when excited at 568 
nm. DAPI was used to stain the cell nuclei. Cells were washed with HBSS, and then 
incubated in 300 nM solution of DAPI in PBS buffer for 5 min before finally fixing them 
with 4% paraformaldehyde. Stained nuclei were excited using a mercury-arc lamp and 
observed under the fluorescence microscope. 
 
2.8 Confocal microscopy 
At different time points after transfection, each coverslip was removed from 6-well plates 
and washed in a stream of PBS. Cells were fixed with 4% paraformaldehyde. After drying 
the bottom of coverslip, it was mounted on glass slides, and one drop of PBS was placed in 
between to keep the cells from drying out. Imaging was done with a Hamamatsu Orca CCD 
camera on a Nikon Eclipse inverted microscope equipped with standard epifluorescence 
illumination and differential interference contrast (DIC) optics. Confocal images were 
collected with a Prairie Technologies Confocal Microscope (Prairie Technologies, Madison, 
WI). All imaging and physiological functions were controlled by Prairie Technologies 
software. Image analysis was done with MetaView software (Universal Imaging 
Corporation). An argon/krypton mixed gas laser with excitation lines at 488 and 568 was 
used to induce fluorescence. Excitation of EMA bound to DNA was achieved by using the 
488 nm excitation line, with the resulting fluorescent wavelengths observed by using a 600/40 
nm notch filter. Red fluorescence of lysotracker dye was induced by the 568 nm excitation 
line and detected again using a 600/40 nm notch fitler. A z-series of typically 25 images with 
a spatial resolution of 0.3 to 0.5µm was collected.  
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3 Results 
3.1 Morphology 
Amphiphilic pentablock copolymers with hydrophobic PEO blocks and hydrophilic PPO 
blocks form micellar structures in aqueous solutions. The cryo-TEM is an excellent 
technique to observe the conformation and morphology of such structures as the micelles are 
preserved in the sample preparation process. The vitrification process captures the micellar 
structures in a state as close as possible to the native state without the need for artifact-
inducing staining-and-drying32. Fig. 1a show that micelles of pentablock copolymers have 
spherical or disc shaped morphology at pH 7.4 with a size range of 20 to 40 nm diameter. 
Since the pKa of PDEAEM block is around 7.4, it displays good solubility in aqueous buffers 
at pH 7.4 and forms the part of the hydrophilic corona. However, when the copolymers are in 
a buffer of pH 4.7, mimicking the environment inside the lysosomes, there is increased 
protonation of tertiary nitrogens in PDEAM groups. Thus, the micelles with hydrophilic 
PDEAEM groups on their surface have increased positive surface charge on them. This 
results in the repulsion of positively charged polymer chains in the corona of micelles and 
among the neighboring micelles. As a result, as seen in Fig. 1b, the size of micelles at pH 4.7 
is much smaller than that observed at pH 7.4 and they are more sparsely located.  
PDEAEM blocks of the pentablock copolymer are partially protonated at pH 7.4, and 
can therefore electrostatically condense the negatively charged plasmid DNA into 
nanocomplexes. Representative images of DNA condensates formed using these amphiphilic 
copolymers at N:P ratio 13 and pH 7.4 are shown in Fig. 2a.  It can be noticed that plasmid 
DNA is condensed into fine thread like nanostructures of around 100 nm size. Most of these 
long extended threads tend to enclose and form rings. It has been shown by several 
researchers that uncondensed plasmid DNA displays a relaxed, large open-loop structure 
with little twisting or fasciculation of the strands33,34. Compared to that relaxed morphology, 
the structures observed in Fig 2a are more defined, condensed, and compact, and it is 
apparent that DNA condensation has occured. Similar loose rings and extended linear 
plectonemic-like structures of polymer/DNA complexes have been reported previously using 
AFM and TEM with PEG-b-PLL35 and, TEM on PEG-g-PEI36 block copolymers. It should 
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be noted, as has also been argued previously33, that compact toroids of DNA condensates 
seen in several studies with cationic polymers using conventional TEM35,37 were formed as a 
result of constriction of loose rings, like the ones observed in images shown in this report, 
during dehydration. The hydrated natural form of the polyplexes, preserved in cryo-TEM and 
AFM samples, is much looser than that revealed by TEM. A comparison of AFM and TEM 
images of PEG-poly(amidoamine)-PEG copolymer / DNA complexes shown by Rackstraw 
and colleagues also supports this argument33. They suggested that dehydration of samples in 
TEM imaging reduced the size of structures obtained and alter the relative proportions of the 
condensate types (ring like or linear), as opposed to structures obtained from AFM imaging 
performed in PBS. 
More condensed and compact nanostructures were obtained when larger amount of 
copolymer to DNA (N/P) ratio was used. As shown in Fig. 2b and c, at N/P 26 the thread like 
nanostructures are less extended, greater in numbers, and had a greater tendency to bend into 
ring like structures. This can be explained by the greater cationic charge provided by larger 
molar concentration of protonated nitrogens to electrostatically bind plasmid DNA. On 
further increasing the polymer concentration to get an N:P ratio of 52 in the formulation, 
more compact DNA condensates were formed, as seen in Fig. 2d. The thread like structures 
were more like rods, and tend to bend into smaller ring shaped structures. Small spherical 
micellar like structures (~25nm in diameter) were also noticed decorating these DNA 
condensates, also seen in Fig. 2c. These are the micelles of extra pentablock copolymer used 
at this high N:P ratio. This suggest not all copolymer is used up in condensing the plasmid 
DNA, and a lower N:P ratio would be enough to form DNA condensates of this size. 
The pentablock copolymers presented here are pH sensitive polymers, with a good 
buffering capacity at low pH, a property that help polymer/DNA condensates in the escape 
from low pH endosomal vesicles during their intra-cellular trafficking38. The tertiary 
nitrogens of PDEAEM group in the copolymer get protonated at low pH, giving them 
enhanced positive surface charge. To observe the effect of this increased cationic charge on 
condensation of DNA, we examined the morphology of polyplexes formed in a buffer of pH 
4.7, found in the acidic lysosomal vesicles of the cells. As shown in Fig. 3a and b, the DNA 
condensates formed similar thread like structures as observed at pH 7.4; however they were 
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less extended, and had greater tendency to form closed loops or rings. The number of 
condensates that could be seen in all the images were also significantly less than that 
observed with similar N:P ratio at pH 7.4 (Fig. 2a).  A probable reason could be that since 
copolymers had greater cationic charge at lower pH, the subsequent polyplexes had higher 
positive surface charge as lesser amount of it was neutralized in DNA condensation. This 
would have resulted in repulsion between the condensates, and hence they were found in less 
density in any imaged region. Also to be noticed are free polymer micelles decorating these 
threads like structures of polyplexes (Fig. 3a). This further confirms that at pH 4.7 smaller 
amount of cationic copolymer was required to completely condense the plasmid DNA, and 
rest of it was left free in solution. Fig. 3c shows that at higher N:P ratio of 26 in pH 4.7 
buffer, as expected, more compact condensates of polyplexes were formed and greater 
amount of free polymeric micelles decorating the thread like structures were present. 
As had been suggested earlier that nucleic acid compaction rather than surface charge 
was critical for efficient nuclear trafficking39, this cryo-TEM study indicates that DNA 
condensates of 100-150 nm formed by pentablock copolymers should have a good capability 
to deliver the DNA to the cell nuclei.  
 
3.2 Intra-cellular trafficking 
Cells grown on PLL coated coverslips were transfected with EMA-labeled DNA, or its 
condensates with linear PEI (ExGen) or pentablock copolymers. Previous biocompatibility 
studies have indicated that pentablock copolymers are non-cytotoxic at lower N/P ratios and 
provide efficient transfection in the SKOV3 cells20. Since efficient DNA condensation was 
observed at N/P ratio of 13 in cryo-TEM studies, all pentablock copolymer polyplexes used 
in presented confocal microscopy studies were made at N/P 13. Polyplexes at N/P ratio 26, 
though provide better transfection because of better DNA compaction, were found to have 
greater cytotoxicity20 (unpublished data22). Cells were observed for the location of 
fluorescence from EMA-DNA at different time points after transfection. Lysosomes and 
nuclei were labeled in some of the slides to examine the entrapment of DNA inside these cell 
organelles. Since EMA is a membrane impermeable dye, all the fluorescence of EMA seen 
inside the cells is due to EMA covalently bound to the DNA. Efforts were made to make sure 
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that any EMA just intercalated into the grooves of DNA is removed during purification in 
DNA labeling process. Plasmid DNA containing covalently bound EMA is not capable of 
getting transcribed and produce reporter protein40. Therefore, unlabelled plasmids were used 
for gene expression experiments. Images were taken at settings, e.g. laser intensity, PMT 
voltage, and pin-hole size, where no background fluorescence from the cells could be 
detected (Fig. 4). Nuclei of SKOV3 cells stained with DAPI are shown in Fig 4 to give a 
perspective of their shape and size.  
After incubating the cells with pentablock copolymer/DNA complexes for 30 min, a 
faint fluorescence could be seen homogenously all over the coverslip, outlining the cells, 
with little clumps forming on the cell membrane. Most of the polyplexes at this time point 
were expected to be removed from the coverslip during the washing step since they were not 
yet internalized by the cells. After 2 to 4 hr of incubation, faint fluorescence outside the cells 
disappeared (Fig. 5). All the fluorescence was on the inner surface of cell membrane, with 
most of it localized in small discrete spots. These spots may be some discrete features on the 
cell membrane, such as coated pits, where most of the polyplexes attached to the cell 
membrane, and were then up taken into the cells via endocytosis. The observation of 
fluorescence all along the perimeter of cell membrane suggests that some polyplexes did 
enter the cells by a mechanism other than endocytosis. It could be by fusion of positively 
charged complexes with the anionic plasma membranes followed by trafficking of the 
amphiphilic copolymer across lipid bilayer as observed with other amphiphilic lipids and 
micellar polymeric structures41-43. Between 2-6 hrs, the number of such discrete spots of 
fluorescence increased, and so did their size, as they moved away from the cell membrane 
toward the nucleus (Fig. 5). The increase in size may be due to the fusion of endosomes with 
lysosomes. By 6 hr post-transfection (Fig. 5, a central 0.35 μm thick x-y plane of the cells), 
the fluorescence from labeled DNA was dispersed all over in the cytoplasm enclosing a dark 
patch with no fluorescence at all; the patch with no fluorescence is the nucleus and is clearly 
outlined by fluorescence.. Some fluorescence in the cytoplasm was localized in descrete 
vesicles of defined shapes, most likely representing the polyplexes entrapped in endosomes 
or lysosomes. The diffused fluorescence in the cytoplasm suggests that some of the 
polyplexes had already escaped out of the endosomes. Most of this diffused fluorescence was 
 149
located around the nucleus, suggesting that the polyplexes escaped the lysosomes mainly in 
the peri-nuclear region. To ensure entrapment of labeled DNA in endosomes, the low-pH 
vesicles of endosomes/ lysosomes were labeled with LysoTracker dye, and confocal images 
of lysosomes and DNA in same planes were aligned. As shown in Fig. 6, central plane of an 
SKOV3 cell 7 hr after transfection had yellow spots in the cytoplasm that represent the red 
colored endosomes containing green fluorescence of entrapped labeled DNA. It should be 
noticed that there is green fluorescence outside these vesicles too. The color of lysosomes 
containing labeled DNA varies between various shades of yellow to red, indicating different 
amounts of DNA entrapped inside.  
By 10 hr post-transfection, fluorescence from labeled DNA could be detected inside the 
nuclei of SKOV3 cells (marked with arrow in Fig 7). Different planes of an SKOV3 cell 
around a central plane are shown as a montage in Fig. 7 to confirm the localization of 
fluorescence inside the nucleus. A lot of labeled DNA could also be detected in the 
perinucear region, suggesting nuclear import of polyplexes is one of the rate limiting steps. 
Another representative image showing fluorescence from labeled DNA in a central plane of 
SKOV3 cells in presented in Fig. 8 along with their z-plane. Four distinct observations can 
be made in this image. First, fluorescence is localized inside the nuclei clearly marking the 
whole nuclei in the x-y plane. Second, most of the diffused fluorescence noticed in the 
cytoplasm at earlier time points has disappeared completely in some parts. Third, some 
fluorescence is seen on the peripheral cell membrane clearly outlining the cells. This might 
be due to the recycling endosomes that finally merge back with the cell membrane at the end 
of their cycle. Labeled-polyplexes still attached to the inner surface of these vesicles appear 
on the surface of the cell membrane when the vesicles fuse back with it. Fourth, the 
fluorescence in the cytoplasm is organized on one side of the nucleus in a distinct structure 
that resembled gogli-apparatus, and most likely involved microtubule organizing center. In a 
recent study by Suh et al24 it was suggested that besides thermal-motion driven diffusion, 
PEI/DNA nanocomplexes were actively transported through cytoplasm along the 
microtubules by motor-proteins towards the micro-tubule organizing center located adjacent 
to the cell nucleus. Such active transport along the microtubules might also be involved in the 
trafficking of cationic pentablock copolymer/DNA polyplexes, resulting in the accumulation 
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of these polyplexes in the perinuclear region. The faster accumulation of ExGen/DNA 
complexes than those of pentablock copolymers in the perinuclear region and their 
subsequent earlier detection in the nuclei possibly indicates they have higher diffusion rate 
(thermal and active taken together) in the cytoplasm. Another possibility may be that 
microtubule associated motor protein-driven active transport is more involved in trafficking 
of ExGen/DNA complexes than with pentablock copolymers. The cells in Fig. 7 and 8 were 
stained with lysotracker dye but the fluorescence was too weak to be detected suggesting that 
most of the low pH vesicles have disappeared from cytoplasm after either being disrupted by 
copolymers, or by final fusion with the cell membrane at the end of their cycle.  
Cells transfected with the EMA-DNA using ExGen were imaged to investigate any 
difference in the intra-cellular pathway of these polyplexes from those of pentablock 
copolymers. The fluorescence from labeled DNA was found to be localized in the low-pH 
vesicles of the cells up to 4.5 hr after transfection, as shown in an aligned central plane of an 
SKOV3 cell in Fig. 9. This suggests that ExGen polyplexes also get entrapped into the 
endosomes and need to escape them to get into the nucleus. Nuclei of these ExGen 
transfected cells in Fig. 9 can be seen as a dark patch outlined with the fluorescence in 
perinuclear region. Fluorescence of labeled DNA could be detected in the nuclei of cells by 
only 6 hr post-transfection (as compared to 10 hr with pentablock copolymers). One of such 
bright spots is marked with an arrow in Fig. 10 showing a montage of different planes of an 
SKOV3 cell, ensuring localization inside the nucleus. Fluorescence in the perinculear region 
was localized in discrete spots, suggesting the ExGen/DNA complexes were bound to some 
intra-cellular components, potentially lysosomes or micro-tubule organizing center24. This is 
in contrast to the diffused fluorescence observed in Fig 7 in the perinuclear region of cells 
transfected with pentablock copolymers.  However, most of the fluorescence had disappeared 
from the cytoplasm of these cells too. This is more clearly visible in ExGen transfected 
SKOV3 cells shown in Fig. 11. To reiterate, labeled DNA can be detected either in the 
nucleus of the cells, or in few discrete patches in the cytoplasm. It can be ensured by looking 
at the x-y plane and z-plane that these bright spots are not inside the nuclei. The dark patches 
in the cytoplasm could also be noticed.  
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In the cells incubated with only EMA-DNA, all the fluorescence was always found in 
discrete patches in the cytoplasm, with none of it ever detected inside the nucleus. However, 
the fluorescence of labeled DNA could be seen in the cytoplasm even 15 hr post-transfection 
(data not shown). This may be due to the small fragments of degraded labeled DNA still 
trapped in the recycling endosomes/ lysosomes. 
The present study suggests, within the confinement of variables studied, that polyplexes 
of both pentablock copolymers and ExGen get trapped in the acidic endosomal vesicles and 
their escape from these vesicles is not a limiting step in the final delivery of ferried DNA to 
the nucleus. The pentablock copolymers have a pKa of pH ~7.3 with a good buffering 
capacity at low pH17. This property potentially aids in the escape of their polyplexes from the 
endosomal vesicles via proton sponge hypothesis38, similar to that hypothesized for ExGen25. 
The diffused fluorescence in the perinuclear region and inside the nucleus 10 hr post-
transfection of cells does confirm their escape from endosomes. A critical barrier in the 
trafficking of polyplexes to the nucleus is getting passed the nuclear membrane. Though real 
mechanism of polyplex entry into the nucleus is still elusive25,26, it may involve interaction of 
cationic copolymer/DNA complexes with anionic phospholipids located in the cytoplasm and 
on the nuclear membrane44,45. As hypothesized earlier25, one possible mechanism of nuclear 
entry could be that as polyplexes are released from endosomes, they retain a portion of 
phospholipid coated membrane electrostatically bound to them. This membrane fragment 
could fuse with the nuclear membrane and facilitate entry of bound polyplexes into the 
nucleus. This argument is supported by the observation that naked DNA, which could not 
bind to the phospholipids, was never detected inside the nucleus. Nevertheless, large 
fluorescence of labeled DNA in the perinuclear region even 10hr post-transfection does 
suggest that nuclear import of polyplexes is the primary rate-limiting step in pentablock 
copolymers mediated gene transfection and should be of focus in their further development. 
Adding nuclear localization signals (NLS) to the reactive ends of pentablock copolymers can 
possibly aid their nuclear import46. Further, previous studies with PEI and PLL have shown 
that nuclei of cells directly microinjected with their polyplexes did show transgene 
expression39. This suggests that even if pentablock copolymers were bound to DNA inside 
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the nucleus, the nuclear machinery is capable of releasing the plasmid bound to cationic 
copolymers and transcribe it for protein expression. 
Although detailed mechanism of nuclear entry and endosomal escape still needs to be 
elucidated, this work confirms that cationic pentablock copolymers reported here do deliver 
the DNA into the nucleus. The trafficking involves uptake by endosomes, diffusion in the 
cytoplasm, escape from endosomes, accumulation in the perinuclear region and final uptake 
by cell nucleus. 
 
3.3 Transfection efficiency 
The final confirmation of delivery of the exogenous gene ferried by copolymers into the 
nucleus of the cells was made by observing the expression of green fluorescence protein 
(GFP) encoded by the pEGFP plasmid. Fig. 12a and b show fluorescent images of GFP 
expressed in SKVO3 cells 48 hr post-transfection with pentablock copolymer/DNA 
complexes. The intracellular GFP can be seen to fill the cytoplasm of the cells. The intensity 
of fluorescence in the cells varied from low to high, suggesting amount of GFP expression 
differed among the cells. One possible reason explaining this could be that different amount 
of DNA was delivered to the nuclei of different cells. The number of SKOV3 cells 
expressing GFP protein19, and total amount of reporter luciferase protein expressed in the 
cells after transfecting with a luciferase expressing plasmid has been reported in previous 
reports19,20. The transfection efficiency of the pentablock copolymers was found to be 
comparable to ExGen.   
 
4 Conclusions 
The novel cationic amphiphilic pentablock copolymers exist as spherical micelles in 
aqueous solutions and efficiently condense plasmid DNA into linear or ring shaped thread 
like structures of 100 to 150 nm diameter. At lower pH, or at higher concentration of 
copolymer, the condensates were more compact. Lower amount of copolymer was required 
to condense DNA at acidic pH. Intracellular trafficking studies revealed that the 
copolymer/DNA complexes were efficiently taken up the cells all along their perimeter, 
mainly via endocytosis. The buffering capacity of copolymer at low pH aids in the release of 
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polyplexes from endosomal vesicles possibly via proton sponge hypothesis. Polyplexes could 
escape the endosomes to assemble in the perinuclear region and finally get localized in the 
nucleus of the cells. Transport of copolymer/DNA complexes was slower than ExGen/DNA 
complexes in the cytoplasm, indicating involvement of different mechanisms in the 
trafficking of the two copolymers. The study indicates that nuclear import of polyplexes, and 
not their diffusion through cytoplasm, is the limiting step in their intra-cellular trafficking 
and should be of focus in their further development.  
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Fig. 1: Micellar structures of pentablock copolymers formed in aqueous buffers at (A) pH 
7.4, and (B) pH 4.7.  
 
Fig. 2: Plasmid DNA condensed in extended thread like nanostructures with pentablock 
copolymers in a pH 7.4 buffer at (a) N/P13, (b and c) at N/P 26, and (d) at N/P 52. More 
compact nanostructures with a greater tendency of extended threads to bend into rings were 
formed at higher N/P ratios. A large number of polymeric micelles decorating the DNA 
condensates can also be observed at these higher N/P ratios. 
 
Fig. 3: Plasmid DNA condensed in extended thread like nanostructures with pentablock 
copolymers in a pH 4.7 buffer at (A and B) N/P13, (C) at N/P 26. 
 
Fig. 4: Background fluorescence from SKOV3 cells. Image at the top left shows a central 
plane of the cells obtained with confocal microscopy using a 488 nm laser and 600/40 notch 
filter at settings (e.g. laser intensity, PMT voltage, pin-hole size) similar to that used for all 
other images. At the top right is a digital image of the cells nuclei. At the bottom is a digital 
image of another set of cells nuclei stained with DAPI. Scale bar is 10 μm. 
 
Fig. 5: Labeled DNA in SKOV3 cells transfected using pentablock copolymers (a) 2 hr, (b) 4 
hr, and (c) 6 hr after transfection. Scale bar is 10 μm. 
 
Fig. 6: Labeled DNA localized in acidic endolysosomal vesicles (labeled with LysoTracker 
Red®) of an SKOV3 cell 7 hr after transfection using pentablock copolymers. Image shows a 
central plane of the cells. Left image shows green fluorescence from DNA, center one shows 
fluorescence from acidic vesicles and the right image is formed by aligning other two 
images. Scale bar is 10 μm. 
 
Fig. 7: Labeled DNA localized in (marked with arrow) and around the nucleus of an SKOV3 
cell 10 hr after transfection using pentablock copolymers. The image shows a montage of the 
images of different planes of the cell (~0.35μm thick). Inset shows a digital image of the cell 
nucleus. Scale bar is 10 μm. 
 
Fig. 8: Labeled DNA localized in and around the nucleus of the SKOV3 cells 10 hr after 
transfection using pentablock copolymers. The image at the left shows a central plane of the 
cells (~0.35μm thick), the center image shows z-plane of the cells, and the right one is a 
digital image of the cells nuclei. Scale bar is 10 μm. 
 
Fig. 9: Labeled DNA localized in acidic endolysosomal vesicles (labeled with LysoTracker 
Red®) of an SKOV3 cell 4.5 hr after transfection using ExGen. Left image shows green 
fluorescence from DNA, center one shows fluorescence from acidic vesicles and the right 
image is formed by aligning other two images. Scale bar is 10 μm. 
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Fig. 10: Labeled DNA localized in (marked with arrow) and around the nucleus of an 
SKOV3 cell 6 hr after transfection using ExGen. The image shows a montage of images of 
different planes of the cell (~0.35μm thick). Inset shows a digital image of the cell nuclei. 
Scale bar is 10 μm. 
 
Fig. 11: Labeled DNA localized in and around the nucleus of the SKOV3 cells 6 hr after 
transfection using ExGen. Top left image shows a central plane of the cell, top right shows a 
digital image of the cell nuclei, bottom left shows the complete cell formed by stacking all 
planes together, and bottom right shows the z-plane of the cells. Scale bar is 10 μm. 
 
Fig. 12: Expression of green fluorescent protein in SKOV3 cells 48hr post-transfection with 
pentablock copolymer/pEGFP DNA complexes at (a) N/P 5, and (b) N/P 13. 
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Fig. 1: Micellar structures of pentablock copolymers formed in aqueous buffers at (A) pH 
7.4, and (B) pH 4.7.  
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Fig. 2: Plasmid DNA condensed in extended thread like nanostructures with pentablock 
copolymers in a pH 7.4 buffer at (a) N/P13, (b and c) at N/P 26, and (d) at N/P 52. More 
compact nanostructures with a greater tendency of extended threads to bend into rings we
formed at higher N/P ratios. A large number of polymeric mi
re 
celles decorating the DNA 
ondensates can also be observed at these higher N/P ratios. 
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Fig. 2d.
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Fig. 3: Plasmid DNA condensed in extended thread like nanostructures with pentablock 
copolymers in a pH 4.7 buffer at (A and B) N/P13, (C) at N/P 26. 
 
 163
 
 
C
 
Fig. 3c. 
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Fig. 4: Background fluorescence from SKOV3 cells. Image at the top left shows a central 
plane of the cells obtained with confocal microscopy using a 488 nm laser and 600/40 notch 
filter at settings (e.g. laser intensity, PMT voltage, pin-hole size) similar to that used for all 
other images. At the top right is a digital image of the cells nuclei. At the bottom is a digital 
image of another set of cells nuclei stained with DAPI. Scale bar is 10 μm. 
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Fig. 5: Labeled DNA in SKOV3 cells transfected using pentablock copolymers (a) 2 hr, (b) 4 
hr, and (c) 6 hr after transfection. Scale bar is 10 μm. 
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Fig. 6: Labeled DNA localized in acidic endolysosomal vesicles (labeled with LysoTracker 
Red®) of an SKOV3 cell 7 hr after transfection using pentablock copolymers. Image shows a 
central plane of the cells. Left image shows green fluorescence from DNA, center one shows 
fluorescence from acidic vesicles and the right image is formed by aligning other two 
images. Scale bar is 10 μm. 
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Fig. 7: Labeled DNA localized in (marked with arrow) and around the nucleus of an SKOV3 
cell 10 hr after transfection using pentablock copolymers. The image shows a montage of the 
images of different planes of the cell (~0.35μm thick). Inset shows a digital image of the cell 
nucleus. Scale bar is 10 μm. 
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Fig. 8: Labeled DNA localized in and around the nucleus of the SKOV3 cells 10 hr after 
transfection using pentablock copolymers. The image at the left shows a central plane of the 
cells (~0.35μm thick), the center image shows z-plane of the cells, and the right one is a 
digital image of the cells nuclei. Scale bar is 10 μm. 
 
 
 169
 
 
 
Fig. 9: Labeled DNA localized in acidic endolysosomal vesicles (labeled with LysoTracker 
Red®) of an SKOV3 cell 4.5 hr after transfection using ExGen. Left image shows green 
fluorescence from DNA, center one shows fluorescence from acidic vesicles and the right 
image is formed by aligning other two images. Scale bar is 10 μm. 
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Fig. 10: Labeled DNA localized in (marked with arrow) and around the nucleus of an 
SKOV3 cell 6 hr after transfection using ExGen. The image shows a montage of images of 
different planes of the cell (~0.35μm thick). Inset shows a digital image of the cell nuclei. 
Scale bar is 10 μm. 
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Fig. 11: Labeled DNA localized in and around the nucleus of the SKOV3 cells 6 hr after 
transfection using ExGen. Top left image shows a central plane of the cell, top right shows a 
digital image of the cell nuclei, bottom left shows the complete cell formed by stacking all 
planes together, and bottom right shows the z-plane of the cells. Scale bar is 10 μm. 
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Fig. 12: Expression of green fluorescent protein in SKOV3 cells 48hr post-transfection with 
pentablock copolymer/pEGFP DNA complexes at (a) N/P 5, and (b) N/P 13. 
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Abstract 
Polymer/DNA complexes of novel pentablock copolymers of poly (diethylamino ethyl 
methacrylate) (PDEAEM) and Pluronic F127 were investigated from a physiochemical point 
of view for stability and transfection efficiency in serum-supplemented media. Dynamic light 
scattering revealed that the copolymers condensed plasmid DNA into polyplexes of 100 
to150 nm diameter. The transfection efficiency of the copolymers in SKOV3 cells incubated 
in OptiMEM I® media was comparable to that of commercially available ExGen 500®. 
However, in serum supplemented growth media, the pentablock copolymer based systems 
formed large aggregates of >600nm dia, drastically reducing their transfection efficiency. 
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Adding unmodified Pluronic to the formulations stabilized these polyplexes against 
aggregation with serum proteins by sterically shielding their cationic surface charge, 
producing polyplexes of ~150-200nm in serum supplemented buffers which gave high levels 
of transfection. Shielding of cationic surface charges significantly reduced the cytotoxicity of 
cationic coplymers too, thereby further increasing transgene expression. Cryo-TEM 
micrographs showed that adding free Pluronic to the polyplex solutions significantly reduced 
the large number of globules and platelets of serum proteins that were aggregated around the 
thread like nanostructures of polyplexes. Nuclease resistance studies revealed that pentablock 
copolymers by themselves were effective enough to protect the condensed plasmid against 
degradation, and that adding free Pluronic to the formulations had no effect on their nuclease 
resistance efficiency. Though the total amount of DNA retained by polyplexes of ExGen 
500® after nuclease digestion was more than that retained by pentablock copolymers, the 
amount of plasmid retained in supercoiled form by both the systems was not significantly 
different. However, the cytotoxicity of pentablock copolymers was significantly less than the 
ExGen 500® systems. This versatile multi-component micellar system of copolymers 
provides high transfection efficiency with significantly less cytotoxicity in complete growth 
media and warrants good performance in systemic applications.  
 
Keywords: Block-copolymers, Gene delivery, Colloidal stability, Transfection, 
Cytotoxicity 
 
 
1. Introduction  
The delivery of therapeutic genes to the targeted cells using non-viral vectors is widely 
being explored nowadays as a viable alternative to viral vectors, especially via cationic 
polymers [1, 2]. More than a dozen new first generation and second-generation polymeric 
systems have been reported just in the past 5 years [3, 4]. Researchers have increasingly 
recognized that dangers associated with domesticating viruses for gene delivery such as 
insertional mutagenesis, potential oncogenesis, immunogenicity and, long-term effect of the 
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integrated transgene, along with production and packaging problems, can successfully be 
overcome by designing intelligent synthetic non-viral systems [5, 6].  
Cationic polymers electrostatically condense negatively charged DNA into nanoparticles, 
forming stable polymer/DNA complexes, “polyplexes” [7]. However, though many of these 
polymeric vectors perform well in vitro in reduced serum conditions, they suffer from serious 
drawbacks when tested in vivo [8]. Binding of these polycations to DNA imparts excess 
positive surface charge to the complexes, which results in non-specific interactions with 
cellular blood components (erythrocytes), vessel endothelia and plasma proteins in an in vivo 
application [9]. In a systemic application, this leads to their aggregation and accumulation in 
the “first pass organs” such as lungs (consequently causing pulmonary embolism), liver and 
spleen, and finally opsonization and clearance by the reticuloendothelial system (RES), 
limiting their therapeutic applications [10, 11]. Particle size, charge and stability of these 
polyplexes are key factors in determining their biodistribution, circulation time and 
transfection efficiency in vivo [12]. Different strategies have been developed to improve the 
in vivo stability and efficacy of first-generation polymers [13, 14], resulting in a variety of 
second generation copolymers made by covalently linking polycations to a non-ionic water 
soluble polymer, such as poly(ethylene glycol (PEG) [15-19], transferrin [20, 21], or poly(N-
(2-hydroxypropyl)methacrylamide (pHPMA) [22, 23], forming a block or graft copolymer 
architechture. Adding such hydrophilic ligands or grafts to the polycations increases their 
aqueous solubility, and shields their surface charges, creating a steric barrier against 
aggregation in blood streams or extra-cellular matrix [23, 24]. 
Recently we reported the development of novel amphiphilic pentablock copolymers which 
form thermo-reversible injectable gels, as potential vectors for sustained gene delivery [25]. 
These copolymers have triblock Pluronic F127 in the center, with cationic PDEAEM 
poly(diethylaminoethylmethacrylate) groups attached to their ends using an atom-transfer 
radical polymerization (ATRP) reaction scheme [26]. The copolymers form micelles because 
of the lower critical solution temperature (LCST) of hydrophobic PPO chains, and retain the 
thermoreversible gelation properties of the Pluronic. The cationic PDEAEM groups 
(pKa~7.3) electrostatically condense DNA into nanoparticles, and provide a good buffering 
capacity at low pH that aids in the release of entrapped polyplexes from the acidic endosomal 
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vesciles[27]. As in Pluronics, where the presence of hydrophobic PPO chains provide them 
with the unique ability to be incorporated into cell membranes [28, 29], the PPO chains in the 
pentablock copolymers are expected to enhance cell interactions and increase translocation of 
polyplexes into the cells, with minimal damage to the cell membrane integrity, as compared 
to the cationic homopolymers PDEAEM or PDMAEM (poly 
dimethylaminoethylmethacrylate) [30]. These novel pentablock copolymers provide very 
good transfection efficiency, comparable to ExGen 500® (linear PEI), in reduced serum 
growth media, with minimal cytotoxicity [31], and are expected to retain the biological 
response modifying properties of the Pluronics [32] as well, making them good candidates to 
be further investigated for gene therapy.  
Here we report the design of formulations of these novel copolymer/DNA complexes to 
impart serum stability. Since pentablock copolymers are derived from Pluronic F127, it was 
observed that adding Pluronic F127 to the polyplex formulations added stabilization in serum 
supplemented media, preventing formation of large aggregates. Both copolymers 
(pentablocks and Pluronic F127) form micelles in aqueous solutions. It was speculated that 
when free F127 is added to the polyplex solution, the hydrophobic PPO chains of free 
Pluronic would bind to the PPO chains of pentablock copolymers on the surface of 
polyplexes, while the PEO chains of free Pluronic would shield their surface charge. This 
self-assembly of two copolymers could then sterically stabilize the polyplexes against 
aggregation with serum proteins. In the present work we have tested the stability and 
transfection efficiency of this multi-component gene-delivery system in serum supplemented 
media. The formulations were investigated from a physiochemical point of view by 
measuring their particle size, zeta-potential, and resistance of incorporated DNA towards 
nuclease digestion in serum containing buffers at various concentrations of constituent 
components.  The goal was to investigate how efficiently, and at what weight ratios, adding 
free Pluronic stabilizes the polyplexes, and to assess the role of each component in the 
overall transfection process. 
The knowledge obtained from the current work will be applied toward optimizing the 
design of this multi-component micellar system for ongoing in-vivo gene delivery studies in 
our labs. These pentablock copolymers are particularly promising toward clinical gene 
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therapy because they are derived from Pluronics which are known to exhibit biological 
activity [32], such as sensitizing multi drug resistant (MDR) cancer cells [33], and effects on 
cell membrane properties [28]. Complete understanding of this copolymer system is further 
important in its development as a controlled gene delivery system, as injectable aqueous 
pharmaceutical formulations of these copolymers can form thermo-reversible gels in situ at 
physiological temperatures [26, 31], a valuable characteristic which can be exploited for 
sustained delivery of polyplexes to localized tissues. 
 
2 Materials and Methods 
2.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), OptiMEM I®, fetal bovine serum (FBS), 
0.25% trypsin-EDTA solution, Hank’s buffered salt solution (HBSS), Ultra-pureTM agarose, 
EDTA, TAE buffer, Lysotracker Red® dye and, ethidium bromide were purchased from 
Invitrogen Inc, CA. HEPES salt, Heparin Sodium salt (cat # H-4784) and XTT (2,3-
bis[2methoxy-4-nitro-5-sulfophenyl]-2H-tetrazolium-5- carboxyanilide inner salt) assay kit 
(Tox-2) were purchased from Sigma, MO. Renilla luciferase assay system kit was purchased 
from Promega Corporation, WI. The Qiagen Maxi Prep kit was purchased from Qiagen, CA. 
ExGen 500® (written as ExGen henceforth), GeneRulerTM DNA ladder plus, and 6x 
TriTrackTM loading dye solution were purchased from Fermentas Life Sciences, MD. DNase 
I was purchased from Ambion Inc, TX. Ultrapure water with at least 18 megaohm resistivity 
was used. 
 
2.2 Polymers 
Pluronic F127 [(PEO)100-b-(PPO)65-b-(PEO)100] micro pastille surfactant was donated by 
BASF (Florham Park, NJ, USA) and used without further modification. The pentablock 
copolymers used for this reported study, PDEAEM8-PEO100-PPO65-PEO100-PDEAEM8, 
containing 20wt% of PDEAEM, with Mn = 18520 and Mw/Mn = 1.14 as judged by 1H NMR 
(in deuterated chloroform) and GPC (THF mobile phase, poly(methylmethacrylate) 
calibration standards) respectively, were synthesized as previously reported [26]. It can be 
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calculated that 1μg of this copolymer has 1.03 nM of nitrogen residues. The molecular 
weight of the DEAEM monomer is 185. 
 
2.3 Plasmid DNA 
A 4.1 kb plasmid pRL-CMV for encoding Renilla luciferase (Promega Corporation, 
WI), and a 4.7 kb pEGFP-N1 (ClonTech, CA) plasmid encoding for green fluorescence 
protein (GFP) were used as the reporter genes.  DH5α E. coli cells were transformed with the 
plasmid DNA and incubated in selective Luria-Bertani (LB) medium. Amplified plasmid 
DNA was purified using the Maxi-Prep DNA Purification Kit. The concentration and purity 
of the resulting DNA in TE buffer, pH 7.4 was determined by measuring the absorbance, A, 
at 260 nm and 280 nm. All DNA used had a A260/A280 ratio of at least 1.80. 
 
2.4 Polyplex formulation 
Copolymer to DNA ratios are expressed as molar ratio of nitrogen (N) in the pentablock 
copolymer to phosphate (P) in DNA, and written as N:P. The average molecular weight of a 
nucleotide is approximately 308. Using the fact that 1μg of DNA contains 3nM of 
phosphates, the amount of polymer required for corresponding N:P ratios was calculated. 
Polyplexes were formed by following the precise order of mixing DNA, copolymers and 
Pluronic F127. Pentablock copolymers were first dissolved in 0.5x HBS (Hepes buffer 
saline- 20mM of HEPES with 145mM NaCl), pH 7.0 at 4°C. For luciferase transfection and 
cytotoxicity experiments in 96-well plates, polyplexes were prepared with 2.4 μg pRL-CMV 
in a final volume of 800 µl, and were then divided into four equal parts of 200 µl for four 
wells in the plate, such that each well received 0.6 μg of plasmid. First, an aliquot of DNA 
(1μg/µL) in TE buffer pH 7.4 was taken into a 1.5 ml Eppendorf tube, and was made up to 
100µL using 0.5x HBS buffer pH 7.0. Pentablock copolymer solution (2mg/ml) in 0.5x HBS, 
pH 7.0 was then added to DNA in the required amount to obtain the desired N:P ratio. The 
tube was vortexed gently, and left to incubate for 20 min at room temperature. If required, 
Pluronic F127 solution (25mg/ml) in 0.5x HBS, pH 7.0 was then added to the polyplex 
solution in the tube in the desired wt ratio of F127 to pentablock copolymer. The tube was 
vortexed again gently and incubated for another 10 mins, before making up the final volume 
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to 800 µL using desired growth media, OptiMEM I® or DMEM containing 10% FBS. For 
transfecting cells in 12-well plates with pEGFP, 3μg of DNA per well was used, and samples 
were prepared separately for each well using the above stated procedure, except that they 
were made up to final volume of 1ml. For light scattering experiments, samples were 
prepared in 0.5x HBS buffer with 1μg of DNA, and were made up to a final volume of 1ml 
with plain buffer or serum supplemented buffer, with final solute concentration between 0.3 
to 0.8mg/ml. 
 
2.5 Cell line 
The SKOV3 human ovarian carcinoma cell line (from Iowa Cancer Research 
Foundation) was used for all cytotoxicity and transfection experiments. Cell cultures were 
maintained in a humidified environment with 5% CO2 at 37°C and passaged regularly to 
allow them to remain sub-confluent. Cells were fed with DMEM supplemented with 10% 
fetal bovine serum (FBS) and 1μM L-glutamine, unless otherwise stated. Neither antibiotics 
nor antimycotics were used to avoid the possibility of artificial membrane permeabilization 
effects from these agents. 
 
2.6 DNA condensation, nucleases resistance, serum stabilization 
Agarose gel electrophoresis was performed on polyplexes made at different N:P ratios.  A 
total of 0.125 µg of DNA per lane was used. Samples were prepared using an aliquot of 1 μg 
of pEGFP (0.1 μg/µL) in an Eppendorf tube. Buffer (0.5x HBS, pH 7.0) was added to the 
tube to make final polyplex solution volume of 100 µL. Then polymer solution (1mg/ml) was 
added to obtain the desired N:P ratio. Tubes were vortexed gently and incubated for 20 min 
at room temperature. For samples needing F127, required amount (wt. ratio 5:1 or 10:1 to the 
pentablock copolymer) was added from a 25mg/ml stock solution in 0.5x HBS buffer, pH 
7.0, and samples were incubated for another 10 min. The final 100 µL sample was divided 
into 4 equal parts of 25 µL each for electrophoresis.  
To evaluate resistance to nuclease digestion imparted by polymers, 25 µL polyplex 
solutions, containing 0.25 µg plasmid DNA, were incubated with 3 µL of 10x DNaseI buffer 
and 1 µL of DNase1 (2 IU/µL), giving 2 IU/μg DNA, for 15 mins at 37°C. Immediately 
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following incubation, 5 µL of 0.5 M EDTA was added, and samples were placed in an ice 
bath for 15 min to inactivate DNaseI. To examine the stability of polyplexes in the presence 
of serum proteins, 25 µL polyplex solutions were incubated with 25 µL 0.5x HBS buffer 
containing 20% FBS for 30min in a 37°C incubator. Immediately following incubation, 5 µL 
of 0.5M EDTA was added, and the samples were placed in an ice bath for 15 min to 
inactivate any nucleases in the serum.   
To asses the integrity of plasmid DNA inside polyplexes, 100 mg/mL heparin solution, 
an anionic glycosaminoglycan (GAG), was added to the polyplex solutions to the final 
concentration of 1%w/v and incuabated for 30min, ensuring complete dissociation of DNA 
from the polymers. After adding 5-7 μL of 6x loading buffer, samples were loaded on a 1% 
agarose gel stained with ethidium bromide (0.25 µg/mL).  The gel was run in TAE buffer at 
50V for 2.5 hrs.  Visualization and image capture was accomplished using a UV-
transilluminator under a Kodak EDAS 290 digital imaging suite (Fisher Scientific; Pittsburg, 
USA).  A 1kb+ DNA ladder and pEGFP-N1 DNA served as controls. All the experiments 
were repeated atleast 4 times to ensure reproducibility, and obtain error bars on band 
densitometry data. 
 
2.7 Particle size and zeta(ζ) potential 
Z-average diameter and polydispersity of the copolymers and polymer/DNA complexes 
were measured in Malvern disposable polystyrene cuvettes DTS 0012 at 37°C by a Malvern 
Zetasizer Nano-ZS90 system, equipped with 4 mW 633 nm He-Ne laser (Malvern 
Instruments, Southborough, MA, USA). Data analysis was carried out by the Dispersion 
Techonology Software (DTS) version 4.2. The instrument was calibrated with an aqueous 
polystyrene dispersion of 100 nm particles, using viscosity and refractive index of pure water 
at 37 °C. All water and buffers were double filtered using a 0.2 μm polyethersulfone (PES) 
sterile syringe filters (Fisher Scientific, MO) to remove any dust particles. PES has both, very 
low protein binding and, very low extractables, and is recommended for filtering cell culture 
media.  The test solutions were vortexed gently and incubated for 30 min at 37°C before 
measurements. The ζ-potential of the polyplexes was measured at 37 °C in Malvern zeta 
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potential cuvettes DTS 1060. The instrument was calibrated using a polystyrene dispersion 
with a known ζ-potential.  
 
 
2.8 Cryo-TEM 
Vitrified specimens of the polymer/DNA complexes were prepared for transmission 
electron microscopy (TEM) in a controlled environment vitrification system (CEVS) at 25°C 
and 100% relative humidity, as previously described [34]. Briefly, a drop of the solution was 
applied onto a perforated holey-carbon film, supported on an electron microscopy 200-mesh 
copper grid, and held by tweezers in the vitrification system chamber. The sample was 
blotted with a filter paper, and immediately plunged into liquid ethane at its freezing point (–
183°C). The vitrification process captured the copolymers and their DNA condensates in the 
sample in a state as close as possible to the native state without the need for artifact-inducing 
staining-and-drying [35]. Samples were examined in a Philips CM120 or an FEI T12 G2 cryo-
dedicated transmission electron microscopes (Eindhoven, The Netherlands), operated at 120 
kV, using either an Oxford CT-3500 (for the CM120; Oxford Istruments, Abingdon, 
England) or a Gatan 626 (for the T12; Gatan, Pleasanton, CA) cooling holders and transfer 
stations. Specimens were equilibrated in the microscopes below –178°C, examined in the 
low-dose imaging mode to minimize electron beam radiation damage, and recorded at a 
nominal underfocus of about 2µm to enhance phase-contrast. Images were acquired digitally 
by a MultiScan 791 (CM120) or a US1000 (T12) cooled charge-coupled-device cameras 
(Gatan, Pleasanton, CA), using the Digital Micrograph software. 
 
2.9 Transfection and cytotoxicity 
To determine the total protein expressed by a luciferase reporter gene in the transfected 
cells, a luciferase assay was employed. Cells grown in a 96-well plate up to 70% confluency 
were transfected with various polyplex solutions in 200 µL media using 0.6 µg of DNA per 
well. After 3 hrs incubation, the polymer solutions were aspirated; cells were washed with 
HBSS buffer and incubated for another 45 hrs in complete growth media. For luciferase 
assay, cells were then lysed by incubating with 40 µL lysis buffer (Renilla Luciferase Assay 
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Lysis Buffer, Promega) for half an hour at room temperature, and the luminescence of the 
expressed reporter protein was measured on an automated Veritas™ Microplate Luminometer 
using the Promega Renilla Luciferase Assay System (Madison, USA). Cells incubated with 
naked DNA (without polymer) were used as negative controls.  
 Luciferase activity (RLU) in each well was not normalized by the total amount of 
protein (mg) as that gives artificially high values (RLU/mg) in the samples where total 
protein level has been reduced by the cell death. Instead, since all experiments were 
performed with same initial number of cells per well (~1.2 x 104) in a 96-well plate, 
luciferase expression is reported as RLU/well for each case, along with percentage cell 
viability found in each well using  XTT assay. For XTT assay (Tox-2, Sigma), 40 µL of XTT 
stock solution prepared in phosphate buffer saline (PBS) pH 7.4 was added to each well of 
96-well plate containing 200 µL of growth media, giving a final XTT concentration of 0.2 
mg/mL. Plates were shaken on a gyratory shaker to enhance the dispersion of XTT, and were 
returned to incubator for another 4 hrs. The concentration of formazan crystals formed by the 
cleavage of tetrazolium ring of XTT by the mitochondrial dehydrogenases of viable cells 
[36] was found by measuring the absorbance at 450 nm using a BioTek EL-340 plate reader 
(Winooski, Vermont, USA). Background absorbance measured at 630nm was subtracted 
from the main readings. Viability was calculated relative to control cells not exposed to the 
polymers. 
To measure the transfection efficiency of polymers in terms of the percentage of cells 
transfected in a population, SKOV3 cells seeded in 12-well plates were transfected with the 
pEGFP plasmid following procedures similar to those used in 96-well plates. Cells were 
harvested 48 hr after transfection and flow-cytometry was performed using a Beckman-
Coulter Epics ALTRA Fluorescence-activated cell sorter (Fullerton, USA), as described in an 
earlier report[25].   
 
2.10 Statistics 
Where appropriate, the data is presented as mean and standard deviation (SD). Four 
samples were used for each case in all the experiments; mean and SD were calculated over 
them. Significant differences between two groups were evaluated by Students’ t-test, and 
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between more than two groups by one-way ANOVA analysis of variance, followed by 
Tukey’s test. The level of significance was set at p<0.05, unless otherwise stated. 
 
 
3 Results and discussion 
3.1 Colloidal stability 
The size distribution of the polymers and polyplexes in buffer solutions at pH 7.0 and 
37°C was measured in the absence and presence of serum, with different concentrations of 
unmodified free Pluronic F127 added to the formluations. The size and stability of 
polyplexes formed at N:P ratios from 5 to 30 investigated. For most of the samples, single 
narrow peaks of the scattered light intensity were obtained, while for samples with 
aggregates, the intensity of scattered light peaked at two different particle sizes, shown as 
unimodal or multimodal distribution of particles diameter in Fig. 1. Pentablock copolymers 
and Pluronic F127 had average cumulative micelle sizes of 33nm and 23 nm diameter, 
respectively, while serum particle sizes were around 9 nm, all with PDI less than 0.1. A 2 
mg/ml solution of pentablock copolymers and F127 (5:1 w/w) together had an average 
micelle size of 25±2 nm. All other results are presented in Fig. 1. All samples were 
investigated for up to five hours repeatedly to confirm dispersion stability over time. Fig. 1a 
shows that the pentablock copolymer condensed DNA to form stable polyplexes above N:P 
ratio 5, with diameter less than 175nm and low PDI. The size of the condensates decreased 
systematically on increasing the N:P ratios from 5 to 20. This decrease in diameter of 
polyplexes reflects the process of DNA condensation induced by cationic polymers, and has 
been explained in several studies by the coil-globule transition of plasmid DNA molecules 
upon complexing to take the compact conformation [19, 37]. However, when these 
polyplexes were incubated with buffer containing 10% FBS, the peaks became wider (high 
polydispersity), and secondary peaks denoting large aggregates appeared at higher N:P ratios 
(Fig. 1b).   
The effect of adding free Pluronic to the formulation was evaluated by first measuring 
the resulting polyplex sizes in buffers without serum. Fig. 1c shows that at wt ratio of 5:1 
(F127 / pentablock), stable polyplexes of 145±11 nm diameter with low polydispersity were 
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formed at all investigated N:P ratios. Small secondary peaks at 25-30 nm in the figure denote 
free particles (micelles) of excess pentablock and Pluronic self-assembled together. At higher 
N:P ratios, when polyplexes are actually smaller in size (notice N:P 20 Fig. 1a), but have 
higher surface charge, more F127 micelles attach to them to neutralize their surface charge. 
Thus particle size apparently remained constant at all N:P ratios in the presence of Pluronic.  
Fig. 1d shows the fate of these Pluronic stabilized polyplexes in buffers supplemented 
with 10% (v/v) FBS. Stable polyplexes of around 175nm in diameter, with no other 
aggregates in solution, were observed up to N:P 15. However, small distinct peaks of large 
aggregates of ~700±200 nm could be noticed at higher N:P ratios (Fig. 1d). Small peaks 
observed at ~8 nm and ~30 nm represent serum particles, and free pentablock/ Pluronic 
micelles, respectively, as had been noticed independently.  These peaks however have been 
omitted in Fig. 1b and 1e to make the peaks of DNA condensates look more legible.  
Adding F127 in w/w ratio of 10 to the formulations stabilized polyplexes in serum 
supplemented buffers at even higher N:P ratios. As shown in Fig. 1e, polyplexes of ~200nm 
diameter were formed up to N:P 20. At N:P 30, average particle size increased to 337±90 
nm. These results again indicate that more F127 is needed to stabilize the particles with 
larger surface charge density at higher cationic copolymer concentrations. It should be noted 
that since at higher N:P ratios the size of polyplexes is larger in formulations containing free 
Pluronic than the ones without it (compare Figs. 1c and 1a), it would take fewer such 
polyplexes to make same size aggregates (700+ nm), suggesting that smaller amount of 
plasmid is lost to the aggregates.  
Zeta potential of the particles in different formulations was measured in plain buffers 
containing no serum proteins. The measurements confirmed that pentablock copolymers and 
their polyplexes have excessive cationic surface charge. Pentablock copolymers by 
themselves gave zeta potentials of +6.0±1.3mV (with peak width of 10mV), and serum 
particles showed -6 mV (with peak width of 12 mV). After DNA condensation, the zeta 
potential of copolymer/DNA complexes (at N:P 20) was still around +2.2±0.23 (with peak 
width of 12 mV). However, when free F127 was added to the polyplex formulations in wt 
ratio 5:1 to pentablock copolymer, the zeta-potential was reduced to almost zero (0.037±0.5 
mV, with peak width of 11 mV).  
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Cryo-TEM images of the polplexes were obtained to demonstrate the effect of F127 on 
their microscopic structure and aggregation in a 10% FBS supplemented buffer. Fig. 2a 
shows that polyplexes in formulations not containing F127 formed large masses of 
aggregates with serum proteins. Short thread like structures of polyplexes entangled with a 
large number of platelets and globules of serum proteins were observed. However, as shown 
in Fig. 2b, in formulations containing 5:1 w/w F127/pentablock copolymer fine extended 
thread like structures of polyplexes were observed, with significantly fewer numbers of 
globular molecules of the serum proteins around them. The representative micrographs 
shown here suggest that charged polyplexes attract more serum proteins to them and result in 
the formation of large masses of aggregates. However, when surface charges of polyplexes is 
sterically shielded by unmodified Pluronic, fewer globules of serum proteins accumulate on 
the polyplexes, and their long fine thread-like structure remains intact.   
 
3.2 DNA integrity and protection 
To serve as an efficient gene delivery vector, the copolymers should preserve the 
integrity of DNA while condensing it and ferrying to the nucleus of the targeted cells. One 
important factor in the activity of plasmid DNA is the conformation in which it exists in the 
solution. A plasmid can be in one of the three states: linear (after getting nicked), open 
circular (with only one strand nicked), and supercoiled. A varied degree of supercoiling 
might also exist depending upon the writhes in the plasmid. Fig. 3a shows the pEGFP 
plasmid in lanes 3-8 released from the polyplexes formed with pentablock copolymers at N:P 
ratios of 10 and 20, with either 10:1 (w/w), 5:1 (w/w), or no F127 added to the formulation. 
Lane 2 has plasmid released from the polyplexes of ExGen. As control, lane 1 contains naked 
plasmid incubated with 1% w/v heparin. Comparing plasmid in these two lanes with that 
released from polyplexes in other lanes, it can be observed very clearly that there is no 
difference in the plasmid conformation and band intensity in each conformation. The band 
intensities were measured in arbitrary units using KODAK 1D image analysis software (data 
not shown here). There is no presence of a band representing linear DNA, confirming that the 
plasmid is not cut by the condensation with polymer, and its integrity is maintained in 
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respective formulations. As expected, no effect of adding free Pluronic in the formulations is 
observed on the integrity of condensed plasmid. 
Polyplexes were also investigated for their resistance towards plasmid degradation by 
nucleases. DNA released from the polyplexes post incubation with DNase1 was run on the 
agarose gels to examine its remaining integrity and topology. Fig. 3b shows that copolymers 
and ExGen provide partial DNase1 protection to the condensed DNA. Lane1 contains native 
plasmid, which exist in two conformations- open circular, and supercoiled, most of it in the 
latter form. Lanes 2-8 have DNA bands on the top of the lanes, confirming that there is some 
plasmid left after nucleases digestion, and that it is still condensed by the polymers. Lane 9 
had naked DNA that was completely digested by DNase1, confirming the activity of 
nucleases. To examine the amount and integrity of DNA inside polyplexes in lanes 2-8, it 
was released using heparin salt, and run in lanes 10-16. Plasmid in lane 10 was condensed 
using ExGen at N:P 6. As can be seen, in contrast to naked DNA in lane 1, little amount of 
plasmid is in the supercoiled form, and most of it is in the open circular state. There is also a 
light DNA band between supercoiled and open circular DNA bands. This might be a linear 
plasmid, or can be a relaxed supercoiled form of plasmid with relatively less number of 
writhes. Comparing this to the plasmid released from polyplexes of pentablock copolymers 
in lanes 11-16, two points can be inferred. First, the total amount of DNA retained in ExGen 
polyplexes is greater than that in polyplexes of pentablock copolymer. Second, the total 
amount of DNA retained in supercoiled form is almost same with both cationic polymers. 
Another point to be noted is that nuclease resistance provided by pentablock copolymers is 
good enough at N:P 10, and does not improve on increasing the N:P ratio to 20, and that 
there is no significant improvement of adding free Pluronic in either ratio 5:1 or 10:1 to the 
formulations on the nuclease resistance efficiency. Densitometry data obtained over four 
similar experiments on this nuclease resistance efficiency of polymers is plotted in Fig. 3c, 
and clearly reiterates above stated inferences. 
Fig. 3d shows the stability of polyplexes after incubation with serum proteins. Lanes 1 
and 2 contain native plasmid before and after incubation with serum proteins. It can clearly 
be noted that plasmid is partially degraded in lane 2, and all the supercoiled plasmid is 
converted into circular form, indicating all the molecules of plasmid got nicked by nucleases 
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in serum proteins. Lanes 3, 4 and 5 contain plasmid released from polyplexes of ExGen (N:P 
6), pentablock copolymer (N:P 20) with no free Pluronic and pentablock copolymer (N:P 20) 
with 5:1 free Pluronic, respectively, and lanes 6, 7, 8 contain plasmid released from these 
polyplexes post incubation with serum proteins, respectively. As can be seen, the integrity 
and topology of plasmid DNA remains intact in all the polyplexes after incubation with 
serum proteins, and is similar to that before incubation with serum proteins, and is similar to 
the naked DNA. These results confirm that both cationic polymers provide almost complete 
protection to condensed DNA against serum proteins, and that there is no significant 
observable effect of adding free Pluronic to copolymer systems on the stability of polyplexes 
in serum.  
 
3.3 Transfection and cytotoxicity 
DNA condensates of pentablock copolymers showed remarkably high transfection 
efficiency in the reduced serum media OptiMEM I®. As shown in Figure 4a, transgene 
expression of luciferase obtained with pentablock copolymers at N:P 10 and above was only 
one order less than that obtained with ExGen. The luciferase expression increased on 
increasing the N:P ratios, but it was concomitant with a reduction in the viability of the cells 
(Fig. 4b). Thus, a increase in transfection efficiency of copolymers at higher N:P ratios was 
offset by an increase in toxicity, displaying an overall reduced protein expression per well.  
However, when F127 was added to the polyplex solutions in F127/pentablock w/w 5:1, there 
was a significant decrease in the toxicity of the copolymers. This in turn increased the total 
luciferase expression per well at higher N:P ratios, and an overall higher expression was 
obtained with such a formulation at N:P 15. It should be noted that though ExGen gave one 
order of magnitude higher protein expression than the copolymers at N:P 12, the cell viability 
in the presence of ExGen was reduced to 70% as compared to 90% with the pentablock 
copolymers.  
Fig. 5 shows the transfection efficiency and cytotoxicity of the copolymers in complete 
growth media, containing 10% FBS. As expected from the light scattering study above, little 
transfection was obtained by incubating cells with only pentablock-copolymer/DNA 
complexes, as most of these charged complexes bind to serum proteins in the media to form 
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large aggregates that are unable to get across the cell membrane. This is also evident from the 
increased cell viability (Fig. 5b) in complete growth media with polyplexes at N:P ratios 10, 
15, and 20, as compared to that in OptiMEM I® (Fig. 4b). Since most of the charged 
complexes formed neutralized aggregates with serum proteins, few cationic complexes were 
left in the complete media to interact with the cells, thus decreasing the observed cytoxicity. 
However, when F127 was added to the formulation F127/pentablock wt ratio 5:1, 
significantly higher transfection was obtained at all N:P ratios, with total luciferase 
expression, at N:P 15 and higher, as good as that obtained with pentablock copolymers in the 
serum-free media. This confirms that most of the polyplexes were prevented from 
aggregating with serum proteins, and could get across the cell membrane to deliver their 
DNA payload to the nucleus. This charge shielding effect of F127 was also evident from the 
reduced toxicity of the complexes on addition of F127 (Fig. 5b) leading to lower cationic 
surface charge, less cell membrane damage, and increased cell metabolic viability. 
Different concentrations of free Pluronic were added to the polyplex solutions to shield 
their surface charge and to find the optimum formulation. Results with F127/pentablock wt 
ratio 10:1 are also presented here for comparison. As shown in Fig. 5, though there is no 
significant effect of higher F127 concentration at lower N:P ratios, a significant increase in 
transfection efficiency and cell viability is observed at N:P 25 and 30.  This can be explained 
by the fact that at higher N:P ratios a larger amount of unbound cationic copolymer is present 
in the media, and polyplexes have higher surface charge density. Thus, there is an increase in 
both the total charged surface area to be shielded (because of increased free copolymer 
micelles), and total surface charge to be shielded. Hence, an increased concentration of free 
F127 is required to form stabilized dispersions in serum-supplemented media. This also 
suggests that for an in vivo formulation, where large doses of DNA will be injected in a 
single dose, higher amount of free F127 should be used to shield higher concentration of 
copolymers in the solution. 
SKOV3 cells were also transfected with a pEGFP gene in the presence and absence of 
serum to evaluate transfection efficiency of polymers in terms of percentage of cells 
expressing the transgene product. Pentablock copolymer/ DNA complexes with 
F127/pentablock wt ratio 5:1 were used. As reported in Fig. 6, similar to results obtained 
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with luciferase transfection, the transfection efficiency of copolymers increased with the N:P 
ratio. The pentablock copolymers transfected upto 21% cells in reduced serum media, and 
upto 17% cells in complete growth media, which is similar to or better than the efficiency 
obtained with ExGen. 
4 General discussion 
This work reports the critical evaluation of the design and stability of polycation-DNA 
complexes based on novel pentablock copolymers. These pentablock copolymers were 
chosen for further investigation because they had previously been shown to efficiently 
deliver condensed DNA to the targeted cells in low serum OptiMEM I® media, and had 
exhibited significantly low cytotoxicity. Furthermore, these copolymers self-assemble to 
form thermo-reversible hydrogels at physiological temperatures, a characteristic property that 
can be used to deliver polyplexes in a sustained fashion when injected intramuscularly or in a 
localized tumor. To exploit these advantages of these novel copolymers as a gene delivery 
vector in an in vivo application, we have tried to improve and evaluate their colloidal stability 
in serum supplemented media. 
At physiological pH 7.4, tertiary amines of PDEAEM blocks (pKa~7.3) in the pentablock 
copolymers are partially protonated. Thus the cationic copolymers condense DNA via 
electrostatic interactions into nanoparticles. It was observed that the size of these condensates 
decreased, as the amount of copolymer added to the DNA increased. However, the extra 
cationic copolymer used results in excess positive surface charge on the polyplexes. Thus 
they tend to form large aggregates with anionic serum proteins; such aggregates cannot cross 
cell membranes to deliver the ferried DNA to the nucleus. Thus all DNA is lost to the 
aggregates and little transfection is obtained.  
Because the pentablock copolymers discussed here have a Pluronic core in their 
architecture, it was hypothesized that adding unmodified Pluronic to a solution of pentablock 
copolymer/DNA complexes will lead to formation of polyplexes with a more hydrophilic 
corona that will sterically shield the cationic surface charge. Pluronics had previously been 
shown to enhance the uptake of plasmid DNA and cell transfection when added along with 
cationic polymers [38]. When poly(N-ethyl-4-vinylpyridinium bromide) (pEVP-br) and DNA 
complexes were mixed with 1% Pluronic P85, the DNA uptake in the cells as well as the 
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transgene expression were significantly increased compared to the cells treated with the 
pEVP-br and DNA complex alone[39]. Another recent study showed that when free Pluronic 
was added to the complexes of P123-g-PEI(2K) and DNA, they formed more hydrophilic 
stable dispersions in the presence of serum proteins, and showed enhanced transfection 
efficiency, P123:P123-g-PEI(2k) (9:1) [40]. Gebhart et al suggested in that study that free 
Pluronic sterically stabilized the polyplexes by self-assembling with polycations in such a 
fashion that it masked the hydrophobic PPO chains of the P123 grafted on PEI.  However, 
that system exhibited low level of DNA protection against DNaseI, and gave much lower 
transfection efficiency as compared to ExGen. 
The first objective of this work was to understand the process of polyplex formation, and 
the mechanism of their complexation with serum proteins. Dynamic light scattering revealed 
that fine polyplexes of ~100 to 150 nm, formed by pentablock copolymers in serum free 
buffers, aggregated to yield big particles of ~700 – 1000 nm in the presence of serum. 
However, when F127 was added to these formulations in F127/pentablock wt ratio 5:1, 
polyplexes of ~150 nm were formed, that formed stable dispersions of ~150 – 200 nm even 
in serum supplemented buffers. Though some aggregates of ~ 400-700 nm radii were also 
observed at N:P 20 and above, their formation was also avoided when F127 was increased to 
wt ratio 10:1 in the formulations. These observations confirm that adding F127 to the 
charged polyplex solutions sterically stabilizes the cationic polyplexes against aggregation 
with serum proteins. Cryo-TEM micrographs further confirmed that adding F127 to the 
polyplexes reduced the number of globules of serum proteins attached to them, preventing 
formation of large aggregates.  
The mechanism of the process can most likely be explained as follows, and is sketched in 
Fig. 7. F127 has same hydrophobic PPO core as pentablock copolymers discussed in this 
report. On adding F127 to polyplex solutions, hydrophobic PPO blocks of F127 are attracted 
to the PPO blocks of the extra pentablock copolymers on the surface of polyplexes. While the 
two hydrophobic cores self-assemble, the long PEO chains of F127 sterically shield the 
cationic PDEAEM groups of the pentablock copolymers. By adding F127 at a w/w ratio of 
5:1 (or more) to the pentablock concentration in the solution, several F127 unimers/micelles 
are available per extra pentablock micelles on the polyplex surface. Thus, nanoscale 
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polyplexes with narrow polydispersity are formed that have condensed DNA in their core, 
and a hydrophilic corona formed by PEO chains of F127 and pentablock copolymers. The 
masking of charged PDEAEM groups by long PEO chains of several Pluronic micelles 
reduces the zeta potential of particles to zero and prevents their interaction with serum 
proteins, while the hydrophilic surface with PEO chains prevents the aggregation of particles 
with each other. Also, if there is any free pentablock copolymer in the solution, the unimers/ 
micelles of pentablock and F127 arrange themselves in a dynamic equilibrium to form 
sterically stabilized micelles with no zeta-potential. Further, since both the copolymers have 
the same amphiphilic architecture, the resulting polyplex solutions still retain the thermo-
gelling properties, and form thermo-reversible hydrogels at 37°C. 
The order of addition of F127 to the formulation was also investigated by observing its 
impact on the size of the particles, and their transfection efficiency. Several formulations 
were investigated, but two were in particular important -- one as reported above, where 
Pluronic was added to the formulation after 20 min incubation of DNA with the pentablock 
copolymer, and second, where Pluronic was added to the DNA aliquots before adding 
pentablock copolymer to the formulation. No significant difference was observed (data not 
shown), and the first formulation was adopted for the rest of the study. It should be noted 
though that the polyplexes were formed in serum-free buffers, and serum supplemented 
media was added only after addition of Pluronic to the system. The formation of large 
aggregates of polyplexes with serum proteins is a very rapid and irreversible process, and 
therefore their surface charge needs to be shielded before serum is added to the system.  
The next objective of this work was to confirm the stability of the condensed DNA 
inside these copolymers. Agarose gel electrophoresis results show that plasmid DNA is 
retained in its supercoiled topology even after condensation by both ExGen and pentablock 
copolymers. There is no effect of adding free Pluronic to the formulations of copolymer’s 
polyplexes, suggesting it is the cationic PDEAEM blocks of copolymers that are responsible 
for condensing the DNA. However, after incubation with DNase1, only partial protection is 
imparted to plasmid by both ExGen and copolymers, with most of the plasmid converted 
from supercoiled form to open circular or a relatively relaxed supercoiled form. This 
conversion of topology might suggest that the integrity of the plasmid is compromised. 
 
 192
Another explanation could be that dissociation of plasmid from the polymers after DNase1 
incubation might result in the change of twists and writhes of the DNA molecule, such that 
the supercoiled plasmid becomes relatively relaxed, reducing its mobility.  Although the 
ExGen based polyplexes protected the largest quantity of DNA, the portion of the 
supercoiled fraction retained was the same as that with pentablock copolymers, which many 
would agree is the fraction with greatest integrity. This is evident from the good transfection 
efficiency obtained with pentablock copolymers too. However, the larger quantity of saved 
DNA can explain the one order of magnitude higher total gene expression obtained with 
ExGen. There was no effect of adding free Pluronic to the copolymer’s polyplex 
formulations on the quality of protection provided against DNase1.  
The pentablock copolymer-based polyplexes were found stable in the presence of serum 
proteins, retaining both, the total amount of DNA, and complete portion of supercoiled DNA. 
Again, free Pluronic had no effect on the stability and protective capacity of polyplexes in 
serum. This means that low transfection obtained by copolymers without free Pluronic in 
serum-supplemented media is not because of the degradation of polyplexes or the condensed 
DNA inside, but by the aggregation of polyplexes with serum proteins, leading to big 
aggregates (as evident by light scattering) that cannot cross the cell membrane. Thus, the sole 
function of free Pluronic added to the system is to provide colloidal stability to the 
polyplexes, and prevent aggregation, allowing the copolymers ferry the DNA into the cells.  
Finally, the levels of transgene expression obtained with the pentablock copolymers 
correlated well with the particle size study. Adding free Pluronic prevented aggregate 
formation between polyplexes and serum proteins, and provided significantly improved 
plasmid DNA uptake in SKOV3 cells in serum-supplemented growth media. Another 
advantage of the charge-shielding action of F127 was significant reduction in the cytotoxicity 
of the polyplexes. This is of significance as it allowed working at higher copolymer 
concentrations without compromising the cell viability. For transfection in reduced-serum 
media, a N:P ratio of 10 was found to be optimum, while for transfection in complete growth 
media, N:P ratio of 20 was optimum, providing good transgene expression, while 
maintaining cell viability up to 90%. The total luciferase expression in the cells was one 
order higher with ExGen than that obtained with pentablock copolymers, and that could be 
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explained by the larger quantity of plasmid retained by ExGen systems after nuclease 
incubation. However, the ExGen polyplexes were significantly more toxic at these 
concentrations. The pentablock copolymers used in this study had 20wt% of PDEAEM 
content. Perhaps using longer cationic chains in the copolymer can increase their nuclease 
resistance capabilities, and thus improve their transfection efficiency. Furthermore, since the 
number of cells expressing GFP after transfection with pEGFP using pentablock copolymers 
was similar to those obtained with ExGen, it indicates that pentablock copolymers are able to 
successfully deliver the ferried gene to the nucleus of as many cells as ExGen, and their 
transfection efficiency is limited by the amount of gene delivered. 
A final comment worth to be made is that this is a very dynamic gene delivery system 
and can be easily tailored to specific therapeutic applications. Pluronic F127 was used is this 
study because first, it has long hydrophilic chains, and second, it is already approved for use 
in pharmaceutical preparations, which means the toxicological data exists, and can therefore 
speed the preclinical development of pentablock copolymer formulations. However, there are 
many other Pluronics that may be used in these formulations as free Pluronic to shield the 
surface charge of polyplexes, or can be substituted in pentablock copolymers for F127. A 
detailed review on Pluronics with their structure, characteristics, and drug delivery 
applications is discussed elsewhere [32]. Also, the wt% of cationic component PDEAEM can 
be controlled in the pentablock copolymers conferring varying degrees of cytotoxicity, 
transfection efficiency, and pH-sensitivity to the polyplexes [25, 31]. The increase in 
PDEAEM content increases the cytotoxicity of copolymers, but decreases the amount of 
copolymer required to condense the DNA. However, it was observed that copolymers 
containing 25wt% of PDEAEM required at least 10:1 wt ratio of free Pluronic to form 
stabilized dispersions with no aggregates in serum supplemented buffer at N:P ratios where 
they gave good transfection with low cytotoxicity, similar or better than that obtained with 
the copolymers reported here (data not shown).   
 
 
5 Conclusions 
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In summary, we have shown that adding Pluronic F127 to the polyplexes of pentablock 
copolymers increased the DNA uptake and expression in the cells in complete growth media 
primarily by stabilizing the size and stability of the polyplexes. The addition of F127 also 
showed improved biocompatibility of polyplexes due to masking of their cationic surface 
charge. We determined that pentablock copolymers provide an efficient protection to 
condensed DNA against nucleases and serum proteins, and adding free F127 to the 
formulations did not enhance their nuclease protection efficiency. While the total amount of 
DNA retained after a nuclease digestion was more with polyplexes of ExGen, the amount of 
supercoiled DNA retained was same by both cationic polymers. Though the transgene 
expression obtained with ExGen was one order of magnitude higher than with 
pentablock:Pluronic copolymer system, the latter had significantly higher biocompatibility 
both in the presence and absence of serum. However, the transfection efficiency of this 
copolymer system in terms of total number of cells transfected was similar to that of ExGen. 
Furthermore, these formulations of polyplexes self-assemble at higher concentrations and 
physiological temperatures to form thermo-reversible gels that can act as a reservoir to 
release polyplexes in a sustained fashion when injected intramuscularly or into a localized 
tumor. This quality of these novel copolymer/DNA complexes, together with the serum 
stability, nuclease resistance, biocompatibility and high transgene expression shown in this 
report, makes it a versatile multi-component gene delivery system, and warrants good 
performance in in vivo applications. 
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Fig. 1: Polyplex sizes at different N:P ratios in presence and absence of serum in 0.5x HBS 
buffer at 37°C. Effect of Pluronic F127 on the stability of polyplexes in serum supplemented 
buffer is shown. (A) polyplexes in buffer, (B) polyplexes in buffer with 10%serum 
(C)polyplexes with 5:1 F127 in buffer, (D)polyplexes with 5:1 F127 in buffer with 10% 
serum, (E)polyplexes with 10:1 F127 in buffer with 10% serum. 
 
Fig. 2: Micrographs of pentablock copolymer/DNA complexes (N:P 10) in a serum 
supplemented (10% v/v) buffer with, (A) no free Pluronic, or (B) free Pluronic (5:1 w/w 
Pluronic : pentablock copolymer) added to the formulation. 
 
Fig. 3a: Integrity of pEGFP plasmid released from the polyplexes after incubating them with 
heparin. Lane 1: Native plasmid with heparin; lane 2: ExGen at N:P 6; lane 3,4: pentablock 
copolymer at N:P 10 and 20 respectively, with 10:1 F127; lane 5,6: pentablock copolymer at 
N:P 10 & 20 respectively, with 5:1 F127; lane 7,8: pentablock copolymer at N:P 10 & 20 
respectively, with no F127.  
 
Fig. 3b: Effect of DNase1 on the stability of condensed plasmid. Lane 1: Native pEGFP 
plasmid. All other lanes have polyplexes incubated with DNase1. Lane 2: ExGen N:P 6; lane 
3, 4: pentablock N:P 10 & 20 respectively with 10:1 F127, lane 5, 6: pentablock N:P 10 & 20 
respectively with 5:1 F127, lane 7, 8: pentablock N:P 10 & 20 respectively with no F127; 
lane 9: Naked plasmid. Lanes 10-16 contain plasmid released from polyplexes in lanes 2 to 8 
respectively after incubation with heparin. 
 
Fig. 3c: Densitometry analysis on the plasmid DNA retained in polyplexes after DNase I 
digestion, presented in figure 2b (n=4 ± SD). SC: Fraction of the supercoiled DNA retained. 
ExG: ExGen, pent: Pentablock copolymer.  
 
Fig. 3d: Integrity of pEGFP plasmid released from the polyplexes before and after incubating 
with 10% serum. Lane 1: Naked plasmid, Lane 2: Native plasmid after incubation with 
seurm; lane 3: ExGen at N:P 6; lane 4, 5: pentablock copolymer at N:P 20, with no Pluronic, 
and with 5:1 Pluronic, respectively; lane 6,7,8: polyplexes in lane 3, 4, and 5 after incubation 
with serum. 
 
Fig. 4(a): Effect of free Pluronic F127 on transfection efficiency of pentablock copolymers in 
SKOV3 cells incubated in OptiMEM I® media. + p<0.05, * p<0.1, ° p<0.1, *** p<0.005 
(n=4 ± SD). 
 
Fig. 4(b): Effect of free Pluronic F127 on cytotoxicity of pentablock copolymers’ polyplexes 
at different N:P ratios in OptiMEM I® media. Polyplexes, containing 0.6ug pRL, were 
incubated with SKOV3 cells for 3hrs in Opti-MEM I®, and cell viability was measured after 
another 48hrs of incubation in complete growth media (n=4 ± SD). 
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Fig. 4(c): Luciferase expression in SKOV3 cells transfected with pgWiz-luc using pentablock 
copolymers in OptiMEM I® media. Effect of adding free Pluronic to the formulations is 
shown. Total luciferase expressed in the cells is normalized by the cell viability of the cell 
population (n=4 ± SD).  
 
Fig. 5(a): Effect of free Pluronic F127 on transfection efficiency of pentablock copolymers in 
SKOV3 cells incubated in complete growth media. + p<0.05, * p<0.1, ** p<0.05 (n=4 ± SD). 
 
Fig. 5(b): Effect of free Pluronic F127 on cytotoxicity of pentablock copolymers’ polyplexes 
at different N:P ratios in complete growth media. Polyplexes, containing 0.6ug pRL, were 
incubated with SKOV3 cells for 3hrs in complete growth media, and then replaced with fresh 
media. Cell viability was measured after another 48hrs (n=4 ± SD). 
 
Fig. 5(c): Luciferase expression in SKOV3 cells transfected with pgWiz-luc using pentablock 
copolymers in complete growth media. Effect of adding free Pluronic to the formulations is 
shown. Total luciferase expressed in the cells is normalized by the cell viability of the cell 
population (n=4 ± SD).  
 
Fig. 6: Percentage of cells expressing green fluorescent protein after transfection with pEGFP 
using pentablock copolymer/ DNA complexes at different N:P ratios, stabilized with free 
Pluronic (5:1 wt ratio), in the reduced serum growth media OptiMEM I® or complete growth 
media supplemented with 10% FBS. 
 
Fig. 7: Schematic showing how adding free Pluronic to a solution of pentablock 
copolymer/DNA complexes would sterically shield the charged PDEAEM groups (labeled 
green) on their surface. PEO chains are indicated in red, and PPO chains in blue. Purple core 
consist of electrostatically neutralized polymer/DNA condensates.
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Fig. 1: Polyplex sizes at different N:P ratios in presence and absence of serum in 0.5x HBS 
buffer at 37°C. Effect of Pluronic F127 on the stability of polyplexes in serum supplemented 
buffer is shown. (A) polyplexes in buffer, (B) polyplexes in buffer with 10%serum 
(C)polyplexes with 5:1 F127 in buffer, (D)polyplexes with 5:1 F127 in buffer with 10% 
serum, (E)polyplexes with 10:1 F127 in buffer with 10% serum. 
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Fig. 2: Micrographs of pentablock copolymer/DNA complexes (N:P 10) in a serum 
supplemented (10% v/v) buffer with, (A) no free Pluronic, or (B) free Pluronic (5:1 w/w 
Pluronic : pentablock copolymer) added to the formulation. 
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Fig. 3a: Integrity of pEGFP plasmid released from the polyplexes after incubating them with 
heparin. Lane 1: Native plasmid with heparin; lane 2: ExGen at N:P 6; lane 3,4: pentablock 
copolymer at N:P 10 and 20 respectively, with 10:1 F127; lane 5,6: pentablock copolymer at 
N:P 10 & 20 respectively, with 5:1 F127; lane 7,8: pentablock copolymer at N:P 10 & 20 
respectively, with no F127.  
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Fig. 3b: Effect of DNase1 on the stability of condensed plasmid. Lane 1: Native pEGFP 
plasmid. All other lanes have polyplexes incubated with DNase1. Lane 2: ExGen N:P 6; lane 
3, 4: pentablock N:P 10 & 20 respectively with 10:1 F127, lane 5, 6: pentablock N:P 10 & 20 
respectively with 5:1 F127, lane 7, 8: pentablock N:P 10 & 20 respectively with no F127; 
lane 9: Naked plasmid. Lanes 10-16 contain plasmid released from polyplexes in lanes 2 to 8 
respectively after incubation with heparin. 
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Fig. 3c: Densitometry analysis on the plasmid DNA retained in polyplexes after DNase I 
digestion, presented in figure 2b (n=4 ± SD). SC: Fraction of the supercoiled DNA retained. 
ExG: ExGen, pent: Pentablock copolymer.  
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Fig. 3d: Integrity of pEGFP plasmid released from the polyplexes before and after incubating 
with 10% serum. Lane 1: Naked plasmid, Lane 2: Native plasmid after incubation with 
seurm; lane 3: ExGen at N:P 6; lane 4, 5: pentablock copolymer at N:P 20, with no Pluronic, 
and with 5:1 Pluronic, respectively; lane 6,7,8: polyplexes in lane 3, 4, and 5 after incubation 
with serum. 
 
 206
 
1.E+00
1.E+01
1.E+02
1.E+03
1.E+04
1.E+05
1.E+06
1.E+07
1.E+08
OptiMEM 5 10 12 15 ExG 5:1
N:P ratio of copolymers
R
LU
/w
el
l
No F127
5:1 F127
***
***
**
+
+
°
°
 
 
Fig. 4(a): Effect of free Pluronic F127 on transfection efficiency of pentablock copolymers in 
SKOV3 cells incubated in OptiMEM I® media. + p<0.05, * p<0.1, ° p<0.1, *** p<0.005 
(n=4 ± SD). 
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Fig. 4(b): Effect of free Pluronic F127 on cytotoxicity of pentablock copolymers’ polyplexes 
at different N:P ratios in OptiMEM I® media. Polyplexes, containing 0.6ug pRL, were 
incubated with SKOV3 cells for 3hrs in Opti-MEM I®, and cell viability was measured after 
another 48hrs of incubation in complete growth media (n=4 ± SD). 
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Fig. 4(c): Luciferase expression in SKOV3 cells transfected with pgWiz-luc using pentablock 
copolymers in OptiMEM I® media. Effect of adding free Pluronic to the formulations is 
shown. Total luciferase expressed in the cells is normalized by the cell viability of the cell 
population (n=4 ± SD).  
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Fig. 5(a): Effect of free Pluronic F127 on transfection efficiency of pentablock copolymers in 
SKOV3 cells incubated in complete growth media. + p<0.05, * p<0.1, ** p<0.05 (n=4 ± SD). 
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Fig. 5(b): Effect of free Pluronic F127 on cytotoxicity of pentablock copolymers’ polyplexes 
at different N:P ratios in complete growth media. Polyplexes, containing 0.6ug pRL, were 
incubated with SKOV3 cells for 3hrs in complete growth media, and then replaced with fresh 
media. Cell viability was measured after another 48hrs (n=4 ± SD). 
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Fig. 5(c): Luciferase expression in SKOV3 cells transfected with pgWiz-luc using pentablock 
copolymers in complete growth media. Effect of adding free Pluronic to the formulations is 
shown. Total luciferase expressed in the cells is normalized by the cell viability of the cell 
population (n=4 ± SD).  
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Fig. 6: Percentage of cells expressing green fluorescent protein after transfection with pEGFP 
using pentablock copolymer/ DNA complexes at different N:P ratios, stabilized with free 
Pluronic (5:1 wt ratio), in the reduced serum growth media OptiMEM I® or complete growth 
media supplemented with 10% FBS. 
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Fig. 7: Schematic showing how adding free Pluronic to a solution of pentablock 
copolymer/DNA complexes would sterically shield the charged PDEAEM groups (labeled 
green) on their surface. PEO chains are indicated in red, and PPO chains in blue. Purple core 
consist of electrostatically neutralized polymer/DNA condensates. 
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Abstract 
Controlled release systems can enhance gene delivery and increase the duration of 
transgene expression relative to bolus drug delivery in excess buffers. Thermo-reversible 
hydrogels of novel amphiphilic block copolymers of poly(diethylamino ethyl methacrylate) 
and Pluronic® have been investigated in this report as sustained gene delivery systems. 
Aqueous solutions of these thermo-sensitive copolymers self-assemble at physiological 
temperatures above critical concentrations to form elastic hydrogels. The plasmid DNA can 
be condensed by cationic copolymers in solution, which when injected into the body at a 
localized location, would form a hydrogel in situ. The gels can then act as a depot of genetic 
material, providing a sustained release of DNA protected inside the polymeric nanoparticles. 
The release of DNA electrostatically bound to copolymers is controlled only by the 
dissolution profile of the hydrogels, since it cannot freely diffuse out of the polymeric 
network, preventing initial burst observed with other such controlled release gels/ matrices. 
While the hydrogels protect the DNA in the extra-cellular matrix, the released DNA is also 
protected inside the nanoplexes, which further aid in intracellular trafficking and transfection 
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of the cells. These self-assembled injectable hydrogels have clinical advantages over other 
chemically cross-linked hydrogels that involve harsh environment, or scaffolds that need to 
be surgically implanted. The 150 μL gels of copolymers at 15 wt% concentration released 
condensed DNA up to 7 days in vitro, compared to complete release of entrapped naked 
DNA within few hours by parent Pluronic® gels. The dissolution profile of these hydrogels 
could be easily modulated by adjusting the concentration of component polymers; by 
changing the plasmid DNA loading; or by tailoring the PDEAEM content in the pentablock 
copolymers. These gels had greater mechanical rigidity than parent Pluronic® gels. The 
nanoplexes released from the gels were colloidally stable, in nanometer diameter size range, 
and provided efficient transfection in SKOV3 cells significantly greater than naked DNA. 
Such injectable hydrogels of biocompatible cationic self-assembling copolymers display 
great potential as sustained gene delivery devices, and have advantages over systems that 
release naked DNA. 
 
Keywords: Controlled gene delivery, block copolymers, self-assembling, hydrogel, 
nanoparticles 
 
 
1. Introduction 
Great progress has been made in gene therapy in last two decades, with around 1200 
approved clinical trials ongoing at present[1]. Though 70%[1] of these clinical trials use 
engineered viruses to transfer their genes into the somatic mammalian cells, recent set backs 
involving severe immune response[2], secondary oncogenesis[3], and transfection of 
untargeted germ cell lines[4], have re-enforced researchers to develop biologically inactive 
non-viral methods for gene delivery[5]. However, limited success has been achieved with 
non-viral gene delivery methods. They give low levels of transfection with only transient 
expression because of the ultimate loss of the un-integrated plasmid DNA from the 
transfected cell nuclei. Efficient gene delivery systems that produce enough amount of 
therapeutic protein in the transfected tissue to give an appreciable physiological response are 
needed. Injecting gene delivery vectors formulated in large buffer volumes gives limited 
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bioavailability of the bolus dose. Most of the injected plasmid is lost, or is degraded rapidly 
in the tissue, or is removed from the tissue by lymphatic system. Delivering vectors in a 
controlled fashion from sustained gene delivery devices can overcome these extra-cellular 
barriers of transfecting genes into the cells. Such a device would act as a depot of genetic 
material, protecting it against degradation in extra-cellular matrix (ECM), and providing a 
continuous supply of vectors to the targeted cells over a period of time, maintaining an 
elevated DNA concentration in the cellular microenvironment, increasing the transfection 
probability, and thus generating prolonged gene expression. Besides a localized 
injection/implantation of these controlled delivery systems in target tissues can avoid escape 
of delivered vectors to distant sites which could otherwise lead to toxicity to untargeted cells 
and unwanted immune responses. Such a system also decreases the amount of genetic 
material needed for therapy by preventing its rapid loss from the tissue, and circumvents 
repeated administration of the drug. 
Hydrogels are very attractive controlled delivery systems for hydrophilic 
macromolecules such as DNA because they have high loading efficiency, provide a 
protective environment and allow easy control of encapsulated gene transport by adjusting 
cross-linking densities to modulate network structure. Hydrogels of natural polymers like 
gelatin, chitosan, collagen and agarose, have been used as implantable matrices for sustained 
gene delivery[6]. The entrapped DNA is released as polymers degrade by the cell-secreted 
enzymes in the tissue. However, this limits control over the release profiles from these 
hydrogels, and can reduce the ability to obtain sustain release for longer period of times. 
Synthetic polymers like polyanhydrides[7], functionalized PEG[8, 9], oligo(poly(ethylene 
glycol) fumarate) (OPF)[10] can be chemically crosslinked to produce mechanically strong 
hydrogels that can entrap large amounts  of DNA. They offer broader control over the release 
characteristics by manipulating chemical crosslinking. However, involved gelation 
conditions, chemical environment, organic solvents and harsh physical forces can damage the 
DNA. In addition, their acidic degradation products can degrade the released DNA. 
Physically crosslinked hydrogels that can entrap macromolecular DNA molecules under mild 
conditions by the simple self-assembly of thermo-sensitive polymers have great advantages 
over other systems[11]. Particularly interesting polymeric systems are those which allow 
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preparation of formulations in aqueous solutions and demonstrate in situ hydrogel formation 
after injection into the body by phase transition, without any chemical reaction or external 
stimulation[12, 13].  
Amphiphilic multi-block copolymers, with a hydrophobic and a hydrophilic polymer 
block in their molecular architecture, can display thermo-reversible gelation and have been 
well investigated for sustained drug delivery[11, 14]. These copolymers self-assemble in 
aqueous solutions to form micellar structures with a hydrophobic core and a hydrophilic 
corona. At higher concentrations and above a critical gelation temperature (CGT), these 
micellar solutions form a lyotropic liquid crystalline phase that results in a transparent 
hydrogel. As the water diffuses into the gel matrix, solvating a boundary layer of gel and 
decreasing the polymer concentration below the critical concentration, the gel boundary 
dissolves, allowing the entrapped drug molecules to be released along with polymer 
molecules[11, 15]. Though lot of studies have been reported on using such in situ gelling 
hydrogels for delivering protein therapeutics[16-18] and hydrophobic drugs[19-21], their use 
for gene delivery has not been explored much. 
Thermo-reversible gels of Pluronic block copolymers (PEG-PPO-PEG) [poly(ethylene 
oxide) (PEO) and poly(propylene oxide) (PPO)] have been used for localization and 
sustained delivery of plasmid DNA and viral vectors[22, 23]. However, Pluronic hydrogels 
have low mechanical strength, and a loosely cross-linked network structure, which results in 
rapid release of entrapped DNA molecules through diffusion. In an in vitro study, entrapped 
plasmid DNA was released out very fast in an early incubation stage with subsequent 
negligible releases after 3 days[24]. Recently we reported a family of novel amphiphilic 
pentablock copolymers as non-viral vectors for gene delivery[25]. The copolymers were 
prepared by adding poly(diethylamino ethyl methacrylate) (PDEAEM) blocks to the sides of 
Pluronic block copolymers using an Atom Transfer Radical Polymerization (ATRP) reaction 
scheme[26]. While the copolymers show reversible thermo-reversible gelation properties like 
Pluronics[27, 28], the cationic PDEAEM groups condense the negatively charged DNA and 
show pH buffering capacity at low pH[25, 26]. The nanoplexes of the copolymers are 
biocompatible and give DNA transfection efficiency comparable to that of commercially 
available linear PEI ExGen 500®[29]. Aqueous solutions of these copolymers at 
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concentrations above 15wt%, sol at room temperature, form self-assembled thermo-
reversible hydrogels at physiological temperatures[28]. The solution to hydrogel transition is 
driven by an increase in volume fraction of copolymer micelles (as in PEG-PPO-PEG) due to 
hydrophobic interactions between collapsed hydrophobic blocks, resulting in ordered packing 
of the micelles into a crystalline lattice[11, 28]. In this report we have investigated these 
hydrogels for long term gene delivery. The cationic copolymers can condense DNA in 
aqueous solution at room-temperature into nanoplexes. When injected subcutaneously into a 
tissue, these solutions of nanoplexes containing 15wt% w/w or more copolymer instantly 
form elastic hydrogel in situ at the site of injection. Under in vivo conditions, the ingress of 
tissue fluid into the hydrogel would result in dissolution of the hydrogel matrix, giving a 
sustained release of DNA electrostatically bound to copolymers. Thus, while gels can act as a 
DNA depot, the released DNA is also protected inside nanoplex nanoparticles in both ECM 
and inside the cells, with copolymers aiding in intracellular localization by endocytosis and 
release from endosomes after entrapment. Such in situ gelling self-assembled hydrogels 
display great potential as injectable sustained gene delivery devices, and have advantages 
over systems that release naked DNA. This report examines the mechanical properties of 
these hydrogels, their sustained in vitro DNA release profile, and the stability and activity of 
released condensed DNA. 
 
 
2. Materials and Methods 
2.1 Materials 
Dulbecco’s Modified Eagle Medium (DMEM), OptiMEM I®, fetal bovine serum (FBS), 
0.25% trypsin-EDTA solution, Hank’s Buffered Salt Solution (HBSS), Ultra-pureTM 
Agarose, EDTA, TAE buffer, and ethidium bromide were purchased from Invitrogen 
(Carlsbad, CA). HEPES salt and Heparin Sodium salt (cat # H-4784) were purchased from 
Sigma (St Lousi, MO). Luciferase assay system kit was purchased from Promega 
Corporation (Madison, USA). ExGen 500® (written as ExGen henceforth), and 6x 
TriTrackTM loading dye solution were purchased from Fermentas Life Sciences (Hanover, 
MD). 
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2.2 Polymer synthesis 
Pluronic F127 [(PEO)100-b-(PPO)65-b-(PEO)100] micro pastille surfactant was donated by 
BASF (Florham Park, NJ) and used without further modification. Pentablock copolymers of 
PDEAEM-PEO-PPO-PEO-PDEAEM were synthesized using an Atom Transfer Radical 
Polymerization (ATRP) reaction scheme as explained in detail elsewhere[26]. Molecular 
weight and poly-dispersity of the copolymers were measured using H1 NMR (in deuterated 
chloroform) and GPC (THF mobile phase, poly(methylmethacrylate) calibration standards). 
Copolymers reported in this study had 20wt% of PDEAEM, with architecture- PDEAEM8-
PEO100-PPO65-PEO100-PDEAEM8, and Mn = 18520 and Mw/Mn = 1.14 Copolymers were 
synthesized with a molecular weight less than 20KDa so that they can be removed from the 
body via renal clearance system after gene delivery in in vivo applications. It can be 
calculated that 1μg of this copolymer has 1.03 nM of nitrogen residues. The molecular 
weight of the DEAEM monomer is 185. 
 
2.3 Plasmid DNA 
Plasmid DNA encoding for luciferase gene, gWiz-luc, with 6732bp was obtained from 
GeneTherapy Systmes Inc, CA and was used as the reporter gene. DH5α E.coli cells were 
transformed with the plasmid DNA and incubated in Kanamycin selective Luria-Bertani 
(LB) medium. Amplified plasmid DNA was purified using the Maxi-Prep DNA Purification 
Kit from Qiagen (Valencia, USA). The concentration and purity of the resulting DNA in TE 
buffer, pH 7.4 was determined by measuring the absorbance (A) at 260 nm and 280 nm. All 
DNA used had a A260/A280 ratio of at least 1.80. 
 
2.4 Nanoplex formulation 
Copolymer to DNA ratios are expressed as molar ratios of nitrogens (N) in the 
pentablock copolymer to phosphates (P) in DNA, and written as N:P. The average molecular 
weight of a nucleotide is approximately 308. Using the fact that 1μg of DNA contains 3nmol 
of phosphates, the amount of polymer required for corresponding N:P ratios was calculated. 
Nanoplexes were formed by following the precise order of mixing DNA, pentablock 
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copolymers and Pluronic F127. Pentablock copolymers were first dissolved in 0.5x HBS 
(Hepes buffer saline- 20mM of HEPES with 145mM NaCl), pH 7.0 at 4°C. For luciferase 
transfection in 96-well plates, nanoplexes were prepared with 2.4μg pRL-CMV in a final 
volume of 800ul and were then divided into four equal parts of 200ul for four wells in the 
plate such that each well got 0.6μg of plasmid. First, an aliquot of DNA (1 μg/μL) in TE 
buffer pH 7.4 was taken into a 1.5 mL Eppendorf tube and made up to 100 μL using 0.5x 
HBS buffer pH 7.0. Pentablock copolymer solution (2 mg/ mL) in 0.5x HBS, pH 7.0 was 
then added to DNA in the required amount to obtain the desired N:P ratio. The tube was 
vortexed gently, and allowed to incubate for 20 min at room temperature. If required, 
Pluronic F127 solution (25 mg/mL) in 0.5x HBS, pH 7.0 was then added to the nanoplex 
solution to obtain desired wt ratio of F127 to pentablock copolymer. The tube was vortexed 
again gently and incubated for another 10 mins, before making up the final volume to 800 μL 
using desired growth media, OptiMEM I® or DMEM containing 10% FBS.  
 
2.5 Hydrogel formulation 
15% w/w copolymer/DNA gels were prepared as follows. First, an aliquot of desired 
amount of plasmid DNA (1 µg/µL) was taken in a 1.5 mL Eppendorf tube in the amount of 
0.5x HBS, pH 7.0 buffer that would make final volume of formulation 150 μL. Freshly 
prepared pentablock copolymer solution (100 mg/mL) was added to DNA to give an N:P 
ratio of 25.  The solution was stirred gently and incubated for 20 minutes at room 
temperature to allow DNA condensation by the cationic copolymer. Next, an aliquot of free 
Pluronic solution (200 mg/mL) was added to the mixture to obtain a wt ratio of Pluronic : 
pentablock copolymer 5:1 or 10:1. The formulation was stirred again and incubated for 10 
minutes to allow copolymers to self-assemble. At this step, colloidally stabilized nanoplexes 
were formed, which have been shown previously to give transfection comparable to that of 
ExGen in serum supplemented growth media (unpublished data[30]). Extra pentablock 
copolymer or free Pluronic was added to this formulation in solution or powder form to 
obtain final polymeric concentration of 15wt% and the desired final wt ratio of Pluronic to 
pentablock. The Eppendorf tube was incubated on ice for half an hour to let copolymers 
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dissolve, mix homogenously and self-assemble, and later transferred into a 37°C incubator to 
allow the formation of hydrogel for in vitro dissolution.   
2.6 Dissolution study 
Self-assembled hydrogels of polymer/DNA complexes (total volume ~150 μL) 
contained in 1.5 mL Eppendorf tubes were dissolved in 500 μL of pre-warmed 0.5x HBS, pH 
7.4 buffer. The buffer was added from the side of the tubes to avoid any erosion of gel 
surface by tangential forces of flow. The tubes were transferred to a portable shaking 
incubator maintained at 100rpm, and 37°C. As the gel dissolved over time, 400ul aliquot of 
buffer was collected at different time points and was replaced with same amount of fresh pre-
warmed buffer. Collected samples were stored at 4°C until further examined for 
electrophoretic mobility, size, zeta-potential or DNA content. To measure the DNA 
concentration in the samples, 100 mg/mL heparin solution, an anionic glycosaminoglycan 
(GAG), was added to the solutions to the final concentration of 1%w/v and incubated for 
30min, ensuring complete dissociation of DNA from the polymers. Negatively charged GAG 
are long unbranched polysaccharides with repeated sulfated or carboxylic disaccharide units. 
The polyanionic heparin thus competes with DNA to bind the cationic polymer [31], and 
have been shown to effectively dissociate plasmid DNA from the polymer/DNA complexes 
without any DNA degradation, making it available for the fluorescent stains to bind with[32]. 
The DNA concentration was then measured using fluorescence picogreen assay, which 
detects only double stranded DNA and is less affected by the presence of impurities than 
conventional spectrophotometer measurements. A BioTek Synergy HT multi-detection 
microplate reader (Vermont, USA) was used. 
 
2.7 Dynamic Mechanical Analysis 
A Rheometric Scientific’s rheometer was used to monitor the mechanical properties of 
the copolymer hydrogels as a function of time and temperature. Dynamic time sweep test 
was conducted on the Advanced Rheometric Expansion System (ARES) in a shear strain-
controlled mode. The principle of the test is that as a rotary actuator (servomotor) applies 
shear deformation on the sample in the form of strain, the sample in response generates toque 
which is measured by the transducer. Strain and torque are used to calculate dynamic 
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mechanical test data such as modulus and viscosity. A parallel-plates type of geometry (test 
fixture) was used, with plate diameter 25mm, and gap between the plates maintained around 
0.5mm during the test. Polymer solutions at 4°C were transferred to the top surface of 
rheometer plate maintained at room temperature using a needle and syringe, making sure it is 
spread evenly on the plate with no bubbles. Soon after, the upper plate (probe) was lowered 
to contact the sample, maintaining a gap of 0.5mm between the plates. An approximately 
300ul of the sample was used. The mechanical test was started instantly, where the 
temperature of the plates was set to 37°C. It took less than a minute for the plates to reach 
37°C from room temperature, and thus gave a chance to identify the sol to gel transition point 
by monitoring changes in storage and loss modulus with time and temperature. Frequency of 
the actuator was maintained at 10Hz, and strain was fixed at 10%. Minimum applied 
dynamic force was 1gmf, with maximum auto-tension displacement 3mm, and maximum 
auto-tension rate 0.01mm/s. Since the sample chamber could not be humidified during the 
course of the experiment, the gels started dehydrating on prolonged exposure to high 
temperatures. To avoid this, the measurements were made up to a maximum of 10 minutes. 
  
2.8 Particle size and zeta potential 
Z-Average diameter and polydispersity of the freshly prepared copolymers, 
polymer/DNA complexes solutions, and those released from nanoplex gels were measured in 
Malvern disposable polystyrene cuvettes DTS 0012 at 37 °C on a Malvern Zetasizer Nano-
ZS90 system, equipped with 4 mW 633nm He-Ne laser (Malvern Instruments, 
Southborough, MA, USA). Data analysis was done by the Dispersion Techonology Software 
(DTS) version 4.2. The instrument was calibrated with an aqueous polystyrene dispersion of 
100 nm particles, using viscosity and refractive index of pure water at 37 °C. All water and 
buffers used for sample preparation were double filtered using a 0.2μm polyethersulfone 
(PES) sterile syringe filters (Fisher Scientific, MO, USA). Polymer solutions and buffers 
containing 10% serum were also filtered using these syringe filters to remove any dust 
particles. PES has both, very low protein binding and, very low extractables and, is 
recommended for filtering cell culture media.  The test solutions were vortexed gently and 
incubated for 30min at 37 °C before measuring the size distribution and surface charge 
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properties of the nanoplexes. The ζ-potential of the nanoplexes was measured at 37 °C in 
Malvern zeta potential cuvettes DTS 1060. The instrument was calibrated using a 
poly(styrene) dispersion with a known ζ-potential.  
 
2.9 Agarose gel electrophoresis 
Samples released from the nanoplex gels were run on an agarose gel to check if naked 
DNA or DNA complexed with cationic copolymer was released, based on the mobility of the 
DNA during electrophoresis. To assess the integrity of plasmid DNA inside nanoplexes, 100 
mg/mL heparin solution, an anionic glycosaminoglycan (GAG), was added to the nanoplex 
solutions to the final concentration of 1%w/v and incubated for 30min, ensuring complete 
dissociation of DNA from the polymers. After adding 6x loading buffer, samples were 
loaded on a 1% agarose gel stained with ethidium bromide (0.25 µg/mL). The gel was run in 
TAE buffer at 50V for 2.5hrs.  Visualization and image capture was accomplished using a 
UV-transilluminator under a Kodak EDAS 290 digital imaging suite (Fisher Scientific; 
Pittsburg, USA).  A 1kb+ DNA ladder and pgWiz-luc DNA served as controls. All the 
experiments were repeated at least 4 times to ensure reproducibility and get error bars on 
band densitometry data.  
 
2.10 Cell line 
The SKOV3 human ovarian carcinoma cell line, obtained from ATCCTM (Manassas, 
VA), was used for all experiments. Cell cultures were maintained in a humidified 
environment with 5% CO2 at 37°C and passaged regularly to allow them to remain sub-
confluent. Cells were fed with DMEM growth media supplemented with 10% FBS and 1μM 
L-glutamine, unless otherwise stated. Neither antibiotics nor antimycotics were used to avoid 
the possibility of artificial membrane permeabilization effects from these agents. 
 
2.11 Transfection efficiency 
In order to determine the total protein expressed by a reporter gene in the transfected 
cells, a luciferase assay was employed, using pgWiz-luc as the reporter gene. Cells were 
seeded in a 96-well plate up to 70% confluency prior to transfection, and were then 
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transfected with various freshly prepared nanoplex solutions or nanoplexes released from 
nanoplex gels in 200 µL media using 0.6µg of DNA per well, unless otherwise stated.   After 
3hrs incubation, the polymer solutions were aspirated; cells were washed with HBSS buffer 
and incubated for another 45hrs in complete growth media. For luciferase assay, cells were 
then lysed by incubating with 20 μL lysis buffer (Passive Lysis Buffer, Promega) for half an 
hour at room temperature, and the luminescence of the expressed reporter protein was 
measured on an automated Veritas™ Microplate Luminometer using the Promega Luciferase 
Assay System. Cells incubated with naked DNA (without polymer) were used as controls.  
 
2.12 Statistics 
Where appropriate, the data is presented as mean and standard deviation (SD). Four 
samples were used for each case in all the experiments and, mean and SD were calculated 
over them.  Significant differences between two groups were evaluated by Students’ t-test 
and between more than two groups by one-way ANOVA analysis of variance, followed by 
Tukey’s test. The level of significance was set at p<0.05, unless otherwise stated. 
 
 
3. Results and Discussion  
3.1 Dissolution profile 
Self-assembled hydrogels containing DNA condensed by pentablock copolymers were 
prepared using various formulations to control the DNA release profiles and mechanical 
strength of the gels. These gels have advantage of allowing pharmaceutical formulation 
preparation in aqueous solution. The future objective is to use these DNA loaded gels for 
long-term gene delivery in localized muscle or tumor tissues to generate a localized or 
systemic sustained protein expression, where a maximum volume of 150 μL solution can be 
injected at a time in mice. Therefore, for in vitro studies, hydrogels with volumes no greater 
than 150 μL were prepared and investigated. Previous cytotoxicity studies have indicated 
using an in vitro model that pentablock copolymer gels of 25% w/w concentration were non-
toxic to SKOV3 cells[29]. Since copolymer/DNA solutions form strong elastic hydrogels at 
as low as 15wt% polymer concentration, the dissolution profile of only these low polymer 
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concentration gels were further evaluated, decreasing the chances of any toxicity or 
inflammation in an implanted tissue in vivo. Furthermore, it was observed in previous studies 
(unpublished data[30]) that nanoplexes of pentablock copolymers had cationic surface 
charge, and adding free Pluronic to them in a wt ratio of 5:1 to 10:1 (Pluronic/pentablock 
copolymer) shielded  their surface charge, and successfully prevented their aggregation with 
serum particles. This was proved by showing efficient cell transfection and transgene 
expression in SKOV3 cells in serum supplemented complete growth media. Therefore, to 
ensure colloidal stability of the nanoplexes released from the hydrogels, free Pluronic was 
also added to the formulations in wt ratio of 5:1 to 10:1, while still maintaining total 
polymeric concentration (pentablock copolymer plus Pluronic) in solution as 15 wt%. This 
further decreased the amount of pentablock in the hydrogels, making them more 
biocompatible.  
Nanoplex solutions (150 μL) containing 20μg of plasmid DNA and 15 wt% of 
copolymers were prepared using different amounts of free Pluronic to investigate their effect 
on the dissolution profiles of their gels. A 150 μL Pluronic gel (15 wt%) dissolved 
completely within 6 hr[17] releasing all entrapped naked DNA (data not shown). As shown 
in Fig. 1, nanoplex gels made with pentablock copolymer and Pluronic dissolved up to 5 
days, providing a first order sustained release profile of compacted DNA. Release rate of 
nanoplexes from the hydrogels made with 10:1 Pluronic was similar to those made with 18:1 
Pluronic. Since DNA is electrostatically bound to the pentablock copolymers in the 
hydrogels, its release rate is governed only by the dissolution profile of the hydrogels, and 
not by diffusion. This also prevents initial burst release of DNA from the hydrogels, as 
observed in controlled drug delivery devices of inert polymers. Hydrogels made with 25 wt% 
total polymeric concentrations using excess Pluronic containing nanoplexes made at N:P 25 
dissolved for longer times. However, the rate of nanoplex release was similar to other 
hydrogels. The release rate decreased at the end of dissolution. Hydrogels loaded with higher 
amount of plasmid DNA provided a more sustained release profile (data not shown). This 
was in agreement with other investigators who have shown that adding macromolecules like 
proteins[18], polysaccharides[19], or electrolytes[33] to the Pluronic hydrogels made them 
more rigid by increasing the self-assembly of polymeric network, and thus decreased their 
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dissolution rate. Similar decrease in dissolution rate of these pentablock copolymer gels 
loaded with lysozyme protein was observed in a recently reported study by our group[17].  
 
3.2 Mechanical strength 
DMA studies gave the storage modulus of the hydrogels, and also provided the time it 
took for the sol formulation to form a gel when it was transferred from 4°C to 37°C. As 
shown in Fig. 2, hydrogels formed with only pentablock copolymers were mechanically 
stronger, with their curing time much shorter than all other gels. Pluronic gels had the least 
storage modulus, and they took a very long time to form stiff gels. In fact, with 15wt% 
Pluronic solutions, the storage modulus, G’ never crossed over the loss modulus, G”, 
suggesting they formed only strongly viscous solution but never turned into a gel. Hydrogels 
containing 5:1 and 10:1 Pluronic to pentablock copolymers by wt had intermediate 
mechanical strength and viscosity, though there was not much difference between their 
moduli. The mechanical properties of the gels are summarized in Table 1. A high storage 
modulus is desired in the hydrogels as it assures that the currents in tissue fluid or blood 
stream will not distort their shape easily, and they can stay as an assembled depot for longer 
period of times, with less surface area exposed to fluids to diffuse in and dissolve them. 
Instant increase in the viscosity of the formulations as they are transferred from 4°C to the 
parallel plates of rheometer at 37°C is shown in Fig. 3. The quick onset of gelation signifies 
that the easily injectable aqueous formulations will instantly form a localized gel depot in the 
tissue when injected subcutaneously, giving very less time for the formulation to run off the 
tissue and get dissolved in tissue fluid or up-taken by the lymphatic system, but still enough 
time to fit into the injected body cavity or defect. 
 
3.3 Stability of nanoplexes 
The nanoplex hydrogels dissolved to release nanoplexes, and not naked DNA. No DNA 
band was detected moving down the lanes in agarose gel electrophoresis of the samples 
collected at different days from dissolving hydrogels (Fig. 4). Lanes 2, 3,  and 4 in the 
agarose gel contained respectively samples released at days 1, 3 and 5 from a nanoplex gel 
(10:1 Pluronic : pentablock). However, when the samples were incubated with heparin 
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(1wt%) and run again on agarose gel, the DNA recovered from nanoplexes was found to be 
as intact as control plasmid DNA, with most of it in supercoiled form that many would argue 
is the fraction retaining greatest integrity[34, 35]. The results ensure the stability of plasmid 
DNA in the hydrogels, and in the released nanoplexes that were stored for several days at 
4°C. These nanoplexes of pentablock copolymers have been shown previously to provide 
efficient resistance to DNA degradation by nucleases[25]. 
The colloidal stability of the nanoplexes in released buffer was examined using light 
scattering to measure their size (hydrodynamic diameter) and zeta-potential. As shown in 
Table 2, two ranges of particle size were observed in most of the samples, one between 150 
to 300 nm, and other between 400 to 600 nm. We have shown previously[25, 30] that the 
diameter of a pentablock copolymer/DNA complex stabilized with free Pluronic is between 
150 to 300nm. The first size distribution denotes individual nanoplexes in the buffer, and 
dominates the population in number. Data presented shows the sensitive intensity distribution 
scattered by particles in solution and, can be converted to volume or number distribution 
using Mie theory (for DH>100nm, Mass=f(DH6, RI), where RI is refractive index of the 
particles). Particles larger in diameter produce much higher scattering, even though they 
might be very few in number. For example, the total number particles of diameter 562 nm in 
the day 1 sample in Table 1(a), calculated using DTS software (Malvern Instruments, MA), 
was <1%. The second size range denotes small aggregates of nanoplexes. Since the 
nanoplexes released from the hydrogels were not removed instantly during in vitro 
dissolution in a shaking incubator, they tend to settle down by gravity on the surface of the 
dissolving hydrogel and aggregate with the freshly released nanoplexes. This is not expected 
to happen in an in vivo situation where the released nanoplexes will either be instantly up-
taken by the cells in the surrounding tissue, or will be cleared by lymphatic system. Besides, 
since the size of these aggregates is still on nanometer scale, they can be easily up-taken by 
the cells via endocytosis[36] for subsequent cell transfection. 
Zeta-potential of nanoplexes released in buffer from Pluronic/pentablock nanoplex 
hydrogels was found to be close to zero (0.2±0.5 mV with peak width of 10mV), suggesting 
that their cationic surface charge was effectively shielded by the free Pluronic added to the 
formulations. However, released samples from hydrogels made with only pentablock 
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copolymers (containing stabilized nanoplexes) had partial positive charge of +3.0±1 mV. 
This observed zeta-potential could also be because of excess cationic pentablock copolymer 
chains that do not bound to nanoplexes.  
 
3.4 Transfection efficiency 
Freshly prepared dilute solutions of nanoplexes of pgWiz-luc and pentablock 
copolymers, sterically stabilized with Pluronic/pentablock w/w 5:1, gave excellent 
transfection efficiency when incubated with SKOV3 cells in both – reduced serum media, 
and serum supplemented complete growth media (Fig. 5a). Nanoplexes released from 
hydrogels (Pluronic/pentablock w/w 10:1) provided transfection comparable to freshly 
prepared nanoplexes (Fig. 5b). To ensure the transfection ability of nanoplexes is preserved 
at different steps of hydrogel preparation, freshly prepared formulations with only 2.4 μg 
DNA in 150 μL buffer; with 20 μg DNA in 150 μL (concentrated); and with 20 μg DNA in 
150 μL solution containing 15wt% copolymer, were tested. All these controls provided 
efficient transfection with no significant difference. No transfection was observed with naked 
DNA alone incubated with cells. Though samples collected at later time points (day 5 and 
later) gave reduced luciferase expression, it was still significantly greater than that obtained 
with naked plasmid. The reduced transfection could be due to the aggregation of nanoplexes 
during in vitro dissolution of the gel. The released samples collected at later days had greater 
time to interact with the hydrogels and other nanoplexes in the released buffer. During in 
vitro hydrogel dissolution in a shaking incubator, the released nanoplexes actually settle 
down on the surface of hydrogel by gravity, if not removed instantly. Thus, the freshly 
released nanoplexes from the hydrogel have less chance to mix into the buffer, and end up 
aggregating with nanoplexes settled on their surface. Since these large aggregates are still on 
nanometer scale, they can get enter the cells via endocytosis but might not be able to release 
the entire DNA condensed inside them, giving a low transgene expression. However, this is 
not expected to happen in an in vivo situation, where the released nanoplexes will either be 
instantly uptaken by the cells in the surrounding tissue, or will be cleared by lymphatic 
system, giving no chance for freshly released nanoplexes to aggregate with the accumulating 
nanoplexes.  
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4 General discussion 
In this study we have demonstrated a novel approach of sustained gene delivery that 
involves condensing negatively charged plasmid DNA with cationic block copolymers in 
aqueous solution and in situ gelation of the nanoplex solution by the self-assembling of the 
amphiphilic polymeric micelles. This system thus combines advantages of efficient 
transfection obtained with DNA compacted by polycations, and those of long term gene 
delivery. Though other systems like scaffolds of non-ionic polymers embedded with DNA 
compacted with other polycations have been explored, they have problems of DNA loading 
efficiency, amount of DNA compaction, stability of released DNA in polymer degradation 
products, aggregation of released factors, and involve chemical environment that can damage 
the loaded DNA[37-39]. Besides, the scaffolds need to be surgically implanted into the body. 
The non-invasively injectable hydrogel presented in this study perform address all these 
issues in a single system, and thus present a more versatile approach for sustained gene 
delivery. 
The pentablock copolymers form strong hydrogels, with storage and loss moduli 
significantly greater than parent Pluronic hydrogels. This is of significance from several 
perspectives. First, the gels dissolve to provide a more sustained release profile, up to 7 days, 
compared to few hours given by Pluronic gels[24]. The strong and tighter polymeric network 
makes the hydrogel more rigid, providing more resistance to the diffusion of water into the 
gel, and thereby reducing its dissolution rate. Second, high storage modulus helps in reduced 
deformation of the gel depot by tissue fluid or current of blood in the tissue. Thus reduced 
surface area is presented to the ingressing fluids, extending their dissolution time. 
Furthermore, greater mechanical stability can be instrumental in a tissue engineering 
application where level of gene transfer and expression in surrounding cells is also 
influenced by the mechanical stimulation of the hydrogel matrix[40], and the matrix has to 
provide mechanical support to the cells. The dissolution profile of the gels can be controlled 
by manipulating the content of free Pluronic added to the formulation, or by tuning the 
PDEAEM content in the pentablock copolymers. It was observed that pentablock copolymers 
with greater wt% of cationic PDEAEM group in their architecture formed stronger hydrogels 
and had longer dissolution time period[17].  
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It was confirmed that these hydrogels release DNA electrostatically bound to pentablock 
copolymers. This ensures that DNA is not just entrapped inside the hydrogels, but is also 
condensed by the copolymers. Therefore, there cannot be escape of DNA just by diffusion 
from the hydrogels. In non-ionic Pluronic gels, or in scaffolds of non-ionic polymers loaded 
with cationic polymer/DNA complexes, there is an early loss of entrapped DNA by fast 
diffusion through the loosely bound polymeric network. However, with pentablock 
hydrogels, DNA is released only along with the dissolution of polymer hydrogel. As the 
water diffuses into the gel matrix, solvating a boundary layer of gel and decreasing the 
polymer concentration below the critical concentration, the gel boundary dissolves, releasing 
DNA bound to the cationic copolymer. This provides a more sustained release profile, and 
prevents initial burst observed with other controlled gene delivery systems.  
The integrity of DNA, with most of it in supercoiled topology, was maintained inside the 
released nanoplexes. The nanoplexes released were colloidally stable, with a large fraction 
existing as nanoparticles of diameter 100 to 250nm. Small aggregates of size up to 700nm 
were also formed. We suggest that these aggregates were formed in in-vitro study because of 
the deposition of released nanoplexes on the surface of dissolving hydrogel. In an in vivo 
situation, where released nanoplexes will be quickly removed from the hydrogel surface, 
such aggregates are less likely to occur. However, the aggregates are still in nanometer scale, 
and should be easily uptaken by cells via endocytosis[36]. Hydrogels containing Pluronic in 
5:1 or 10:1 wt ratio were shown to provide similar sustained release profiles, much better 
than only Pluronic gels. The nanoplexes released from these gels were sterically stabilized by 
free Pluronic, which shield their surface charge, and thus prevent aggregation with serum 
proteins. It has been reported previously by our group that these sterically stabilized 
nanoplexes are colloidally stable in serum supplemented buffers, and provided efficient 
resistance against DNA degradation by nucleases (unpublished data[30]).  
Nanoplexes released from hydrogels formed using Pluronic/pentablock copolymers in wt 
ratio 10:1 were shown to provide transfection as good as freshly prepared nanoplexes. 
Though samples collected at later time points (day 5 and later) provided reduced reporter 
transgene expression, it was still significantly greater than that obtained with naked DNA. 
Besides, this should not deter the efficiency of this gene delivery system. In the treatment of 
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a lot of localized disease conditions, such as angiogenesis, bone regeneration, restenosis (a 
vasculo-proliferative condition), and inducing neovasculature in cardiac and limb ischemia, 
sustained and regulated gene expression is more effective than administrations of doses with 
high transient expression[41-44].  
These controlled release gels provide some fundamental advantages for a clinically 
feasible sustained gene delivery system. The formulations are easily injectable, and form 
self-assembled gels within injected tissue soon after administration, preventing any run-off of 
the dose. The gels are tissue-comfortable, improving the patient’s compliance, and can be 
adherent to a variety of tissues like skin, tumors, muscles, eye, mucosa. The system releases 
DNA condensed with the polymers, instead of naked DNA as released by other investigated 
systems. Thus, besides ensuring protection of DNA from nucleases in extra-cellular matrix, 
the released polymer/DNA complex facilitates easy access across the cell membrane via 
endocytotosis, protect DNA from nucleases inside the cell, and helps in escaping the low-pH 
hostile environment of endosomes. The copolymers have a molecular weight of less than 
20Kda, and can thus be removed from the body through renal clearance after bioabsorption. 
These self-assembling thermo-reversible gels have potential advantages over other 
chemically cross-linked gels. Further, the non-invasive injection is better than surgical 
implantation and removal of synthetic matrices or devices for controlled gene delivery. From 
a product design perspective, the formulations are cost-effective and amenable to scale-up. 
The manufacturing process should be relatively simple, and the final formulation can be 
lyophilized in a single vial. Another advantage of these hydrogels is the possible co-delivery 
of bioactive molecules with the genes of interest. For example, additional nucleic acid, 
proteins, peptides, or small molecule drugs could be potentially delivered slowly over time 
within same formulation to enhance or modulate protein expression or activity. The micelles 
of the pentablock copolymers facilitate the encapsulation of less hydrophilic proteins/ drugs 
in their hydrophobic cores, increasing their bioavailability, and reducing systemic 
toxicity[17]. 
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5 Conclusions 
In summary, we have designed and developed a novel polymeric in situ gelling 
injectable system for long-term DNA delivery to the localized tissues. Such hydrogels protect 
the DNA in the matrix and increase its retention time of plasmid DNA in the tissue. The gels 
have higher mechanical strength than parent Pluronic hydrogels, and release condensed DNA 
that provides transfection at much higher levels than naked DNA, unlike other controlled 
gene delivery systems where encapsulation material is inert and do not aid in cell 
transfection. The release of condensed DNA is controlled only by the dissolution of the 
hydrogel, and not by the diffusion of DNA through polymeric network. The dissolution 
profile of hydrogels can be easily modulated by changing the formulation or architecture of 
the pentablock copolymers.  Finally, the hydrogels facilitate simple aqueous pharmaceutical 
preparation that can be easily injected subcutaneously into the body. 
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Table 1: Mechanical properties of the self-assembled hydrogels (15 wt%) made with 
pentablock copolymers and free Pluronic. 
 
15wt% 
hydrogel 
Time(s) to form 
gel (G’/G’’ 
crossover) 
Modulus (Pa) 
at gelation 
point 
Max G’ 
(Pa) 
Max G” 
(Pa) 
Max 
Viscosity, η 
(Pa-s) 
Pentablock 98.4 93.04 5553 966 897 
Pluronic/Pent 
5:1 
125.6 135.6 
 
3362 2273 635 
Pluronic/Pent 
10:1 
157.7 202.2 3564 2420 672 
Pluronic - - 1749 2117 436 
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Table 2: Hydrodynamic diameter of released polyplexes in samples collected at different 
days from the dissolving 15wt% hydrogels containing 20μg plasmid DNA, made with 
different ratios of free Pluronic and pentablock copolymer (n≥3, SD- Standard Deviation). 
 
(a) Hydrogel with Pluronic/Pentablock copolymer in wt ratio 10:1. 
Day Size (nm) SD % Intensity 
1 123 58 14.4 
 592 167 67.4 
3 151 56 41.6 
 674 187 30.7 
5 185 81 55 
 537 149 37 
 
(b) Hydrogel with Pluronic : Pentablock copolymer in wt ratio 5:1. 
Day Size (nm) SD % Intensity 
1 155 54 23.5 
 562 232 66.8 
3 165 19 85.7 
5 198 74 51.4 
 613 212 44 
 
(c) Hydrogel made with only pentablock copolymer. 
Day Size (nm) SD % Intensity 
1 164 84 16.2 
 686 149 71.9 
3 231 40 39.4 
 421 187 18 
5 172 114 82.4 
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Fig. 1: Cumulative release profile of DNA (condensed in polyplexes) from the 150 μL 
hydrogels of pentablock copolymer (pent) and Pluronic F127 formulated in different wt 
ratios. Each hydrogel contained 20 μg of plasmid DNA (n=3). 
 
Fig. 2: Change in the storage (G’) and loss (G’’) modulus of the 15wt% self-assembled 
hydrogels of copolymers, as they are transferred from a 4°C solution in a syringe to the 
parallel plates of rheometer at 37°C. The point at which G’ crosses over G’’ gives time at 
which an elastic gel is formed.  
 
Fig. 3: Instant increase in the viscosity of the hydrogels as a 15wt% solution of the 
copolymers at 4°C is transferred to the parallel plates of rheometer at 37°C. Effect of the 
amount of free Pluronic added to the hydrogels is also shown. 
 
Fig. 4: Mobility of polymer/DNA complexes released from hydrogels at different time 
points. Lane 2, 3, 4 contain polyplexes released on day 1, 3, 5 respectively, and lanes 5,6,7 
contain DNA recovered from those polyplexes after incubating them with heparin. Lane 1 
contains naked pgWiz-luc plasmid.  
 
Fig. 5: Total luciferase expression in SKOV3 cells transfected with (A) nanoplexes prepared 
at different N:P ratios with 2.4 μg DNA in 800μL buffer, displaying stability in serum 
supplemented growth media; (B) nanoplexes at N:P 25 prepared with either 2.4 μg DNA in 
150μL buffer (fresh), or with 20 μg DNA in 150 uL (concentrated), or with 20 μg DNA in 
150 μL solution containing 15wt% copolymer, or those released from 15wt% copolymer 
hydrogels at different time points. 
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Fig. 1: Cumulative release profile of DNA (condensed in polyplexes) from the 150 μL 
hydrogels of pentablock copolymer (pent) and Pluronic F127 formulated in different wt 
ratios. Each hydrogel contained 20 μg of plasmid DNA (n=3). 
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Fig. 2: Change in the storage (G’) and loss (G’’) modulus of the 15wt% self-assembled 
hydrogels of copolymers, as they are transferred from a 4°C solution in a syringe to the 
parallel plates of rheometer at 37°C. The point at which G’ crosses over G’’ gives time at 
which an elastic gel is formed.  
 
 241
 
 
0
100
200
300
400
500
600
700
800
900
1000
0 100 200 300 400 500 600 700
Time (s)
V
is
co
si
ty
, E
ta
 (P
a-
s)
Pentablock
Pluronc F127
Pluronic/Pent 10:1
Pluronic/Pent 5:1
 
Fig. 3: Instant increase in the viscosity of the hydrogels as a 15wt% solution of the 
copolymers at 4°C is transferred to the parallel plates of rheometer at 37°C. Effect of the 
amount of free Pluronic added to the hydrogels is also shown. 
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Fig. 4: Mobility of polymer/DNA complexes released from hydrogels at different time 
points. Lane 2, 3, 4 contain polyplexes released on day 1, 3, 5 respectively, and lanes 5,6,7 
contain DNA recovered from those polyplexes after incubating them with heparin. Lane 1 
contains naked pgWiz-luc plasmid.  
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Fig. 5: Total luciferase expression in SKOV3 cells transfected with (A) nanoplexes prepared 
at different N:P ratios with 2.4 μg DNA in 800μL buffer, displaying stability in serum 
supplemented growth media; (B) nanoplexes at N:P 25 prepared with either 2.4 μg DNA in 
150μL buffer (fresh), or with 20 μg DNA in 150 uL (concentrated), or with 20 μg DNA in 
150 μL solution containing 15wt% copolymer, or those released from 15wt% copolymer 
hydrogels at different time points. 
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CHAPTER 8 
CONCLUSIONS  
 
 
The overall objective of the presented research work was to develop and characterize 
novel polymeric gene delivery vectors based on copolymers of Pluronic and 
poly(diethylamino ethyl methacrylate) (PDEAEM);  and develop their injectable in situ 
forming self-assembled hydrogels for long-term sustained gene delivery. In order to achieve 
this objective, the research was divided into three specific goals and the main findings are 
summarized below. 
 
The specific goals of the project were: 
 
SG1 
To characterize the physiochemical properties of pentablock copolymers pertaining to 
plasmid DNA compaction and protection against nucleases; and, hydrodynamic size, surface 
charge, and morphology of polymer/DNA complexes in aqueous solutions. 
 
SG2 
To tailor the copolymer design and, improve the colloidal stability of their DNA 
complexes with optimized formulations for maximum gene transfection in cells with 
minimum cytotoxicity, and investigate their intracellular trafficking pathway to identify steps 
that limit their transfection efficiency. 
 
SG3 
To develop injectable self-assembled in situ forming hydrogels of pentablock copolymer/ 
DNA complexes for long-term sustained gene delivery- modulate their in vitro dissolution 
profile, and improve the formulations for maximum gene stability and transfection efficiency 
of released polymer/DNA complexes. 
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Physiochemical properties of the pentablock copolymers and their complexes (polyplexes) 
with plasmid DNA molecules were characterized using Multi-Angle Laser Light Scattering 
(MALLS), Dynamic Light Scattering (DLS), and Zeta-sizer. Copolymer itself was found to 
exist as micelles above critical concentrations in aqueous solutions with hydrodynamic 
diameter of ~25nm and each micelle containing approximately 132 polymer chains. Cationic 
copolymers efficiently condensed negatively charged DNA into nanoparticles of 100-150nm 
in diameter at appropriate N/P ratio (molar ratio of nitrogen in polymer to the phosphates in 
plasmid DNA), and provided efficient protection to the condensed plasmid against 
degradation by nuclease enzymes (DNase I). The polyplexes had positive surface charge, 
which depended on the amount of copolymer (N/P ratio) used to condense the DNA. The 
results suggest that copolymer/DNA complexes are small enough to be up taken by cells via 
endocytosis, while the positive surface can help these polyplexes to fuse with negatively 
charged plasma membranes. 
 
Real-space imaging of nanostructures in their native state in aqueous conditions by cryo-
TEM revealed that copolymer exist as spherical micelles, and condense plasmid DNA in 
extended linear thread like structures that tend to bend into rings. DNA condensates were 
found to be more compact at higher N/P ratios, as also suggested by DLS. Similar compact 
condensates were obtained at lower N/P ratios in low pH buffers, indicating copolymers have 
higher cationic surface due to increased protonation at low pH. This pH sensitive quality of 
copolymers to absorb protons at low pH is instrumental in the escape of polyplexes from 
acidic endosomal vesicles after cellular uptake. 
Intra-cellular trafficking studies of the copolymer/DNA complexes using fluorescent 
labeling and confocal microscopy confirmed that cationic polyplexes do fuse with the cell 
membrane all along its perimeter, and are uptaken predominantly by endocytosis. The 
labeled plasmid was found to be entrapped into the endosomes, and later in matured 
lysosomes, up to 7 hrs post-transfection, and was finally localized in the nuclei of transfected 
cells after 10 hrs post-transfection. The study confirmed that cationic pentablock copolymers 
do deliver the condensed DNA into the cell nuclei, and the trafficking involves entrapping 
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into the endosomes, and final disruption of vesicles arguably with the aid of pH buffering 
capacity of copolymers. 
 
A detailed biocompatibility study of pentablock copolymers and their polyplexes using 
several different cell based assays revealed that copolymers enter the cells with very little 
damage/ leakage to the cell membrane, apposed to other cationic polymers like ExGen 500® 
(linear PEI) where cell death was found to be accompanied with an early loss of cell 
membrane integrity. The coopolymers were found to be significantly less toxic than ExGen, 
both in terms of cell membrane leakage, and in terms of metabolic activity retained by 
incubated cells. It was confirmed that pentablock copolymers did not either induce apoptosis 
into the cells. Polyplexes of copolymers were less toxic than copolymers alone, suggesting 
shielding the positive charge of copolymers decreases their cytotoxicity. It was illustrated 
that the cytotoxicity of the copolymers can be tuned by tailoring their molecular weight or 
cationic content. Optimized formulations with ideal cell incubation periods to provide 
maximum transgene expression of a reporter gene, with minimum cytotoxicity, were shown 
to be obtained by varying the DNA dose, polymer concentration and N/P ratio. 
 
The transfection of efficiency of the pentablock copolymers, the ultimate test to their gene 
delivery efficiency, was conducted on several cancer cell lines all along the research work 
using two different reporter genes- one encoding for GFP to account for the percentage of 
cells expressing the transfected reporter genes, and the another encoding for luciferase 
protein to provide the total amount of transgene expression in a population of the transfected 
cells.  Commercially available polymeric transfection reagent, ExGen 500® was used as 
positive control. Pentablock copolymers were found to transfect as many cells as ExGen, 
confirming their efficient capability to deliver genes to competitive number of cell nuclei. 
The total transgene expression in cells was also comparable, but one order less than that 
obtained with ExGen. Detailed nuclease resistance studies revealed that the total amount of 
DNA retained by polyplexes of ExGen after nuclease digestion was more than that retained 
by pentablock copolymers, accounting for the greater transgene expression of ExGen. 
However, the amount of plasmid retained in supercoiled form by both the systems was not 
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significantly different, which many would argue is the fraction with greatest integrity. 
Besides, the observation that pentablock copolymers have significantly higher 
biocompatibility than ExGen makes them a more favorable gene delivery vector. 
The colloidal stability of pentablock copolymer polyplexes in serum supplemented buffers 
was drastically improved using a novel strategy of adding non-ionic copolymer Pluronic 
F127 to the formulation. Since pentablock copolymers are derived form Pluronic F127, they 
have same hydrophobic core. It was hypothesized that while the hydrophobic cores of two 
copolymers would tend self-assemble together, the long PEO chains of F127 would sterically 
shield the cationic PDEAEM groups of the pentablock micelles. It was confirmed using DLS 
and cryo-TEM that such stabilized copolymer/DNA complexes did not aggregate with 
globular serum proteins; had a neutralized zeta-potential, and formed nanostructures of 
hydrodynamic diameter 150-200nm in serum supplemented buffers. The formulations 
provided increase uptake of plasmid DNA and expression in the cells in complete growth 
media, and displayed improved biocompatibility due to masking of cationic surface charge 
on polyplexes. The results warrant good performance of this multi-component gene delivery 
system in systemic applications in vivo. 
 
Finally, sustained release of polymer/DNA complexes was investigated from their thermo-
reversible hydrogels. At higher concentrations and above a critical gelation temperature 
(CGT), micellar solutions of pentablock copolymers with hydrophobic cores and hydrophilic 
coronas form a lyotropic liquid crystalline phase that results in a transparent hydrogel. 
Similar hydrogels were formed by polymer/DNA complexes at higher copolymer 
concentrations and physiological temperatures that provided sustained release of these 
complexes when dissolved in excess buffers. Hydrogels formed with 150 μl formulations, 
maximum injectable volume in mice muscles, gave sustained release of DNA up to 7 days. 
The free flowing formulations at low temperatures containing 15wt% copolymers instantly 
formed elastic hydrogels when transferred from 4°C to 37°C rheometer plates using 1ml 
syringes equipped with 27G needles (ones used for normal insulin injections in body). 
Different formulations were investigated to obtain tailored release profiles, and improve gene 
stability. The hydrogels had greater storage mechanical strength than parent Pluronic 
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copolymers, with a faster curing time to gel. The release of DNA electrostatically bound to 
copolymers is controlled only by the dissolution profile of the hydrogels, since it cannot 
freely diffuse out of the polymeric network, preventing initial burst observed with other such 
controlled release gels/ matrices. Polyplexes released from these hydrogels were colloidally 
stable, in nanometer size range, and provided transfection efficiency comparable to the 
freshly prepared polyplexes.  
 
 
In summary, the dissertation provides the development and complete in vitro evaluation of 
a novel polymeric gene delivery vector. The biocompatible copolymers provide efficient 
gene transfection in cells with little or no cytotoxicity in vitro compared to other 
commercially available transfection reagents, and warrant good performance in systemic 
applications in vivo. At higher concentrations, the copolymer/ DNA complexes form non-
invasively injectable in situ forming self-assembled hydrogels that provide long-term 
sustained DNA release, and have distinct clinical advantages over other chemically cross-
linked hydrogels that involve harsh environment, or matrices that need to be surgically 
implanted. The presented work lays a firm foundation for a multitude of gene therapy studies 
that can be performed with these systems.  
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CHAPTER 9 
FUTURE DIRECTIONS 
 
 
A comprehensive systematic evaluation of the novel polymers introduced in this thesis 
was provided based on their physiochemical properties, biocompatibility, colloidal stability 
and transfection efficiency in vitro. One of the immediate extensions of this work is to use 
this analysis, and optimized formulations of copolymers, to deliver reporter genes in 
localized tissues in a mice model after direct subcutaneous injections. Formulations with 
lower polymer concentrations should be first evaluated for transfection efficiency of the 
copolymers and any inflammation caused by them. Later, the formulations with higher 
polymer concentrations that would form hydrogels in situ after injection should be tested for 
long-term sustained systemic or localized reporter protein expression. Preliminary studies 
were performed to deliver luciferase reporter genes to the localized tumors of human 
prostrate cancer cell (DU 145) grown on the flanks of nude mice using sol formulations (that 
do not form gel in situ). The study was used to optimize the in vivo formulations and their 
preparation for improved gene delivery, but was too small to deliver statistically significant 
results. However it did confirm that polymers were able to deliver the genes to the tumor 
cells, as evident by transgene expression shown in Fig. 1, and that the copolymers caused 
mild to moderate inflammation (Fig. 2), as evident by little infiltration of leucocytes in the 
tumor tissue. Mild inflammation was found along the needle path even in tumors injected 
with only plain buffers, and in tumors with no injections because of the invasive growth of 
tumors. Since the growth of tumors varied in mice, it accounted for another variable for 
observed differences in evaluating gene delivery efficiency of copolymers. To overcome this, 
we have a new protocol for in vivo mice studies approved by animal care committee at Iowa 
State University where polymer/DNA complexes will be injected in the femoral muscles of 
mice, and reporter gene expressing an extra-cellullar protein will be employed. Thus, level of 
systemically expressed protein can be measured at different time points by simply taking a 
blood sample from the same mice each time, a great facility for long-term gene delivery 
study using copolymer gels as it would limit the number of test mice needed.  
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Fig. 1: Emission of photons from the tumors growing on the flanks of mice during the 
reaction of luciferin substrate, injected intra-peritoneally, with the luciferase enzyme 
expressed in the tumor cells after their successful transfection with a plasmid encoding it 
using pentablock copolymers. The image gives both, the total amount of gene expressed, and 
its 2-D distribution, inside the tumor. The image was obtained using Xenogen’s (MA, USA) 
in vivo bio-photonic imaging station. Inset shows a mouse with a tumor grown on its flank. 
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A
 
 
B 
Fig. 2: H&E stained slices (5-10μm) of paraffin embedded tumors, showing infiltration of 
leukocytes in the tumor tissue two days after injection with (a) pentablock copolymer/ DNA 
complexes, and (b) ExGen/DNA complexes. 
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Though the morphology of polymer/DNA complexes has been well studied using cryo-
TEM in this thesis, a detailed study to investigate the interactions of polymer molecules with 
plasmid DNA is need. Molecular architecture and macroscopic self-assembly of polymer 
micelles and their DNA condensates can be deciphered accurately using Small Angle 
Neutron Scattering (SANS). Detailed structure studies can be done with SANS using contrast 
variation technique where desired molecules can be made opaque to incident neutron beam 
by making the scattering length density of solvent equal to that of the molecule. This tool can 
be used to preferentially visualize the DNA or polymer molecules in the polyplex solution, 
by making one of them opaque to the neutrons. This feature is really interesting as it can 
provide the exact location of polymer and DNA in a polymer/DNA complex, and can thus 
help identify how to improve the protection of DNA condensed inside polyplexes against 
degradation by nucleases. 
 
Finally, the pentablock copolymers have reactive ends in their architecture that facilitate 
covalent attachment of cell-specific ligands for target recognition, or nuclear localization 
signals (NLS) for improving nuclei translocation, or fluorophores for intra-cellular 
trafficking of polymers using fluorescence confocal microscopy. In particular, attaching cell 
binding ligands such as Epidermal Growth Factor (EGF) to the polymers will preferentially 
increase their uptake in the cells over expressing these receptors (like most of the cancer cell 
lines, in particular A431 human epidermoid carcinoma) by receptor mediated endocytosis, 
and reduce their uptake by non-targeted cells. These ligands can also aid in shielding the 
surface charge of the polymer/DNA complexes, preventing their aggregation with serum 
proteins, and reducing their opsonisation by the immune system. 
 
Once a safe and efficient gene delivery system using these pentablock copolymers is 
developed, it can be used to ferry suicide genes like Herpes simplex type 1 thymidine kinase 
gene (HSV1-TK) or Escherichia coli Cytosine Deaminase (CD) gene to selectively kill the 
targeted cancer cells in vivo. 
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